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Introduction 
This thesis describes the results of the second COPE study, designed after analysing the 
results of the first COPE study on chronic obstructive pulmonary disease (COPD) self-
management (1). Before presenting the design and results of COPE-II, we will first in-
troduce the topic of this study. We present the definition and epidemiology of chronic 
obstructive pulmonary disease (COPD), the characteristic acute deteriorations in pa-
tient condition, known as exacerbations, and the definition and position of self-
management within the continuum of disease management. This will be followed by 
the rationale, specific research aims and design of the COPE-II study. The introduction 
ends with an outline of this thesis.  
 
COPD and exacerbations 
COPD is a preventable and treatable disease with significant extra-pulmonary effects 
that contribute to the burden of disease on patients. The pulmonary component is char-
acterised by airflow limitation that is not fully reversible. The airflow limitation is 
usually progressive and associated with an abnormal inflammatory response of the 
lung to noxious particles or gases (2). COPD is the fifth leading cause of death in high-
income countries and the sixth in low-income and middle-income countries (3). The 
prevalence and burden of the disease are projected to increase in the coming decades. 
This is due to aging of the world’s population and continued exposure to COPD risk 
factors, of which tobacco smoking is the most important (2). In the Netherlands, the 
overall incidence and prevalence of COPD in general practices are estimated to be 0.2% 
and 2%, respectively. Both the incidence (40-45 years: 0.1%; 80-85 years: 1.1%) and 
prevalence rates (40-45 years: 0.8%; 80-85 years: 11.8%) increase with age. In the 
younger age category (40-45 years), the male:female ratio is almost equal (1.1:1.0), 
whereas in the elderly (80-85 years), COPD is more prevalent in men (3:1) (4).  
COPD is characterised by episodes of acute deterioration in respiratory health, 
termed exacerbations. These exacerbations account for much of COPD patient morbid-
ity, mortality, and cost (5). It has proven extremely difficult to reach a broadly accepted 
definition of a COPD exacerbation (6). One of the earliest and most quoted definitions 
of an exacerbation is the symptom-based definition of Anthonisen et al (7). Since then, 
many definitions have been published in the literature (6). Several attempts have been 
made to achieve consensus about the definition of an exacerbation (6), but until today, 
no single definition has been broadly accepted. 
 
COPD self-management programmes  
Self-management is a term applied to programmes that aim to teach patients the skills 
needed to carry out disease-specific medical regimens, to guide change in health behav-
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iour, and to provide emotional support to enable patients to adjust their roles for opti-
mal function and control of their disease (8). Therefore, the term self-management 
education programmes can be misleading because it implies only a transfer of knowl-
edge. Self-management programmes play an increasing role in the management of 
COPD patients, but there is still no clarity about the exact definition, necessary content, 
and effectiveness (of components) of COPD self-management programmes (9). 
A self-management programme should always be aimed at behavioural change. As 
in the COPE-I study, we have chosen to include elements of the ASE model (Attitude, 
Social support and self-Efficacy) for behavioural change in the COPE-II study (10). The 
ASE model is based on a social cognitive theory claiming that behaviour is influenced 
by outcome expectations, in particular the individual’s confidence in his ability to per-
form a given behaviour (self-efficacy).   
Self-management programmes are a component of disease management, defined as 
a ‘system of coordinated health care interventions and communications for patients 
with conditions in which self-care is significant’ (www.dmaa.org). Other characteristics 
of disease management are facilitation of the physician-patient relationship, use of evi-
dence-based practices and patient empowerment, and continuous assessment of health 
outcomes. In a recent systematic review, Adams et al. (11) demonstrated that reduction 
of health care use can be accomplished by disease management programmes consisting 
of self-management education, delivery of services and decision support, but not by 
programmes consisting solely of self-management education. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Continuum of disease management 
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The degree of disease management by the patient is usually inversely related to the 
degree of disease management by health care providers. When COPD becomes more 
severe and opportunities for disease management by the patient decrease, the need for 
disease management by health care providers will increase, and vice versa (Figure 1). 
Self-management programmes aim to increase disease management by the patient and 
can be applied, with different content and components, throughout the entire contin-
uum of disease management. Programmes with a minimum of supervision, including 
promotion of a healthy lifestyle (smoking cessation, physical activity), may be offered 
to patients with less severe COPD. When the ability of the patients to manage their own 
disease decreases due to increased disease severity or comorbidity, multidisciplinary 
pulmonary rehabilitation will become an increasingly important component of the pa-
tient’s health care. Self-management incorporated into pulmonary rehabilitation is the 
most intensive method of trying to achieve a shift from management by health care 
providers to management by the patients themselves.   
 
Rationale for the COPE-II study 
In contrast to self-management for asthma patients (12;13), the effectiveness of (differ-
ent components of) self-management programmes for COPD was unclear at the time 
we launched this study. Therefore, there was an urgent need to assess the effectiveness 
of (components of) self-management programmes. We started by updating the Coch-
rane review of Monninkhof et al. (14) to review the latest evidence (Chapter 2).  
 In the original COPE-study (1), a COPD self-management programme consisting of 
a self-management education course, guidelines for the self-treatment of exacerbations, 
and a physical exercise programme, was evaluated using a control group that received 
only the usual care. The most striking result of the COPE-I study was a twofold in-
crease in the frequency of exacerbations in the intervention group (1). Exacerbations 
were defined by the use of a course of prednisolone and/or antibiotics taken due to 
worsening of the respiratory condition. It remained unclear, however, whether or not 
the higher number of self-initiated courses of prednisolone and antibiotics in the inter-
vention group indicated overtreatment in the intervention group, as mentioned in 
other studies (15-17), or implied undertreatment in the control group. Although the 
original COPE-study also included an exercise programme, no effects on health related 
quality of life or exercise capacity were detected. This lack of effect is likely due to the 
low frequency and intensity of the exercise programme compared to the guidelines 
applied nowadays (18). 
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Objective of this study 
Against this background, we decided to start a new study with the objective to evaluate 
the costs and effects of the major components of a more intense self-management pro-
gramme. We specifically focussed on the following main research questions: 
1. Does a one-year self-management programme, including self-treatment of exacer-
bations, when compared to a similar self-management programme without these 
self-treatment guidelines, lead to a reduction in the severity of exacerbations and 
reduction in costs in COPD patients? 
2. Does a one-year self-management programme, including a community-based 
physiotherapeutic exercise programme (COPE-active), when compared to a similar 
programme without this COPE-active programme, lead to improvement of exer-
cise capacity, daily activity and reduction in costs in COPD patients? 
Because the proper execution of the community-based physiotherapeutic exercise pro-
gramme by the physiotherapists was of paramount importance, we assessed the 
adherence of the physiotherapists with the COPE-active protocol.  
 In addition to the main research questions, we also studied the following sub-
questions: 
1. Does the choice of a definition of an exacerbation influence the outcome of a clini-
cal trial in COPD? 
2. What are the effects of immediate in-hospital reactivation in patients hospitalised 
with a COPD exacerbation? 
We hypothesised that guidelines for self-treatment would lead to earlier initiation 
of treatment of the exacerbations, resulting in a decrease of exacerbation severity (dura-
tion and symptom-intensity). Daily symptom diaries were necessary to assess the 
amount and severity of symptom-based exacerbations in a detailed way. In addition, 
these diaries provided insight into whether or not overtreatment occurred as a result of 
self-treatment of exacerbations.  
We also hypothesised that community-based physiotherapeutic exercise pro-
grammes would fit perfectly into a COPD self-management programme and would 
lead to an improved exercise capacity and daily activity. When the study began, not 
much was known about the effectiveness of community-based physiotherapy (19). We 
therefore designed and evaluated a new community-based physiotherapeutic exercise 
programme (COPE-active) that met the criteria (content, intensity, and frequency) for 
physiotherapeutic exercise programmes in COPD patients (18). Next to physical pro-
gress, we strived for behavioural change towards more exercise in daily life. We 
hypothesised that the training period should be long enough to make the shift from 
exercising under guidance of a physiotherapist to unsupervised exercise at home (20), 
and that home exercise sessions should therefore be part of these small-group physio-
Chapter 1 
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therapeutic exercise programmes. The study objective was to determine the additional 
effect of a community-based physiotherapeutic exercise programme within a COPD 
self-management programme on exercise capacity and daily activity.  
 Protocol non-adherence by health care providers and contamination of control pa-
tients with (elements of) the experimental treatment can both impede study quality and 
diminish effects in randomised controlled trials (21). To gain more insight into both 
aspects with an impact on the effectiveness of the programme, we also studied adher-
ence with a protocol by the physiotherapist and checked whether contamination bias 
had occurred. 
 
Design of the COPE-II study 
In the COPE-II study, a two-by-two factorial design was used (see Table 1), meaning 
that two independent interventions, self-treatment of exacerbations and a community-
based physiotherapeutic exercise programme (COPE-active), were evaluated in one 
study. Patients were randomly allocated to one of four study groups. All patients re-
ceived four self-management sessions. The effect of a self-management programme 
including self-treatment of exacerbations was thus compared with a self-management 
programme only. Patients receiving COPE-active were divided equally over the group 
receiving guidelines for self-treatment of exacerbations and the control group. Simi-
larly, the effect of COPE-active was assessed by comparing a self-management 
programme including COPE-active with a self-management programme only. Patients 
who were instructed to self-treat their exacerbations were divided equally over the pa-
tients receiving COPE-active and control patients. It was assumed that the two 
interventions would not interact with one another.    
All patients and their partners were offered four weekly two-hour small-group 
(approximately 5 patients) self-management sessions, provided by a respiratory nurse 
and a physiotherapist. The intention of the courses was to change the patients’ disease 
behaviour by increasing their knowledge, confronting them with consequences of spe- 
 
Table 1  Description of the design of the COPE-II study, including the two interventions (COPE-active 
and self-treatment of exacerbations) and the measurements at baseline, 7, and 12 months 
Time schedule Interventions Group 1 Group 2 Group 3 Group 4 
Month 0 Baseline measurements X X X X 
Month 1 Self-management courses X X X X 
Month 1 Self-treatment of exacerbations X X   
Month 2-7 COPE-active: ‘compulsory’  X  X  
Month 7 Measurement X X X X 
Month 8-12 COPE-active: ‘voluntary’ X  X  
Month 12 Measurement X X X X 
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cific behaviours, and supplying them with tools to deal with different components of 
the disease. Four, 13 and 26 weeks after the last course, the respiratory nurse contacted 
the patients by phone to review the items addressed during the self-management 
courses. Patients were supplied with a booklet with the content of the courses. 
Patients in groups 1 and 2 were educated in early recognition of exacerbations and 
in starting standardised treatment in case of an exacerbation. To this end, they were 
taught to use an action plan that was linked to the daily diary. Patients in groups 3 and 
4 were instructed to call the study office if they felt in need of assistance due to any 
worsening of their respiratory symptoms, which would normally have prompted them 
to call their chest physician or general practitioner instead. A consultation with a chest 
physician was scheduled within 12 hours.     
Patients in groups 1 and 3 were randomly assigned to participate in the COPE-
active programme. The 11-month training period per patient was divided into two 
parts: a ‘compulsory’ 6-month period followed by an optional but recommended 
5-month period. In addition to improvement of physical condition in the first period 
and preservation of these gains in the second period, changes in behaviour towards 
exercise were an objective for the entire period. Exercises included in the programme 
were bicycling, walking, climbing stairs and lifting weights. Home exercises included 
walking or cycling, and strength exercises for the upper and lower extremities. Fre-
quency of training sessions (first period: 3 times/week; second period: 2 times/week) 
and intensity of the exercises within the programme were in line with the latest reha-
bilitation recommendations (18). During the entire study period, patients in the control 
group were allowed to attend regular physiotherapy sessions if this was prescribed as 
part of their regular care. 
Symptom diaries were completed daily, and measurements of exercise capacity, 
daily activity, quality of life, health status, lung function and fat-free mass were per-
formed at baseline and at 7 and 12 months. Information about hospital admissions, 
emergency room visits, scheduled and unscheduled outpatient visits, telephone calls 
with physicians, consultations with the general practitioner and physiotherapists, and 
medication use was collected during the entire study period for cost-effectiveness 
analyses.  
 
Rationale for the additional research questions 
In designing the COPE-II study, we took the opportunity to assess two additional re-
search questions as follows. 
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1. Does the choice of definition of an exacerbation influence the outcome of a clinical 
trial in COPD? 
It has been extremely difficult to reach a broadly accepted definition of a COPD exacer-
bation. The lack of consensus and the variability in definitions used make it hard to 
compare the results of different studies. It is obvious that some definitions give rise to a 
much higher observed incidence of exacerbations whereas other, stricter definitions 
will lead to a lower observed incidence (16). It remains to be established whether the 
use of different definitions also affects the estimates of treatment effects. In Chapter 7, 
we discuss the relevance of outcome definitions on study results. First, we provide an 
overview of definitions of exacerbations used in the literature. In addition, we present 
an analysis of the impact of the use of different, frequently reported definitions of exac-
erbations on the effect sizes of the COPE study (22), a randomised, placebo-controlled 
trial on discontinuation of inhaled corticosteroids (ICS). 
 
2. What are the beneficial effects of immediate in-hospital reactivation of patients 
with an exacerbation of COPD?  
In patients hospitalised because of an exacerbation, muscle weakening occurs and re-
mains detectable three months after hospitalisation (23). Inactivity during hospitalisa-
tion leads to further decreases in condition and strength (24). Because of feelings of 
illness and shortness of breath, inactivity is the rule rather than the exception (25). Less 
is known about the effects of immediate reactivation in COPD patients hospitalised for 
an exacerbation. Two programmes that started soon but not immediately (3-8 days af-
ter admission) reported positive effects on exercise capacity (26;27). We developed an 
immediate reactivation programme starting within 24 hours after admission: PUL-
MOFIT-MST. We hypothesised that it could reduce the length of hospital stays by 
preventing loss of muscle strength and exercise capacity, thereby initiating a faster re-
turn to the activities of daily living. A study by Bourbeau et al. (8) has already 
confirmed that in patients recently hospitalised because of an exacerbation, compre-
hensive self-management (including self-treatment of exacerbations and a non-
compulsory exercise programme) contributes to improved quality of life and decreases 
the length of future hospital admissions. When it is possible to prevent deconditioning 
in patients during hospitalisation by using immediate reactivation and when an effec-
tive standardised physiotherapeutic programme (e.g., COPE-active) integrated into a 
self-management programme can be started immediately after discharge, patients will 
probably experience even greater benefits with regard to exercise capacity and daily 
activity.  
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Outline of this thesis 
This thesis is directed towards the (cost-) effectiveness of components of self-
management programmes. We start with an update of the Cochrane review ‘Self-
management education for patients with chronic obstructive pulmonary disease’ in 
Chapter 2. Chapters 3 to 5 constitute the core of this thesis, presenting the results of two 
interventions on the course of disease. Chapter 3 presents the costs and effects of self-
management including self-treatment on exacerbations. The effects of COPE-active on 
exercise capacity and daily activity are described in Chapter 4, and the effects on costs 
are presented in Chapter 5. Chapter 6 describes the results of a detailed study on ad-
herence and contamination bias among the physiotherapists who executed the COPE-
active intervention. Additionally, Chapter 7 presents an overview of different defini-
tions used for exacerbations and analyses of how the use of another definition could 
effect trial results in COPD. In Chapter 8, we demonstrate the effect of an immediate 
reactivation programme in patients hospitalised because of a COPD exacerbation. In 
Chapter 9, the major results of these studies are discussed and put into perspective; 
included are recommendations for clinical and public health practice, as well as for fu-
ture research. A summary of the main findings concludes this thesis (Chapter 10). 
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Abstract 
Background There is great interest in chronic obstructive pulmonary disease (COPD) 
and the associated large burden of disease. COPD is characterised by frequent day by 
day fluctuations, and repetitive clinical exacerbations are typical. Self-management is a 
term applied to educational programmes aimed at teaching skills needed to carry out 
medical regimens specific to the disease, guide health behaviour change, and provide 
emotional support for patients to control their disease and live functional lives. In 
COPD, the value of self-management education is not yet clear. The first Cochrane re-
view about self-management was published in 2003. It was intended to shed light on 
the effectiveness of self-management programmes in COPD and the relative efficacy of 
their constitutive elements. No conclusions about the effectiveness of self-management 
could be drawn because of the large variation in outcome measures used in the limited 
number of included studies. This article describes the first update of this review. 
Objectives The objective of this review was to assess the settings, methods and efficacy 
of COPD self-management education programmes on health outcomes and use of 
health care services. 
Search strategy We searched the Cochrane Airways Group trial register, MEDLINE 
(January 1985 to January 2006), reference lists, and abstracts of medical conferences. 
Selection criteria Controlled trials (randomised and non-randomised) of self-
management education in patients with COPD. Studies focusing mainly on pulmonary 
rehabilitation and studies without usual care as a control group were excluded. 
Data collection and analysis Two reviewers independently assessed study quality and 
extracted data. Investigators were contacted for additional information.  
Main results The reviewers included 15 group comparisons drawn from 14 trials. They 
assessed a broad-spectrum of interventions and health outcomes with different follow-
up times. Meta-analyses could often not appropriately be performed because of hetero-
geneity among studies. The studies showed a significant reduction in the probability of 
at least one hospital admission among patients receiving self-management education 
compared to those receiving usual care (OR 0.64; 95%CI (0.47 to 0.89)). This translates 
into a one year number needed to treat (NNT) ranging from 10 (6 to 35) for patients 
with a 51% risk of exacerbation, to an NNT of 24 (16 to 80) for patients with a 13% risk 
of exacerbation. On the disease specific SGRQ, differences reached statistical signifi-
cance at the 5% level on the total score (weighted mean difference (WMD) -2.58; 95% CI 
(-5.14 to -0.02)) and impact domain (WMD -2.83; 95% CI (-5.65 to -0.02)), but these dif-
ference did not reach the clinically relevant improvement of 4 points. A small but 
significant reduction was detected in dyspnoea measured with the BORG-scale (WMD 
-0.53; 95% CI (-0.96 to -0.10)). No significant effects were found either in number of ex-
acerbations, emergency department visits, lung function, exercise capacity, and days 
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lost from work. Inconclusive results were observed in doctor and nurse visits, on symp-
toms other than dyspnoea, the use of courses of oral corticosteroids and antibiotics, and 
the use of rescue medication. 
Authors’ conclusions It is likely that self-management education is associated with a 
reduction in hospital admissions with no indications for detrimental effects in other 
outcome parameters. This would in itself already be enough reason for recommending 
self-management education in COPD. However, because of heterogeneity in interven-
tions, study populations, follow-up time, and outcome measures, data are still 
insufficient to formulate clear recommendations regarding the form and contents of 
self-management education programmes in COPD. There is an evident need for more 
large randomised controlled trials with a long-term follow-up, before more conclusions 
can be drawn. 
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Background 
Chronic Obstructive Pulmonary Disease (COPD) is a serious public health problem. 
According to the Global Burden of Disease study conducted under the auspices of the 
World Health Organization and the World Bank, COPD is currently the fourth leading 
cause of death in the world, with 2.75 million deaths worldwide and a further increase 
in mortality is predicted for the coming years (1). Since many patients with COPD ex-
hibit progressive disability rather than immediate death, mortality data do not present 
a complete picture of the burden of COPD (1). In addition to the burden to healthcare 
systems, a loss in health-related quality of life is seen in many patients. Therefore, ap-
propriate therapies are necessary to deal with this disease.  
Self-management is a term applied to any formalized patient education programme 
aimed at teaching skills needed to carry out medical regimens specific to the disease, 
guide health behaviour change, and provide emotional support for patients to control 
their disease and live functional lives (2). However, the effects of self-management pro-
grammes are still unclear. Data abstracted in the previous version of this review were 
insufficient to form recommendations (3).  
In asthma, patient education and self-management programmes have proven to be 
successful, at least when combined with regular review, in reducing the economic bur-
den of disease, as well as in improving quality of life and lung function (4-7). In COPD, 
pulmonary rehabilitation has been proven to increase exercise capacity, reduce symp-
toms, and improve quality of life (8).  
Worth (9) was the first to describe the effectiveness of a self-management pro-
gramme which encouraged the patient to acquire self-management skills and seek to 
alter behaviour. Unfortunately, this pilot study was uncontrolled and studied a small 
sample of COPD patients (N=21). Impressive reductions in the frequency of exacerba-
tions and home visits by the family doctor were observed, but no changes in lung 
function were found. Several controlled trials have been conducted to evaluate the ef-
fectiveness of COPD self-management education programmes. The first Cochrane 
review was published in 2003 (3). No conclusions about the effectiveness of self-
management could be drawn because of the large variation in outcome measures used 
in the limited numbers of published studies. Several studies have been published since 
the appearance of this Cochrane review. This article describes the first update of the 
review. It assesses the influence of self-management programmes on health outcomes 
and health care utilisation in COPD. 
 
Objectives 
I.  To evaluate whether self-management education programmes in COPD lead to 
improved health outcomes. 
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II.  To evaluate whether self-management education programmes in COPD lead to 
a reduction of health care utilisation. 
 
Criteria for considering studies for this review 
Types of studies Only randomised controlled trials and controlled clinical trials assess-
ing the efficacy of self-management education in COPD patients were included. Studies 
focusing mainly on pulmonary rehabilitation, studies that did not include usual care, 
and studies published before 1985 were excluded since medicinal treatment of COPD 
prior to 1985 is not comparable with current practice and as a result, baseline popula-
tions would not be comparable. 
 
Types of participants Patients with a clinical diagnosis of COPD and not asthma as 
primary diagnosis were included. 
 
Types of intervention The interventions were categorised according to whether or not 
they involved COPD education and/or self-treatment guidelines (i.e. an action plan). 
The operational definition of COPD education was defined as: a programme which 
transfers information about COPD and treatment of COPD in any of the following 
forms: written, verbal, visual or audio. Minimal education included the provision of 
written material alone or a short structured verbal interaction between a health care 
provider and a patient. However, it had to be embedded in a formal programme where 
the primary goal was to improve the knowledge and understanding of COPD. The 
educational programme might be directed towards smoking cessation, improving exer-
cise, nutrition, self-treatment of exacerbations, inhalation technique or coping with 
activities of daily living, or a combination of these.  
The operational definition of self-treatment guidelines (action plan) is: a written 
plan produced for the purpose of patient self-management of COPD exacerbations. It 
informs patients about when and how to adjust and/or start medication in case of an 
exacerbation. 
 
Types of outcome measures Any of the following outcomes: health-related quality of 
life scores, symptom scores, number and severity of exacerbations, courses of oral ster-
oids or antibiotics, use of rescue medication, hospital admissions, emergency room 
visits, use of other health care facilities, days lost from work, lung function, and exer-
cise capacity. 
 
Chapter 2 
 - 24 - 
Search methods for identification of studies 
See: Cochrane Airways Group methods used in reviews. See: collaborative Review 
Group search strategy.  
Trials were identified using the Cochrane Airways Group Specialised Register of 
trials, which is derived from systematic searches of bibliographic databases including 
the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, 
CINAHL, AMED and PsycINFO, and hand searching of respiratory journals and meet-
ing abstracts. All records in the Specialised Register coded as ’COPD’ were searched 
using the following terms: ‘educat*’ or ‘self-manag*’ or ‘self manag*’ or ‘self-car*’ or 
‘selfcar*’ or ‘train*’ or ‘instruct*’ or ‘patient cent*’ or ‘patient-cent*’ or ‘patient-focus*’ or 
‘patient focus*’ or ‘patient-education’ or ‘patient education’ or ‘management plan*’ or 
‘managementprogram*’. Searches are current to January 2006. 
 
Methods of the review 
Study eligibility Two reviewers (TE and EM) independently coded the studies from the 
above searches based on the abstract/keywords/ title: Include: 1) Randomised Con-
trolled Trial (RCT) or Controlled Clinical Trial (CCT), COPD, education/ self-
management; 2) Possible RCT or CCT, but undetermined from the abstract; Exclude: 1) 
non-RCT or non-CCT; 2) pulmonary rehabilitation. Study eligibility, study quality and 
intervention types were independently assessed by two investigators (TE and PV). 
Agreement was examined; disagreement was resolved if possible by consensus, and 
otherwise by consultation with a third reviewer (JP). Articles were included if they 
were randomised or controlled clinical trials of COPD education with usual care as a 
control group, and reported relevant outcomes. 
 
Documented characteristics of included trials We collected the following information 
on studies meeting the entry criteria of the review: I. Demographics: age, gender, socio-
economic status; II. Setting of intervention: primary care, hospital based, group; educa-
tion, individual education, community based; III. Involvement of the partner in the 
intervention; IV. Duration of intervention: number of sessions, hours of teaching, time 
frame; V. Inclusion of physical exercise: type, location, duration; VI. Sample size/power; 
VII. Disease severity; VIII. Intermediate outcomes: COPD specific knowledge, skills, 
inhalation technique, smoking cessation, compliance. 
 
Missing data An attempt was made to contact authors to complete missing data. 
A reminder was sent if the authors did not reply. 
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Study quality Two reviewers (TE and JP) independently assessed the methodological 
quality of the included studies using the criteria list of Jadad et al. (10). The quality 
variables recorded in the criteria list of Jadad were: procedure of allocation, withdraw-
als/drop-outs and blinding of patients and outcome assessment. 
 
Analysis Outcomes were analysed as continuous and/or categorical variables using 
standard statistical techniques: A) For continuous outcomes, the Weighted Mean Dif-
ference (WMD) or Standardised Mean Difference with 95% - confidence intervals were 
calculated as appropriate; B) For dichotomous outcomes, a pooled odds ratios (OR) was 
calculated. Number needed to treats (NNTs) were calculated for hospital admission 
using the pooled OR, using the control group data from individual studies to give 
study -specific NNTs, with Visual Rx. We combined data with a fixed effect model and 
95% confidence intervals. Subgroups of interest were length of follow-up (< or > 
12 months), type of education given (written action plan). 
 
Statistical heterogeneity Variation between study findings was explored using the 
I square statistical measurement (11). Where I square >20% we conducted a sensitivity 
analysis by pooling data with a random effects model. 
 
Primary comparison The primary comparison was self-management versus usual care. 
 
Description of studies 
For details of included studies see Table 1 (including authors, publication date, partici-
pants, interventions, outcomes, notes).  
Searches identified 700 titles and abstracts that were screened to identify 56 poten-
tially relevant articles about self-management education in COPD. Full-text versions of 
these papers were obtained, and independently assessed by two reviewers (TE and 
PV). Six new trials were added to this review, giving a total of 15 group comparisons 
drawn from 14 trials which met the review entry criteria (2;6;12-23). We also included 
one non-randomised study (23). Thirty-seven articles were excluded for the following 
reasons (Table 2): the design of the study was not a CCT or RCT (n=15); the studies 
primarily focused on pulmonary rehabilitation (n=6); most of the patients had asthma 
as primary diagnosis (n=4); the design of the study did not include usual care as a con-
trol group (n=5); the article did not describe the results of the study (n=2); the studies 
were published before 1985 (n=2); the design of the study did not include an education 
part (n=1); the article described a review about the effects of physical activity (n=1); or 
the outcome assessed was not appropriate (n=1). 
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Subjects/recruitment A total of 2239 patients were randomised in the 14 studies; 1924 
(85.9%) patients completed these studies. The drop out rates ranged from 0% to 30.4%. 
Seven studies recruited their patients from outpatient clinics; four from general prac-
tice, one from the community, and two studies recruited patients from a mix of these 
settings. 
 
Interventions All fourteen studies described COPD self-management education com-
pared with usual care. In four studies the education delivery mode consisted of group 
education; in nine of individual education and one study used written education mate-
rial only. In six studies the use of an action plan for self-treatment of exacerbations was 
assessed. The follow-up time was 12 months in eight studies, 10 months in one, 
6 months in three, 12 weeks in one, and 2 months in one study. One study also evalu-
ated the outcome ‘hospital admissions’ after 24-months (2).  
 
Comparisons Fourteen studies that compared self-management education with usual 
care have been included in this review. In one study (15) two intervention groups and 
one usual care group were used. In meta-analyses both intervention groups were com-
pared with the same usual care group, resulting in one extra comparison. 
 
Outcomes (and the number of studies reporting outcome) health-related quality of life 
(HRQoL): 14; symptoms: 5; number and severity of exacerbations: 3; courses of oral 
steroids and/or antibiotics: 5; use of rescue medication: 1; hospital admissions: 10; 
emergency room visits: 5; use of other health-care facilities: 7; days lost from work: 2; 
lung function: 6; exercise capacity: 5.  
 
Missing data Replies were received from all authors who are listed in the acknowl-
edgement section. However, not all authors could provide us with the additional 
requested information. 
 
Methodological quality 
The method to generate the sequence of randomisation was not clear in two of the thir-
teen RCTs. The concealment of allocation was adequate in the other 11 RCTs. None of 
the interventions were blinded, since blinding of the participants with respect to study 
status is almost impossible in clinical trials of behavioural interventions. A description 
of withdrawals and dropouts was given in 12 of the 14 studies. In a telephone call with 
the author of one of the studies in which the reasons for dropout were not described, it 
was emphasized that the dropouts in this study were non-selective (15). Nine studies 
Review on self-management in COPD 
 - 27 - 
(2;6;12;13;16;18;20-22) scored the maximum number of three quality points (10), four 
studies (14;15;17;19) two points and one study (23) scored one point.  
 
Results 
Health-related quality of life Instruments for measurement of HRQoL differed widely 
among the studies. COPD-specific HRQoL was measured by means of the St. George’s 
Respiratory Questionnaire (SGRQ) in seven studies (2;6;13;15;19;20;22). The SGRQ-total 
and -domain scores in the self-management groups were all lower (indicating a better 
HRQoL) or equal to the scores in the usual care groups. The differences on the SGRQ-
total (WMD -2.58; 95% CI (-5.14 to -0.02)) (Figure 1) and impact scores (WMD -2.83; 95% 
CI (-5.65 to -0.02)) (Figure 2) reached statistical significance at the 5% level, but did not 
reach the clinically relevant improvement of 4 points. No significant or clinically rele-
vant difference was found on the SGRQ-symptom score (WMD-1.45; 95% CI (-4.41 to 
1.51)) (Figure 3). The SGRQ-domain physical activity did not show a statistically sig-
nificant effect in favour of treatment (WMD -2.88; 95% CI (-5.9 to 0.13) (Figure 4). The 
level of statistical heterogeneity for this outcome may be related to the outlying effect 
reported in the study of Watson (22), since its removal led to a lower I square statistic 
(65% versus 0%). Exploration of varying study characteristics may identify spurious 
differences since effect sizes from this study for other domains and total score did not 
yield high I square measurements. Martin (19) could not be included in the meta-
analyses due to a lack of required data. In this study, no differences in SGRQ-scores 
after 12 months of follow-up were found.  
In the study of Rea (21) COPD-specific HRQoL was measured with the Chronic 
Respiratory Disease Questionnaire (CRQ). Two of the four dimensions, fatigue and 
mastery (sense of control over the disease), showed a significant improvement after a 
follow-up of twelve months. General HRQoL was measured with the Sickness Impact 
Profile (SIP) in three studies (12;16;18) and with the Short Form 36 (SF-36) health survey 
questionnaire in two studies (15;21). Data from the SIP were not suitable for meta-
analysis and showed incongruent results. One study (16) reported significant im-
provement in total function measured by the SIP in the control group. Conversely, 
another study (12) showed better physical function and total function in favour of the 
intervention group, and the third study (18) showed a significant greater improvement 
in physical function in the intervention group. Meta-analyses were performed on data 
of the SF-36. No between-group differences in any domain were found. Other studies 
used the Health Status Questionnaire 2.0 (17), the General Health Questionnaire (14), 
the Illness Intrusiveness Instrument (15), and a self designed questionnaire (23), to 
measure general health status. In the studies by Howland (23) and Cockcroft (14), gen-
eral HRQoL was not significantly different between the self-management and control 
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group. Gourley (17) showed significantly improved scores for the well-being dimen-
sion of the Health Status Questionnaire 2.0 in the intervention group. Coultas (15) 
found a statistically significant improvement in the perceived Illness Intrusiveness in-
strument in one of the intervention groups (nurse assisted collaborative management) 
compared with usual care. However, the author noted that the clinical relevance of this 
finding was uncertain. 
 
Symptoms The effect of self-management education on COPD symptoms was exam-
ined in five studies (2;13;17;20;22). In the studies by Gourley (17) and Boxall (13), 
dyspnoea was assessed with the BORG-scale. Meta-analysis showed a small but signifi-
cant effect at the 5% level in favour of treatment (WMD -0.53; 95% CI (-0.96 to -0.10)). In 
the study by Gourley (17), the Global Assessment Scale (measuring symptom severity 
on a 6-point scale) was also used. It showed a reduction (not statistically significant) in 
symptom severity in the self-management education group, while in the control group 
no reduction was observed. In the study by Watson (22), patients scored their respira-
tory status in symptom diaries on a four-point scale (usual; mild; moderate; severe). 
They found no significant between-group differences in the proportion of days rated as 
mild, moderate or severe. In the study by Monninkhof (20), no significant between-
group differences were seen in mean breathlessness and sputum production scores 
over two-week periods. However, small differences in mean cough and sputum colour 
scores were seen in favour of the intervention group. Although these differences 
reached borderline significance, the author stated that the differences were probably 
not clinically relevant. Finally, in the study by Bourbeau (2), symptoms during exacer-
bations were scored (breathlessness, sputum volume and sputum colour), but no 
significant differences were found between the scores of the intervention and control 
group. 
 
Number and severity of exacerbations Three studies (2;18;20) reported the number of 
exacerbations. However, different definitions of exacerbations were used. Littlejohns 
(18) reported only the number of acute exacerbations in the intervention group. The 
follow-up of the studies by Bourbeau (2) and Monninkhof (20) was 12 months. Whereas 
Bourbeau found 299 exacerbations in the intervention- and 362 exacerbations in the 
control group, Monninkhof found 360 exacerbations in the intervention- and 177 exac-
erbations in the control group. 
Outcome measures such as courses of oral steroids and/or antibiotics, use of rescue 
medication, hospitalisations, and use of health care facilities can serve as proxy vari-
ables for exacerbations of COPD, because these variables indicate worsening of COPD. 
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Courses of oral steroids and/or antibiotics Five studies assessed the use of oral corti-
costeroids for respiratory problems (6;18;19;21;22). Three studies (6;18;21) contributed 
data to the meta-analysis. Patients receiving self-management education were more 
likely to be prescribed at least one course of oral corticosteroids, but this was not statis-
tically significant (OR 1.44; 95% CI (0.91 to 2.30)). Two studies (6;18) reported increased 
use of oral steroids in the intervention group (Gallefoss (6): intervention group 69% - 
control group: 44%; Littlejohns (18): intervention group 49% - control group 37%), 
while one study reported no difference between the two study groups (21). Watson (22) 
analysed from symptom diaries the days on prednisolone as percentage of the days 
recorded. The intervention group used prednisolone on 15% of the days recorded com-
pared to 9% in the control group. In the study by Martin (19), the frequency of oral 
prednisolone use was higher in the intervention group, but it did not reach significance 
(2.3 versus 1.3 courses per patient per 12 months). 
 Use of antibiotics for respiratory problems was assessed in four studies 
(18;19;21;22). Littlejohns (18) reported that 79% of the patients in the intervention group 
were prescribed antibiotics during the study year, compared to 52% in the control 
group. Watson (22) analysed from symptom diaries the days on antibiotics as percent-
age of the days recorded. The intervention group used antibiotics on 10% of the days 
compared with 4% in the control group. Treatment differences in both studies were 
statistically significant. Two studies reported no significance difference in the use of 
antibiotics between the two study groups (19;21). Rea (21) reported the difference be-
tween the pre trial period and the trial period in percentage of patients using antibiotics 
in both groups: intervention group: -1%; and control group: +2%, whereas Martin (19) 
reported the courses per patient per year: intervention group 3.6 and control group 2.5. 
 
Use of rescue medication Gallefoss (6) reported on the use of short-acting ß2- agonists 
as rescue medication. Use of rescue medication was coded as the Defined Daily Dos-
ages (DDD) for comparison of medications within the same chemical therapeutic 
group. In this study the educated patients used less rescue medication (median DDD 
=125) than the control group (median DDD=209). This reduction was statistically sig-
nificant. 
 
Hospital admissions Ten studies reported COPD-related hospitalisations (2:6:13-15;17-
21). Seven studies were included in the meta-analyses (2;6;13;15;18;20;21). There was a 
clinically and statistically significant reduction of the probability of at least one hospital 
admission among patients receiving self-management education compared to those 
receiving regular care (OR 0.64; 95% CI (0.47 to 0.89)) (Figure 5). Study-specific NNTs 
were between 10 and 30, which indicated some variation in the baseline risk which may 
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relate to length of follow-up and severity (see Table 3). Over the course of a year the 
NNT ranged from 10 (95% CI: 6 to 35) for patients with a 51% risk of exacerbation (Fig-
ure 6), to an NNT of 24 (16 to 80) for patients with a 13% risk of exacerbation (Figure 7).  
Three studies could not be included in the meta-analyses due to a lack of required 
data (14;17;19). In these three studies no statistically differences were found between 
the two study groups. In Martin (19) more hospitalisations were seen in the interven-
tion group (1.1 hospitalisation per patient per year in the intervention group and 0.7 
hospitalisation per patient per year in the control group), whereas in the other two 
studies (14;17) no trend could be detected. The 24-month results on hospital admission 
(all causes) of the study of Bourbeau (2) were presented in a subsequent trial publica-
tion (24). A statistically significant reduction of -0.44 hospitalisations per patient per 
year in favour of the self-management education group was reported. 
 
Emergency room visits Five trials (2;15;17;19;21) reported the effect of self-management 
education on Emergency Room (ER) visits related to COPD. In the study by Martin 
(19), ambulance calls related to COPD were taken as a proxy for ER-visits. Three stud-
ies were included in the meta-analysis (15;17;19). There was no significant difference 
between patients receiving self-management education compared to those receiving 
regular care in the average number of respiratory related ER-visits (WMD 0.07; 95% CI 
(-0.17 to 0.31)). There were conflicting findings between Bourbeau (2) and Martin (19) 
for all cause ER-visits, with a significant treatment effect in favour of self-management 
reported by Bourbeau, and a significant treatment effect in favour of control by Martin. 
Finally, in the study by Rea (21), ER-visits not leading to hospital admissions were re-
ported (intervention group n=5 (6.0%); control group n=7 (13.5%).  
 
Use of other health care facilities Doctor and nurse visits were reported in seven stud-
ies (2;6;15;17;19;20;21). Five studies were used in the meta-analysis (6;15;17;19;22). The 
meta-analysis showed only a trend towards a reduction of doctor and nurse visits per 
patient per year in the self-management group compared to usual care group with a 
Fixed Effect model (WMD -0.28; 95% CI (-0.66 to 0.09)). Due to the high level of hetero-
geneity in this outcome we applied Random Effects modelling as a sensitivity analysis. 
This gave a non-significant difference of 0.02 (95% CI -1.1 to 1.13) (Figure 8). The stud-
ies by Bourbeau (2) and Monninkhof (20) could not be included in the meta-analysis 
because of lack standard deviations, but showed both a reduction in unscheduled doc-
tor and nurse visits per person per year (Bourbeau: mean difference -0.7; Monninkhof: 
mean difference -0.39). 
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Days lost from work Gallefoss (6) reported no significant difference between groups in 
days lost from work. Almost 50% of the COPD-patients in this study were employed, 
and only 3 out of 14 and 2 out of 13 in the intervention and control group respectively, 
reported on absence from work. Blake (12) and Monninkhof (20) both used the term 
restricted activity days, defined as days where work was missed or where activities 
were significantly reduced because of health problems. In the study by Monninkhof 
(20) a reduction in restricted activity days during exacerbation recovery was seen in the 
education group compared with the control group (average number of restricted activ-
ity days: intervention group 4.1 (SD 4.2); control group 5.3 (SD 5.3)). However, in 
neither study were significant between-group differences detected. 
 
Lung function Lung function was assessed as the forced expiratory volume in 1 second 
as percent predicted for age, gender and height (FEV1%-predicted). Six studies in-
cluded in the meta-analysis (2;6;16;18;21;22); five were entered as post-bronchodilator 
levels. One study (18) only reported mean within-group differences, so the results were 
entered as % change in predicted FEV1. No significant difference in deterioration of 
FEV1%-predicted was seen between the intervention and control groups (Standardised 
Mean Difference 0.04; 95% CI (-0.12 to 0.21)). 
 
Exercise capacity In five studies exercise capacity was evaluated (2;13;18;20;21). In four 
studies, the 6 minutes walking test (6MWT) was used (2;13;18;20). Three studies were 
included in the meta-analysis (2;13;20). No significant between-group difference was 
found (WMD -6.25; 95% CI (-24.05 to 11.55), and significant heterogeneity between 
these studies was present (Chi Sq 8.97; P< 0.05). Because of a lack of standard devia-
tions the study by Littlejohns (18) could not be included in the meta-analysis. In this 
study no between-group difference was found. Finally, in the study by Rea (21), the 
incremental shuttle walk test was used; the difference between the intervention (303.3 
metres) and usual care group (283.4 metres) was not clinically relevant or statistically 
significant.  
 
Discussion 
This review systematically evaluated 15 treatment-control comparisons from 14 trials of 
self-management education for patients with COPD compared to usual care as an up-
date of our 2003 review (3). The studies showed a significant and clinically relevant 
reduction in the number of patients with one or more hospital admissions and a small 
but significant reduction of the BORG-dyspnoea score was detected. For Quality of 
Life, a positive trend was seen. No effects were found in number of exacerbations, ER-
visits, lung function, exercise capacity, and days lost from work. Inconclusive results 
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were observed on symptoms other than dyspnoea, doctor and nurse visits, the use of 
courses of oral corticosteroids and antibiotics, and the use of rescue medication.  
Positive effects of self-management education were detected on health care utilisa-
tion. Whereas a decrease in the number of patients with one or more hospital 
admissions and a reduction in doctor and nurse visits for lung disease were seen, an 
increase in the use of oral steroids and antibiotics was detected. However, only the re-
duction in hospital admission reached statistical significance. In the majority of the 
studies included in the meta-analyses, action plans for self-treatment of exacerbations 
were assessed. Self-management education including the use of action plans might 
possibly lead to more and better self-treatment of exacerbation with a perhaps quicker 
initiation of courses of prednisolone and antibiotics. By starting early treatment, this 
might explain the trend towards a reduction in unscheduled doctor and nurse visits 
and the severity of exacerbations. As a consequence, hospital admissions will decrease. 
However, it should be emphasized that in this review, apart from a reduction in hospi-
talisations, no more direct indications are found for a reduction of severe exacerbations 
by a self-management education programme. Subgroup analyses with regard to the use 
of action plans, could not be performed because of a lack of power. The effects of action 
plans have been considered in a Cochrane review (25). As in our review, evidence was 
seen of an increased use of courses of prednisolone and antibiotics. The authors con-
cluded that the action plans aided the patients in recognising and responding to their 
exacerbations through the self-initiation of medication. However, because of insuffi-
cient data, clinical recommendations could not be drawn.  
 A significant improvement was seen in HRQoL. However, this improvement was 
too small to be clinically relevant. On the out-come ‘days lost from work’ no effect was 
found. Because the age profile of many COPD-patients is relatively old, they represent 
a population which is generally retired, and as such this might not be a relevant out-
come. Since in most COPD studies a minority of the patients undertake paid work, 
probably restricted activity days, indicating days in which the normal activities are im-
paired by the disease, would be a better outcome measure. Restricted activity days 
were used as an outcome in the studies by Blake (12) and Monninkhof (20), but no 
clinically relevant differences were found. 
For lung function, we did not expect to find an effect of self-management educa-
tion. The accelerated decline in pulmonary function in COPD-patients is very difficult 
to modify, even with maintenance pharmacotherapy (26). Inconclusive results were 
also observed for COPD symptoms. Although no differences in symptoms of cough 
and sputum were seen, a small but significant reduction in dyspnoea was detected. 
Perhaps, education results in a reduction of fear of becoming short of breath during 
activities in daily life. As a result patients might experience less dyspnoea during activi-
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ties. Self-management education did reduce the need for rescue medication, which 
supports the reduction in breathlessness. However, use of rescue medication was 
measured in only one study, so the evidence for this observation is weak.  
Finally, exercise capacity did not change as a result of self-management. In all stud-
ies that reported exercise capacity as an outcome, an exercise programme was included 
in the intervention, although this was not often an obligatory component of the inter-
vention. Thus it was not clear how many patients really participated in an exercise 
programme. 
A reduction in hospitalisations by self-management education will probably posi-
tively influence the cost-effectiveness of self-management education programmes. Until 
now only two self-management studies (2;20) were evaluated with regard to cost-
effectiveness, but only one (2) appeared to show that self-management programmes are 
cost-effective. Cost-effectiveness analyses should be performed alongside RCTs in the 
future. 
 The review also identified a number of limitations in the current published litera-
ture that need to be considered: 
1. The studies assessed a broad spectrum of outcome measures. Often meta-analyses 
could not be performed because included studies used different outcome measures 
or calculated the same outcome (e.g. ER-visits) in different ways (e.g. mean number 
of visits versus percentage of patients with ER-visits). Such lack of availability of 
data hampered statistical combination and therefore may have biased the estimates 
in the review. Furthermore, establishing disease-specific events was challenging. 
Doctor and nurse visits were described in seven articles, but only two studies pre-
sented the number of visits related to lung diseases. In the other studies no further 
specification of this outcome was provided. Efforts to obtain detailed event data 
from COPD studies are hampered in part by communication difficulties with study 
investigators, and partly because of the influence of co-morbidities which are clini-
cally hard to distinguish. In this review, we have only presented disease-specific 
event-data when these were reported by the individual authors. In future studies, 
more clarity about the specification of this outcome should be strived for. 
2. Variable follow-up. Eight studies followed patients for 12 months, whereas the fol-
low-up of the other six ranged from 2 to 10 months. Because self-management 
education programmes are intended to achieve behavioural changes, differences in 
outcomes should still be measurable after a long-term follow-up. It would be very 
interesting to perform subgroup analyses with regard to follow-up time, however 
these could not be performed because of a lack of power. 
3. The COPD-population was defined in varying detail, and studies used very diverse 
inclusion criteria. Three studies only included patients with a history of hospital 
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admissions or frequent exacerbations (2;14;19), whereas others included practically 
all patients with a diagnosis of COPD (17;23). As a result, heterogeneity in disease 
severity was present. Because of a relatively small number of studies and a small 
overlap in outcome measures, subgroup analysis with regard to the severity of the 
population was not possible. The heterogeneity in the study population might pos-
sibly explain the contradictory results between specific studies (e.g. Bourbeau (2) 
versus Monninkhof (20)). 
4. There was variation in intervention. In addition to education, some studies added 
action plans and/or exercise programmes to the self-management programmes. The 
type and intensity of education also varied from group education, individual educa-
tion, to written education material only. With regard to exercise programmes, 
extensive evidence is available that pulmonary rehabilitation is effective (8) and 
there are also data that support the effectiveness of some out-patient exercise pro-
grammes (27). However, the effects of exercise programmes within self-
management programmes remain unclear. In four studies (2;13;20;21) exercise pro-
grammes were included. These programmes did not (always) meet the standards of 
rehabilitation (e.g. proper structure, frequency and intensity of supervised training 
sessions) and non-participation was not a criterion for study withdrawal, which has 
implications for the consistency of treatment offered within treatment groups. Fu-
ture studies have to be performed to achieve more clarity about the appropriate 
content of exercise programmes within self-management programmes. However the 
above mentioned factors should certainly be improved. Besides an improvement in 
physical condition, behavioural change with regard to exercise should also be an 
important goal. In our opinion the training period should be long enough to make 
the shift from exercising with the physiotherapists to exercising at home (at least six 
months), and home exercise sessions should become a part of the programme (next 
to the supervised sessions with the physiotherapist).  
5. Studies were conducted over a period of 18 years, during which time changes in the 
educational content, the mode of delivery, and background therapy are likely to 
have occurred. In the last few years, improving self-management skills or behav-
ioural change has become increasingly important. Whereas almost no attention was 
given to behavioural change in the older studies, four of the six studies (2;3;15;21) 
published in the last four years were clearly aimed at changing behaviour. Knowl-
edge of the disease does not directly implicate behavioural change. In our opinion 
core-elements of behaviour change (e.g. enhancing self-efficacy expectations or so-
cial support) should be implemented in the self-management educational 
programmes. A theoretical model of behaviour and behavioural change, for exam-
ple the ASE-model (28), can be very helpful in designing a self-management 
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programme. Furthermore, experiences gained within existing programmes have to 
be used for designing new ones. Therefore, not only results of studies should be 
published, but solutions for logistic problems should also be described (e.g. the use 
of a case-manager in the study by Bourbeau (2)).  
For future research it is important to create more homogeneity in the design of studies 
(follow-up period and outcome measures). Because the content of self-management 
changes over time, it may be wise to exclude the oldest studies about self-management 
in the next update of this review. Finally, the effectiveness of the components of self-
management education programmes (i.e. education, action plans, exercise pro-
grammes) should also be evaluated.  
It can be said most confidently that self-management education is associated with a 
reduction in hospital admissions with no indication for detrimental effects in other out-
come parameters. This would in itself suffice to justify a recommendation of self-
management education in COPD. However, due to heterogeneity in interventions, 
study populations, follow-up time, and outcome measures, data are still insufficient to 
formulate clear recommendations regarding the form and contents of self-management 
education programmes in COPD. There is an evident need for more large RCTs with a 
long-term follow-up of at least one year, before more conclusions can be drawn. 
 
Authors’ conclusions 
Implications for practice Self-management education is associated with improvement 
in quality of life (as measured by the SGRQ) and a reduction in hospital admissions 
with no indications of detrimental effects in other outcome parameters. However, be-
cause of heterogeneity in interventions, study populations, follow-up time, and 
outcome measures, data are still insufficient to formulate clear recommendations re-
garding the form and contents of self-management education programmes in COPD. 
Clear benchmarks need to be specified by authoritative bodies about outcome meas-
ures and length of such studies. 
 
Implications for research Future studies with sufficient sample size and longer follow-
up time should focus on: 1) acquisition of self-management skills and behavioural 
change; and 2) the definition of the effective elements of self-management programmes. 
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Table 1  Characteristics of included studies 
Study Blake 1990 
Methods RCT; FUP=12 m; control: usual care. 
Participants Eligible:109; randomised: 94; completed: 83 
Mean age: I: 63 (SD:?) yrs C: 64 (SD:?) yrs; Sex (% male): I: 80% C: 82%; FEV1%pred: ?; 
FEV1/VC: I: 46% C: 43% 
Inclusion: diagnosis COPD: respiratory symptoms + abnormal pulmonary function 
(Daily cough and/or shortness of breath over the preceding six months; FEV1/VC < 
75 % or FVC% pred < 75%). 
Recruitment: outpatients 
Major exclusions: -   
Interventions Mode: individual education + patient brochure + audiotape. 
Content: stress management; relaxation exercise; meditation; guided imagery fo-
cusing on breathing; social and recreational activities; communication skills. 
Duration: 1-4 hrs. 
Action Plan: N 
Outcomes Health status: SIP; hospital days; bed-disability days; restricted-activity days; physi-
cian visits. 
Notes Follow-up data for 6 and 12 months; 19% never smokers 
Allocation  
concealment 
D-not used 
Study Bourbeau 2003 
Methods RCT; FUP=12 m; control: usual care. 
Participants Eligible: 469; randomised: 191; completed: 175 
Mean age: I: 69.4 (6.5) yrs; C: 69.6 (7.4) yrs; Sex (% male): I: 52% C: 59% 
Inclusion: stable COPD with at least one hospitalisation for an exacerbation in 
preceding year; Age =>50 yrs; packyrs => 10; FEV1% pred (post): 25-70%; FEV1/VC 
< 70 
Recruitment: outpatients 
Major exclusions: no previous diagnosis of asthma or left congestive heart failure, 
terminal disease, dementia, uncontrolled psychiatric disease; no pulmonary rehab 
< 1 yrs ago; no long term facility stays. 
Interventions Mode: Individual sessions by an experienced health professional at the patients' 
home. Content: COPD knowledge, breathing and coughing techniques, energy 
conservation during day-by-day activities, relaxation exercises, preventing and 
controlling symptoms through inhalation techniques, understanding and using plan 
of action for acute exacerbations, adopting a healthy lifestyle, leisure activities 
and travelling, a simple home exercise programme, long term oxygen therapy 
when appropriate. Duration: 7-8 week * 1 hour; first two months weekly telephone 
calls, from then once a month a telephone call. 
Exercise evaluation (not mandatory) + exercise teaching. Duration: 3 times a week 
for 30-45 minutes. 
Action Plan: Y 
Outcomes Health status: SGRQ; exacerbations; spirometry: FEV1 (L), forced vital capacity; 
hospital admissions; symptoms; ER visits; outpatients visits; walking distance: 6MWT. 
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Notes Gadoury 2005 presents 2 year data from the Bourbeau study. One outcome was 
analysed: hospital admissions all causes (I: n=91 en UC: n=84). 
Allocation  
concealment 
A-adequate 
Study Boxall 2003 
Methods RCT; FUP=12 weeks; control: usual care. 
Participants Eligible: not clear; Randomised: 60; Completed: 46 
Mean age: I: 77.6 (7.6) yrs; C: 75.8 (8.1) yrs; Sex (% male): I: 47.8; C: 65.2 
FEV1% pred:?; FEV1/VC:? 
Inclusion: diagnosis of COPD by a hospital respiratory specialist; age > 60 years; 
dyspnoe or exertion; live locally; motivated to exercise daily unsupervised; stable 
for two weeks; functionally housebound 
Major exclusions: attending outpatient based pulmonary rehabilitation; restricted 
shoulder movement; living in nursing home; previous lung volume surgery; pain 
limiting mobility. 
Interventions Mode: Exercise programme consisting of walking (level 1-10) and arm exercises 
(level 1-18) + education sessions. 
Content: Patients were required to carry out exercises once daily. Weekly physio-
therapy sessions were scheduled for the first 6 weeks, and then fortnightly visits were 
made until week 12. Visits were used to monitor exercise performance, progress 
exercises, retest (6MWT), and provide encouragement to patients. Educational 
sessions at home were conducted for patients and carers by physiotherapists, oc-
cupational therapists and nurses. Those sessions covered: anatomy and physiology 
of the lungs, use of respiratory devices, medications, breathing techniques (during 
exercises), secretion removal techniques, energy conservation, use of adaptive 
aids, and stress management. Number of visits depended on: patients comprehen-
sion and skill acquisition (approximately 6 a week). Duration: not mentioned 
Frequency (mean): I: 10,8 (3,82); C: 7,0 (3,46) only measurements? 
Action plan: N 
Outcomes Health status: SGRQ; walking distance: 6 MWT; hospital admissions; average length 
of stay (days);  dyspnoea; Borg scale. 
Notes Baseline characteristics are only given of the group patients who completed the 3-
month follow-up period. The intervention group began their programme immedi-
ately, whereas the control group had a 12 week delay before commencing an 
identical programme. 
Allocation  
concealment 
A-adequate 
Study Cockroft 1987 
Methods RCT; FUP=10 m; control: usual care. 
Participants Eligible: 92; Randomised: 75; Completed: 73 
Mean age: I: 69 (?) yrs C: 71 (?) yrs Sex (% male): I: 69 C: 67; FEV1% pred:?; 
FEV1/VC:? 
Inclusion: diagnosis of COPD: all patients suffering from chronic respiratory disability 
that was caused mainly by chronic obstructive airways disease; at least admitted 
twice during previous 3 yrs.  
Recruitment: outpatients 
Major exclusions: disability not caused by a respiratory condition 
Interventions Mode: individual by home visits of a respiratory health worker 
Content: COPD knowledge; symptoms; coping behaviour. Duration: about 10 hrs 
Action Plan: N 
Outcomes Health Status: GHQ; hospital admissions; deaths; knowledge about medication and 
condition; VAS-scales concerning physical and psychological aspects. 
Notes - 
Allocation  
concealment 
B-unclear 
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Study Coultas 2005 
Methods RCT; FUP=6 m; Intervention nurse assisted medical management (MM) versus inter-
vention nurse assisted collaborative management (CM) versus usual care (UC). 
Participants Eligible: 217; Randomised: 217; Completed: 151 
Mean age: MM: 68.3 (6.6) yrs; CM: 70.1 (7.0) yrs; UC 68.8 (10.4) yrs; Sex (% male): 
MM: 42.9; CM: 32.7; UC: 53.8 
Inclusion: COPD related diagnosis code (International Classification of Diseases, 
Ninth revision: codes 491, 492, 496); Age > 44 yrs; current or former smoker (at least 
20 pack years); at least 1 respiratory symptom (cough, shortness of breath, wheeze) 
during the past 12 months; FEV1% pred (pre or post?): < 80%; FEV1/VC (pre or post?) 
< 70 
Recruitment: outpatients 
No exclusion criteria reported 
Interventions Mode: MM = nurse assisted medical management = enhance patient knowledge; 
CM: nurse assisted collaborative management = goals of MM + facilitating the 
adoption of healthy behaviour including life style and self-management skills. 
Content: MM: COPD, symptoms, optimal medical management, smoking cessation, 
action plan for worsening symptoms. Finally a letter was written to the patients GP 
describing the patient's status and suggestions of modifying management consis-
tent with the GOLD guidelines. Duration (mean): MM: 124 min (7 sessions); CM: 207 
min (8 sessions). 
Action plan: Y (not well described) 
Outcomes Health status: SGRQ, SF-36; perceived illness intrusiveness; doctor visits; ER visits; hos-
pital admissions. 
Notes Baseline characteristics are only given of the group patients who completed the 6-
month follow-up period. 
Drop-out percentages are high: MM: 32,0%; CM: 29,2 ; UC: 30,1% 
Patients who dropped out of the study had a more severe airflow obstruction, 
higher levels of distress, and lower quality of life compares with the patients who 
completed the study. 
Content of the interventions is not describes properly, whereas the training of the 
nurses who were providing the intervention was described in detail. 
Outcome measures self-efficacy, social support, the BSI-18 and the CES-D score 
were measured but not reported in the article. 
Allocation  
concealment 
A-adequate 
Study Emery 1998 
Methods RCT; FUP= 2 m; control: usual care. 
Participants Eligible: 92; Randomised: 50; Completed: 49 
Mean age: I: 67 (6) yrs C: 67 (6) yrs; Sex (% male): I: 42 C: 48; FEV1%pred: I: 43 (18) C: 
39 (16); FEV1/VC:? 
Inclusion: Diagnosis of COPD: stable COPD; > 50 yrs; FEV1/VC<70; > 6 months clinical 
symptoms of COPD. 
Recruitment: outpatients + GP-patients + advertisements + word of mouth 
Major exclusions: significant cardiac disease; other diseases affecting exercise toler-
ance or learning skills last 3 months; asthma without fixed obstruction. 
Interventions Mode: group education 
Content: COPD knowledge; therapy; coping; interpreting pulmonary function tests; 
understanding of arterial blood gases; stress management. Duration: 26 hrs 
Action Plan: N 
Outcomes Health status: SIP, HRQoL-MHLC; health knowledge test; FEV1%pred. 
Notes The third arm was disregarded, because it was focussed on pulmonary rehabilita-
tion. 
Allocation  
concealment 
A-adequate 
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Study Gallefoss 1999 
Methods RCT; FUP=12 m; control: usual care. 
Participants Eligible: 68; Randomised: 62; Completed: 53 
Mean age: I: 57 (9) yrs C: 58 (10) yrs; Sex (% male): I:48 C: 52; FEV1%pred: I:59 (9) C: 
56 (11); FEV1/VC: I: 55(9) C:52(10) 
Inclusion: diagnosis of COPD: FEV1pred>= 40% and FEV1pred<80% 
Recruitment: outpatients 
Major exclusions: any serious disease 
Interventions Mode: patient brochure + group sessions 
Content: COPD knowledge; medication; symptoms; exacerbations; inhalation tech-
nique; smoking cessation; relaxation; coping. Duration: max 6.5 hrs 
Action Plan: Y 
Outcomes Health status: SGRQ, hospital admissions, days lost from work, GP-consultation, 
FEV1%pred 
Notes - 
Allocation  
concealment 
A-adequate 
Study Gourley 1998 
Methods RCT; FUP= 6 m; control: usual care 
Participants Eligible: 193; Randomised: 128; Completed: 98 
Mean age: I: 69 (6) yrs C: 69 (9) yrs 
Sex (% male): I: 100 C:100 
FEV1%pred:?; FEV1/VC:? 
Inclusion: diagnosis of COPD: COPD ATS criteria; at least one MDI; > 40 yrs 
Recruitment: outpatients 
Major exclusions: life expectancy < 6 months; hospitalisation or ER-visits during past 2 
wks; lung infection past 2 wks; decompensated CHF class 3 or 4; other lung disease 
except for asthma. 
Interventions Mode: individual verbal education 
Content: COPD knowledge; therapy; coping. Duration: 3 hrs 
Action Plan: N 
Outcomes Health status: HSQ2; patient satisfaction; disease knowledge; disease management 
knowledge; control of disease; symptoms; hospital admissions; ER-visits; use of other 
health care facilities. 
Notes - 
Allocation  
concealment 
D-not used 
Study Howland 1986 
Methods CCT; FUP=12 m; control: usual care. 
Participants Eligible: 923; Randomised: 659; Completed: 538 
Mean age: I: 59 (?) yrs C: 60 (?) yrs; Sex (% male): I: 54% C: 51%; FEV1%pred: ?; 
FEV1/VC: ? 
Inclusion: diagnosis COPD: presence of COAD; FEV1/FVC< 60% or between 60-70% 
with chronic symptoms of cough, wheezing or breathlessness 
Recruitment: community patients 
Major exclusions: - 
Interventions Mode: group education (one for the mildly and one for the severely impaired pa-
tients) 
Content: Severe group: COPD knowledge; nutrition; exercise; smoking cessation; 
Mild group: emphasized prevention and impairment e.g. smoking cessation, building 
and maintaining physical endurance and reducing stress 
Duration: Severe group=12 hrs ; Mild group = 6 hrs 
Action Plan: N 
Outcomes Health status measured by a self designed questionnaire; FEV1%pred. 
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Notes They assessed a severe and a mild group of patients 
Allocation  
concealment 
D-not used 
Study Littlejohns 1991 
Methods RCT; FUP= 12 m; control: usual care 
Participants Eligible: 166; Randomised: 152; Completed: 133 
Mean age: I: 63 (8) yrs C: 63 (7) yrs; Sex (% male): I: 67 C: 63 
Inclusion: diagnosis of COPD: previously documented chronic airflow obstruction; 30-
75 yrs; FEV1%pred < 60%; stable state 
Recruitment: outpatients 
Major exclusions: other major disease; change in medication at least six weeks be-
fore recruitment 
FEV1%pred: I: 45 (22) C: 50 (23) 
FEV1/VC:? 
Interventions Mode: individual by respiratory health worker 
Content: COPD knowledge; inhalation technique; impairment, disability and handi-
cap. Duration: ? 
Action Plan: N 
Outcomes Health status: SIP; number of exacerbations; courses of oral steroids; courses of anti-
biotics; hospital admissions; FEV1% pred; exercise capacity: 6MW 
Notes - 
Allocation  
concealment 
A-adequate 
Study Martin 2004 
Methods RCT; FUP=12 m; control: usual care. 
Participants Eligible: ?; Randomised: 96; Completed: 80 
Mean age: I: 71.1 (range: 68.7-73.5); C: 69.1 (range: 63.5-74.7); Sex (% male): I: 34.1; 
C: 65.3; FEV1% pred:? / FEV1/VC:? 
Inclusion: diagnosis of COPD: moderate to severe (GOLD); age > 35 yrs; at least 1 
hospital admission or two acute exacerbations during last 2 months; Mini Mental 
State Examinations > 22; Major exclusion: terminally ill; coexisting lung cancer; admis-
sion to hospital with cardiac disease within previous year; receiving home oxygen 
therapy 
Interventions Mode: Individualised care plan based on an interview between the patient and the 
respiratory nurse. 
Contents: Instructions regarding: time of interventions such as inhaled / nebulized 
bronchodilator, corticosteroids and antibiotics in relation to the onset of detoriating 
symptoms, use of oxygen and diuretics; use of the care plan. The use of the plan was 
commenced at the time when each patient was in a stable condition. During the 
12-month period all patients were visited by a respiratory nurse at the study start and 
after 3, 6, and 12 months. Duration of visits: ? 
Action plan: Y 
Outcomes Health status: SGRQ; utilisation of health care: GP visits, ambulance calls (interpreted 
as emergency department visits), hospital admissions; medication: courses of oral 
steroids, courses of antibiotics. 
Notes - 
Allocation  
concealment 
B-unclear 
Study Monninkhof 2003 
Methods RCT; FUP= 12 m; control: usual care. 
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Participants Eligible: 615; Randomised: 248; Completed: 236 
Mean age: I: 65 (7) yrs C: 65 (7) yrs; Sex (% male): I: 85% C: 84% 
Inclusion: diagnosis of stable COPD (ATS); age 40-75 yrs; current or former smoker; 
FEV1% pred (pre): 25-80%; FEV1/VC (pre): < 60; reversibility =< 12% pred; TLC > TLC 
pred (1.64*sd) 
Recruitment: outpatients 
Major exclusions: no previous diagnosis of asthma; exacerbation in the months prior 
to inclusion; medical condition with low survival or serious psychiatric morbidity; any 
other lung disease; maintenance treatment of oral steroids or antibiotics. 
Interventions Mode: group education by respiratory nurse. Content: COPD knowledge; inhalation 
technique; importance of exercise; relaxation; nutrition; coping with breathlessness; 
ergonomic posture and energy conservation during daily activities or work; commu-
nication and social relationships; guidelines for self-treatment for exacerbations 
(action plans). Duration: 5 * 2h 
A fitness programme was aimed at coping with disease, recognising their individual 
capacity, social interactions and behavioural change. Duration 1-2 a week for 30-45 
min. 
Action Plan: Y 
Outcomes Health status: SGRQ, EuroQol; self-confidence; walking distance: 6 MWT; exacerba-
tions; symptoms; doctor consultations; hospital admissions; symptoms; days lost from 
work 
Notes - 
Allocation  
concealment 
A-adequate 
Study Rea 2004 
Methods RCT; FUP=12 m; control: usual care. 
Participants Eligible: 158; randomised: 135; completed:117 
Mean age of both groups: 68 yrs (range 44-84); Sex (% male) of the whole study 
populations: 41.5 
Inclusion: a diagnosis of COPD by ICD-9-CM codes and GP-records for a clinical 
diagnosis of moderate to severe COPD. 
Major exclusions: chronic asthma; bronchiectasis; comorbidity more significant than 
COPD; unable to give informed consent; prognosis< 12 months, long term oxygen 
therapy or too unwell; deceased; no longer enrolled with GP-practice or moved out; 
unable to contact patient; insufficient practice nurse. 
Interventions Mode: Timetable for regular maintenance checks and set achievable goals for 
lifestyle changes. 
Content: an action plan with detailing advice how to manage worsening symptoms, 
when to call the GP, and self-medication options decided by the GP. Information 
about smoking cessation and the use of inhalers was given. Annual influenza vacci-
nation and attendance at a pulmonary rehabilitation programme were 
recommended. Monthly visits with practice nurse, and 3-monthly with the GP. More 
visits were demanded if there was a worsening of the symptoms. Duration of visits: ? 
Action plans: Y 
Outcomes Health status: SF-36, CRQ; walking distance: ISWT; hospital admissions; spirometry: 
FEV1; medication: courses of oral steroids, courses of antibiotics; smoking cessation. 
Notes Randomisation is done at the level of GP-practice, analysis are done at patient 
levels. 
Allocation  
concealment 
A-adequate 
Study Watson 1997 
Methods RCT; FUP= 6 m; control: usual care 
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Participants Eligible: 93; randomised: 69; completed: 56 
Mean age: I: 68 (10) yrs C: 67 (8) yrs; Sex (% male): I: 62 C: 67; FEV1%pred: I: 37 (14) C: 
36 (16); FEV1/VC: I: 52 (25) C: 48 (15) 
Inclusion: diagnosis of COPD: COPD (ATS criteria) as major limiting disease; smoking 
history > 10 pack years; FEV1%pred<65%; FEV1/VC < 70 %; bronchodilator therapy 
Recruitment: GP-patients 
Major exclusions: asthma (onset < 35 yrs) as primary diagnosis; cardiac disease as 
primary diagnosis, another functionally limiting disease (except cor pulmonale) af-
fecting mortality 
Interventions Mode: action plan and patient brochure 
Content: COPD knowledge; exercise; smoking cessation; coping (controlling breath-
lessness); nutrition. Duration: < 1 hr 
Action Plan: Y 
Outcomes Health Status: SGRQ; symptoms; GP-visits; courses of prednisolone; courses of antibi-
otics; FEV1%pred 
Notes - 
Allocation  
concealment 
B-unclear 
 
Table 2  Characteristics of excluded studies 
Study Reason for exclusion 
Ashikaga (29) <1985; asthma + COPD 
Brough (30) < 1985; methodological flaws 
Brundage (31) No CCT or RCT 
Carone (32) No results 
Carriei 2005 (33) No usual care as a control group 
Chavannes (34) Review 
De Assuncao (35) No CCT or RCT; asthma 
Devine (36) No CCT or RCT: meta-analysis 
Ferrari (37) No CCT or RCT 
Gallefoss (38) No adequate outcome 
Garrod (39) Abstract only; primary focused on pulmonary rehabilitation 
Gibbons (40) No results 
Gibbons (41) No CCT or RCT 
Griffiths (42) No results for solely COPD 
Grosbois (43) No CCT or RCT; pulmonary rehabilitation 
Hausen (44) No CCT or RCT; 76% asthma 
Hausen (45) No CCT or RCT 
Janelli (46) No CCT or RCT 
Lorig (47) No CCT or RCT 
Macfarlane (48) No results for solely COPD 
Maltais (49) No usual care as a control group 
Muller (50)  No CCT or RCT; asthma + COPD group 
Murphy (51) No education included in intervention 
Murphy (52) No CCT or RCT 
Nguyen (53) No usual care as a control group 
Pande (54) No CCT or RCT 
Ries (55) Primary focused on pulmonary rehabilitation 
Sassi-Dambron (56) No usual care as a control group 
Scherer (57) No CCT or RCT 
Scherer (58) Primary focused on pulmonary rehabilitation; no adequate outcome 
Stulbarg (59) No usual care as a control group 
Toshima (60) Primary focused on pulmonary rehabilitation 
Tougaard (61) About 90% were asthma patients 
Tougaard (62) The same as Tougaard (61) 
van den Broek (63) Primary focused on pulmonary rehabilitation 
Wedzicha (64) Primary focused on pulmonary rehabilitation 
Worth (65) No CCT 
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Table 3  Numbers needed to treat (NNT) and events rates for respiratory-related 
hospitalisations 
Study ID Control % Duration NNT 
Bourbeau (2) 51 52 10 (6 to 35) 
Boxall (13) 22 12 15 (10 to 52) 
Coultas (15) 10 24 30 (20 to 100) 
Gallefoss (6) 13 52 24 (16 to 80) 
Littlejohns (18) 22 52 15 (10 to 52) 
Monninkhof (20) 13 52 24 (16 to 80) 
Rea (21) 38 52 11 (7 to 37) 
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Total (95% CI)
Heterogeneity: Chi² = 4.72, df = 6 (P = 0.58); I² = 0%
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Figure 1  Comparison self-management versus control for the SGRQ-total 
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Figure 2  Comparison self-management versus control for the SGRQ-impacts 
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Study or Subgroup
Bourbeau 2003
Boxall 2005
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Figure 3  Comparison self-management versus control for the SGRQ-symptoms 
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Figure 4  Comparison self-management versus control for the SGRQ-activity 
 
 
Study or Subgroup
Bourbeau 2003
Boxall 2005
Coultas 2005a
Coultas 2005b
Gallefoss 1999a
Littlejohns 1991
Monninkhof 2003
Rea 2004
Total (95% CI)
Total events
Heterogeneity: Chi² = 4.35, df = 7 (P = 0.74); I² = 0%
Test for overall effect: Z = 2.68 (P = 0.007)
Events
31
5
6
5
3
12
15
18
95
Total
96
23
49
51
31
68
127
83
528
Events
48
5
3
2
4
14
16
20
112
Total
95
23
26
25
31
65
121
52
438
Weight
35.7%
4.3%
3.8%
2.6%
3.9%
12.9%
15.8%
21.0%
100.0%
M-H, Fixed, 95% CI
0.47 [0.26, 0.84]
1.00 [0.25, 4.06]
1.07 [0.24, 4.68]
1.25 [0.23, 6.94]
0.72 [0.15, 3.54]
0.78 [0.33, 1.84]
0.88 [0.41, 1.87]
0.44 [0.21, 0.95]
0.64 [0.47, 0.89]
Treatment Control Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Figure 5  Comparison self-management versus control for the respiratory-related hospital admissions 
 
 
Review on self-management in COPD 
 - 45 - 
 
Figure 6  Ten high risk patients (51% risk of admission without treatment) treated with self-management  
education prevented one hospital admission over one year 
 
 
 
Figure 7  Twenty-four low risk patients (13% risk of admission) treated with self-management education 
prevented one admission over one year 
Chapter 2 
 - 46 - 
Study or Subgroup
1.19.1 doctor and nurse visits: mean number per person per year
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Coultas 2005a
Coultas 2005b
Gallefoss 1999a
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Watson 1997
Subtotal (95% CI)
Heterogeneity: Tau² = 1.04; Chi² = 13.36, df = 5 (P = 0.02); I² = 63%
Test for overall effect: Z = 0.03 (P = 0.98)
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Subtotal (95% CI)
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Test for overall effect: Z = 1.74 (P = 0.08)
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Figure 8  Comparison self-management versus control for the doctor and nurse visits (mean number per 
person) 
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Abstract 
COPD is a chronic disease with high prevalence and quickly increasing incidence rates. 
A large part of the burden of the disease is due to exacerbations which cause about two 
thirds of all costs. We evaluated the effect of self-treatment (ST) of COPD exacerbations 
on the severity of exacerbations during one year. In addition, a cost-effectiveness analy-
sis was performed.   
 Patients were randomly allocated to four two-hour self-management sessions, with 
or without training in ST of exacerbations. Patients in the ST group (STG) received an 
action plan with the possibility to initiate a prednisolone course (with or without anti-
biotics). During follow up all participants kept a daily symptom diary. These provided 
the data to calculate the frequency of exacerbations, the number of exacerbation days 
and mean daily severity scores.  
 Data were analysed of 142 randomised patients (STG: n=70; control group (CG): 
n=72). The frequency of exacerbations was identical in both study groups (mean 3.5). 
Patients in the STG had fewer exacerbation days (median STG: 31; CG: 40). The mean 
severity score of an exacerbation day was 5.1 in both groups. No between-group differ-
ences were found in health related quality of life. Cost-effectiveness analyses showed a 
dominant ST strategy with lower probabilities for hospitalisations (num-
ber/patient/year: STG: 0.20 versus CG: 0.33) and health care contacts (number/ 
patient/year: STG: 5.37 versus CG: 6.51), combined with cost savings (€154 per patient). 
 We conclude that ST of exacerbations incorporated in a self-management pro-
gramme leads to less exacerbation days and lower costs. 
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Introduction 
The course of chronic obstructive pulmonary disease (COPD) is characterised by epi-
sodes of acute deterioration in respiratory health, termed ‘exacerbations’. These 
exacerbations account for much of the morbidity, mortality, and hospital admissions in 
COPD patients (1). The majority of all costs in COPD patients are related to the treat-
ment of acute exacerbations, with the costs of hospitalisations being the major 
component (2). 
 Patients seem to be capable of identifying warning signs and symptoms of exacer-
bations (3), but they often do not report an exacerbation to their physician and are 
therefore potentially delaying treatment (1;4). Proper guidelines for self-treatment (ST) 
of exacerbations might help to induce prompt treatment of exacerbations, thereby ac-
celerating recovery and reducing the risk of hospitalisation (4). Therefore, ST of 
exacerbations has the potential to reduce their severity and associated costs. 
 Until today, there is no consensus about the exact definition of a COPD exacerba-
tion let alone its severity. Several frequently quoted definitions of exacerbations are 
based on respiratory symptoms (1;5), and therefore the number and length of exacerba-
tions can be defined by using daily symptom scores (1). Severity of exacerbations is 
often characterized by type of health care consumption (e.g., courses of steroids, hospi-
talisations) (6), but the number of exacerbation days in combination with daily 
symptom scores as a measure of severity, might be a more precise alternative. Because 
in most COPD patients the presence of symptoms is more the rule than the exception, 
using the change in level of symptoms relative to baseline instead of the absolute level 
could increase the accuracy of the outcome measurement even more (4).  
 We evaluated the effects of ST of exacerbations within a self-management pro-
gramme in a randomised study: the COPE-II study. The severity of exacerbations (total 
number of exacerbation days combined with the average daily severity score) was as-
sessed by determining change relative to baseline in daily symptoms during a one-year 
follow-up. In addition a cost-effectiveness analysis was performed.   
 
Material and methods  
Patients 
From November 2004 through July 2006, 159 patients were recruited from the outpa-
tient department of pulmonary medicine of Medisch Spectrum Twente hospital at 
Enschede, the Netherlands. Patients had to meet the following criteria; 1) a clinical di-
agnosis of COPD according to the GOLD criteria (6); 2) no exacerbation in the month 
prior to enrolment; 3) > 3 exacerbations, defined as respiratory problems that required a 
course of oral corticosteroids and/or antibiotics, or > 1 hospitalisation for respiratory 
problems in the two years preceding study entry; 4) (ex) smoker; 5) age 40-75 years; 6) 
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post-bronchodilator FEV1 25%-80% of predicted; 7) able to understand and read Dutch; 
and 8) written informed consent from the subject prior to participation. Patients were 
excluded if they had: 1) serious other disease with a low survival rate; 2) other diseases 
influencing bronchial symptoms and/or lung function (e.g., cardiac insufficiency, sar-
coidosis); 3) severe psychiatric illness; 4) uncontrolled diabetes mellitus during a COPD 
exacerbation in the past or a hospitalisation for diabetes mellitus in the two years pre-
ceding the study; 5) need for regular oxygen therapy (> 16 hours per day or pO2<7.2 
kPa); 6) maintenance therapy with antibiotics; ; 7) known α1-antitrypsine deficiency; 8) 
disorders or progressive disease seriously influencing walking ability (e.g., amputation, 
paralysis, progressive muscle disease). The hospital’s medical ethics committee ap-
proved the study.  
 
Study design 
A two-by-two factorial design was used, meaning that two independent interventions 
(ST and a community-based physiotherapeutic exercise programme (COPE-active)) 
were evaluated using one design (see online repository). It was assumed that both in-
terventions do not interact with each other. This paper compares the effect of a self-
management programme including ST of exacerbations (intervention group) with a 
self-management programme only (control group). Patients receiving COPE-active 
were equally divided over the intervention and control group using a minimisation 
program (7), minimising differences between groups in gender, current smoking, FEV1 
predicted (< or > 50%), and use of inhaled corticosteroids. Measurements were per-
formed at baseline, and after 7 and 12 months.  
 
Self-management sessions and ST intervention 
Smokers were offered a three month smoking cessation program prior to the group-
allocation (8). After randomisation, all patients and their partners were offered four 
weekly two-hour small-group (approximately 5 patients) self-management sessions 
given by a respiratory nurse and a physiotherapist. The intention of the courses was to 
change the patients’ disease behaviour by increasing their knowledge, confronting 
them with consequences of specific behaviour, and supplying them with tools to deal 
with different components of their disease. Patients of the intervention group addition-
ally received training in ST of exacerbations. Four, 13, and 26 weeks after the last 
course, the respiratory nurse contacted all patients by phone to recall the items ad-
dressed during the self-management courses. Patients were supplied with a booklet 
with the content of the courses. 
 All patients were educated in completing daily diaries, in which they had to report 
whether their major symptoms (breathlessness, sputum production, sputum colour) 
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and minor symptoms (cough, wheeze, running nose, sore throat, and fever (> 38.5˚C)) 
according to Anthonisen (5) were beyond normal. At inclusion all patients received a 
‘what is normal’ card, which described their individual levels of major symptoms in 
stable health state. When patients experienced no deterioration of any of the symptoms 
listed on the diary, they could tick ‘no change in symptoms’. In other cases, they had to 
report on all the symptoms in the diary whether the level of each symptom was nor-
mal, slightly increased, or clearly increased.  
 The start of the exacerbation was defined as ‘a clear negative change in two major 
symptoms or one major and one minor symptom from baseline, for at least two con-
secutive days’. The day that the exacerbation was resolved was defined as the first day 
of: 1) three successive days that the patient had returned to his normal health state; or 
2) seven consecutive days on which patients continuously reported no or only a slight 
increase in symptoms compared to baseline, with no fever or change in sputum colour.  
 Patients in the intervention group were educated in early recognition of exacerba-
tions and in starting standardised treatment in case of an exacerbation. To this end they 
were educated in using an action plan that was linked to the daily diary. Patients in the 
control group were instructed to call the study office if they felt in need of assistance 
for any worsening of their respiratory symptoms, which normally would have 
prompted them to call their chest physician or general practitioner instead. A consulta-
tion with a chest physician was scheduled within 12 hours.    
 In case of an exacerbation (either diagnosed by the physician or by the patient from 
the action plan) a standardised intervention was initiated: prednisolone 30 mg for 
seven days, and when indicated in combination with antibiotics (amoxicillin/clavulanic 
acid (Augmentin®) 500/125 mg) three times daily for a period of seven days or (in case 
of hypersensitivity) doxycycline 100 mg daily for a period of 10 days. 
 
Outcomes 
The total number of exacerbation days was calculated by summing up all exacerbation 
days per patient per year, based on the information from the diaries. The severity of an 
exacerbation day was calculated with help of symptom scores. The major symptoms 
were scored as: normal = 0; small increase = 1; or clear increase = 2. The minor symp-
toms were scored 0, 0.5 and 1, respectively. Sputum colour was scored as: normal = 0, 
different from normal = 2; and fever: no=0, yes=1. Adding all these scores resulted in a 
daily score with a range from 0-11 points. When patients were admitted to the hospital 
a daily score of 15 points was assigned. If patients had less than 4 months of complete 
diary data, they were excluded from the analyses.  
 Health related quality of life (HRQoL) was measured with the self-administered 
Chronic Respiratory Questionnaire standardised (CRQ-SAS) (9). The questionnaire cap-
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tures four domains: dyspnoea, fatigue, emotional functioning, and mastery. A change 
of 0.5 in a domain is considered to be clinically relevant at the individual level (10). 
Health status was evaluated by the self-administrated Clinical COPD Questionnaire 
(CCQ) (11). A change of 0.4 represents the minimal important difference for an indi-
vidual patient (12). Anxiety and depression was measured with the Hospital Anxiety 
and Depression Scale (HADS) (13). This instrument produces separate scores for anxi-
ety and depression ranging from 0-21. A score over 10 is judged to be a predictor of a 
clinical diagnosis of anxiety and depression. Finally, information about hospital admis-
sions, emergency room visits, scheduled and emergency outpatients visits, phone calls 
with physicians, consultations with the general practitioner, and information about 
medication use was collected for cost-effectiveness analyses.  
 
Statistical analyses 
We calculated that 79 patients per treatment group were required to detect a difference 
of 2 exacerbation days (SD 4.5 days) with 80% power and a two-sided 0.05 α-level test. 
All statistical analyses were performed on an intention-to treat basis using SPSS version 
12.0. Between-group differences of ‘exacerbation days/year’ and ‘mean severity 
score/year’ were assessed by comparing the proportion of patients with an individual 
value larger than the median, the 75th, and the 90th percentile. Subsequently chi-square 
statistics for categorical variables were applied. Between-group differences of continu-
ous variables were assessed by analysis of repeated measurements using the SPSS 
mixed models procedure, and in case of continuous variables (number of hospitalisa-
tions, courses of prednisolone / antibiotics) by the Student T-test (normal distribution) 
or the Wilcoxon rank sum test (non-normal distribution).  
 
Cost-effectiveness 
A decision analytical model with a time perspective of 12 months was developed to 
evaluate the cost effectiveness of a self-management programme including ST of exac-
erbations versus a self-management programme only. Resource use was multiplied by 
2004 unit prices (14). Medication costs were based on market prices and included a €6 
dispensing fee and 6% VAT for each prescription. Table 1 presents the percentages, 
which are derived from the COPE-II  study, for each step in the decision analytic model 
(Figure 1). Figure 1 shows, besides the percentages of patients for each step, also the 
percentages of patients in the different branches. For example, the percentage of pa-
tients in the intervention group having at least one exacerbation (90%), one health care 
contact (100%), and one hospitalisation (17.7%) is 15.9% (90% * 100% * 17.7%). The costs 
made by a patient in this branch are €6388. These costs consists of: the costs of a self-
management course including self-treatment (€118), regular medication costs (€761), 
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Table 1  Base case values of percentages of patients with a COPD exacerbation, a hospitalisation and 
medication use for an exacerbation 
 Base case value (95% CI) 
 Self-treatment Control 
 
Patients with an exacerbation (%) 
 
90.0 (83.1 to 96.9) 
 
84.7 (76.3 to 93.1) 
 
Patients with a hospitalisation when having an exacerba-
tion and health care contact (%) 
 
17.7 (8.8 to 26.6) 
 
 
24.6 (14.7 to 34.5) 
 
 
Patients with medication use for an exacerbation when not 
hospitalised but having an exacerbation and a health care 
contact (%) 
90.8 (84.0 to 97.6) 
 
 
61.4 (50.2 to 72.6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Decision analytic model with percentages of patients with exacerbations, health care contacts, 
hospitalisations and medication for exacerbations for the self-treatment and control group 
 
health care contacts costs (€281) (Table 2), and the hospitalisation costs (€5227). In this 
branch medication for an exacerbation is incorporated in hospitalisation costs. The per-
centage of patients in each branch will finally determine the weight of the branch costs 
to the total costs / patient / study group (e.g., 15.9% * €6388). We took the perspective of 
the health care payer. The costs-effectiveness ratio was calculated as costs per exacerba-
tion day prevented, per hospital admission prevented, and per health care contact 
prevented.  
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* Includes €6 pharmacy cost and 6% VAT per prescription 
† Includes (telephone) consultations with the physician and general practitioner, and emergency room visits 
‡ Costs per hospitalisation day: €337 (includes medication costs); mean of 12.21 and 9.08 hospitalisation days 
per admission and 14 and 24 admissions for respectively the self-treatment and control group. The sum of 
€5227 for hospitalisation costs as mentioned in an example in the text are the hospitalisation costs per inter-
vention patient having at least one hospitalisation: average costs of a hospitalisation x (total number of   
hospitalisations in the intervention group / total number of intervention patients with > one exacerbation). 
** Mean of medically treated exacerbations per patient per year for respectively the self-treatment and 
control group: treatment with prednisolone and antibiotics: 2.31 versus 1.43 (€ 27,69 per exacerbation); treat-
ment with solely prednisolone: 0.93 versus 0.82 (€7.79 per exacerbation); and treatment with solely 
antibiotics: 0.21 versus 0.27 (€19.90 per exacerbation) 
 
 For sensitivity analysis a Monte Carlo simulation with 1000 iterations was per-
formed to evaluate the relative impact of likely variations in the parameters in the 
decision analytical model. Therefore, cost parameters and probabilities were varied 
simultaneously over their ranges and associated 95% CI. For the costs of health care 
contacts and hospital admissions a normal distribution was used, while for the costs of 
the self-management programme, exacerbations, and regular medication a triangular 
distribution was used. Logistic normal distributions were used for all probabilities.   
 
Results 
Of the 421 eligible patients, 80 were assigned to the STG and 79 to the control group 
(CG) (Figure 2). Between inclusion and the baseline measurements three patients 
dropped out in each group and insufficient diary data were delivered by 11 patients. 
Baseline characteristics of the remaining 142 patients are presented in Table 3, and were 
similar between both groups with respect to all measured prognostic factors. The drop  
outs (n=11) did not differ from the remaining group with respect to all factors, except  
the Medical Research Council dyspnoea scale (drop outs versus remaining patients: 2.3 
(SD 1.1) versus 3.0 (SD 1.1; p=0.04)). During the one-year follow-up, three intervention 
group patients dropped out, of which one died due to an intracerebral haemorrhage. 
Thus, 67 patients in the STG and 72 patients in the CG completed the one-year follow-
up.   
Table 2  Mean costs (€) per patient per year in patients with and without self-treatment using 2004 costs 
prices 
Costs per patient Self-treatment 
(n=70) 
Control 
(n=72) 
Difference 
Self-management courses 117.68 111.60 6.08 
Regular medication* 761.21 644.00 117.21 
Health care contacts† 
   patients with an exacerbation 
   patients without an exacerbation 
262.49 
   280.52 (90%) 
   100.21 (10%) 
366.70 
   402.94 (84.7%) 
   166.07 (15.3%) 
-104.21 
Hospitalisation costs‡ 823.24 1020.36 -197.12 
Medication for exacerbations**             75.30 51.40 23.90 
Total costs 2039.92 2194.06 € -154.14 
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Figure 2  Flow diagram of subject progress through the COPE-II study 
 
 
Table 3  Mean costs (€) per patient per year in patients with and without self-treatment using 2004 costs 
prices 
Number of patients 
 
Self-treatment 
(n=70) 
Control  
(n=72) 
Age (mean ± sd; years) 63.1 ± 7.9 63.7 ± 8.0 
Male (%) 57.1 61.1 
Smokers (%) 32.9 33.3 
Medical Research Council dyspnoea scale (mean ± sd) 2.31  ± 1.06 2.33 ± 1.14 
Lung function post bronchodilation (mean ± sd) 
     FEV1 (L) 
     FEV1 % predicted value 
     VC (L) 
 
1.44 ± 0.56 
50.7 ± 16.3 
3.64 ± 1.08 
 
1.41 ± 0.50 
49.6 ± 15.3 
3.66 ± 0.85 
Inhaled corticosteroid use (%) 88.6 84.7 
 
 The frequency of exacerbations was the same in both study groups (3.5 (SD2.7)). 
Figure 3 shows that patients in the STG had a lower total number of exacerbation days 
than patients in the CG. Differences were more notable in the group patients with a 
relatively high number of exacerbation days per year (>137 days/year (=P90 of the 
whole study population); p=0.03). The mean severity score of an exacerbation day did 
not differ between both study groups (STG: 5.1 (SD 2.4); CG: 5.1 (SD 3.0)). Additional 
analyses of the more severe exacerbation days (daily score > 6 points, which represents 
a maximum score on all major symptoms), showed a (non significant) trend towards a 
higher number of severe exacerbation days/year in the CG (median STG: 11; CG: 15; 
p=0.31).  
Eligible patients: n=421 Excluded: n=262 
Refused to participate (n=130)
Participation in other research 
projects (n=33)
Transport problems (n=22)
Other reasons (n=77)Randomisation
Withdrawn: n=3
- Co-morbidity; n=1
- Too busy; n=2
Insufficient diary data: n=7
- Not motivated; n=6 
- Not capable; n=1
Withdrawn: n=3
- Co-morbidity; n=2
- Too busy; n=1
Insufficient diary data: n=4
- Not motivated; n=2
- Died (not enough data); n=2
Self-treatment group: n=80 Control group: n=79
Baseline measurement: n=72
Withdrawn: n=0
Baseline measurement: n=70
Withdrawn: n=3
- Failure to return; n=2
- Death; n=1
One-year follow-up: n=67 One-year follow-up: n=72
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Total number of exacerbation days per year
Self-treatment group (n=70) Control group (n=72)
Mean: 42.4 (SD: 41.3) Mean: 64.5 (SD: 74.8) p<0.01*
Median: 31          Median: 40           p=0.06†
P75: 67.5                       P75: 88.3 p=0.38†
P90: 111.9 P90: 196.9 p=0.03†
* Unpaired t-test
† Chi-Square test (respectively < or > 69.4 (p75  overall) and < or > 137.2 (p90 overall))  
Figure 3  Number of exacerbation days per year for patients in the self-treatment  
and control group; the mean, median, 75th and 90th percentile of both study groups  
and the corresponding p-values for group differences are also reflected 
 
 The self-reported number of prednisolone courses was significantly higher in the 
STG (median: STG: 2.3; CG: 1.6; p<0.05), as was the number of antibiotic courses (me-
dian STG: 2.0; CG: 1.0; p<0.05). The number of hospital admissions was 14 in the STG 
and 24 in the CG (p=0.39). No between-group differences were found in the CRQ-
components, the CCQ (sub)-scores, the HAD scores, and FEV1% of predicted.  
 
Cost-effectiveness 
The 12 month costs data are presented in Table 2 and the effect data in Table 4. The ST 
strategy was dominant over the control strategy. Patient in the STG generated €2040 in 
direct medical costs versus €2194 in the CG. So, applying ST saved €154 per patient. 
The number needed to treat (NNT) to prevent one hospitalisation was 7.4, and the NNT 
to prevent one health care contact was 0.9. The results of the sensitivity analysis with 
regard to costs for hospital admissions and health care contacts are shown in Figure 4. 
The dominant outcome: a positive treatment effect in combination with saving money 
was seen in the majority of the outcomes (hospitalisations: 63.3%; health care contacts: 
49.2%). Positive effects, independent of costs, were seen in 95.1% and 74.4% of the itera-
tions for hospitalisations and health care contacts, respectively. 
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Table 4  Effects per patient per year of COPD patients receiving a self-management pro-
gramme with and without self-treatment 
Effect per patient Self-treatment 
(n=70) 
Control 
(n=72) 
Difference 
Number of exacerbation days 42.20 64.50 -22.30 
Number of hospitalisations 0.200 0.334 -0.134 
Number of health care contacts*    5.373 6.513 -1.140 
* Includes (telephone) consultations with the physician and general practitioner, and emergency room visits 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4  Results of the sensitivity analysis (1000 iterations) on cost per hospital admission prevented and costs 
per health care contact prevented. A negative € amount and a positive difference in the hospitalisations 
and health care contacts favors the self-treatment intervention. In addition the percentages of outcomes in 
every quadrant are given    
 
Discussion 
This study showed that ST of exacerbations leads to fewer exacerbation days in combi-
nation with an increase in the use of courses of prednisolone and antibiotics. No 
between-group differences in the number of exacerbations, average daily severity 
score, and HRQoL were found. Cost-effectiveness analyses showed that the ST strategy 
was dominant over (i.e. compared favourably with) the control strategy with lower 
probabilities for hospitalisations and health care contacts in the STG, combined with 
cost savings.  
 Prior to the study we hypothesised that the severity of exacerbations, defined by 
the length of the exacerbation in combination with the daily severity scores, would be 
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influenced by the ST guidelines because ST would lead to a more rapid start of treat-
ment after the early recognition of an exacerbation. A priori, we did not expect an  
effect on exacerbation frequency because ST was initiated after the onset of an exacer-
bation. Both hypotheses were confirmed by our results. Our study data showed a 
reduction of the number of exacerbation days in the STG. Remarkably this was not ac-
companied by a reduction in the mean daily severity score. A closer look suggests that 
this lack of difference in daily severity score between both study groups is, at least 
partly, explained by the fact that ST particularly reduces the number of the less severe 
exacerbation days (towards the resolution phase of the exacerbation) in the STG. As a 
consequence, the average daily severity score (total severity score / number of exacer-
bation days / patient) of the remaining days of the STG goes up. We hypothesise that 
the mean severity score in the CG was higher due to the fact that patients in this group 
experience both a higher number of more severe exacerbation days as well as a higher 
number of less severe exacerbation days. This hypothesis is supported by the (non-
significant) trend towards a larger number of more severe exacerbation days (symptom 
score > 6 points) in the control group.  
 The difference in severity of exacerbations between both study groups might have 
been underestimated. By participating in the self-management programme, patients of 
the CG might have become more aware of the negative consequences of exacerbations 
and might have contacted the hospital quicker than they were used to. Furthermore, 
because of their participation in this study, control patients experienced a very low 
threshold for contacting, and a very short delay in actually being seen by a chest physi-
cian (< 12 hours), relative to usual care practice. This all might have led to a more rapid 
start of treatment and as a consequence a less severe exacerbation.  
 All patients, so also the control group, received a self management programme. 
This increased the costs also in the control group, and raises the question whether a 
control group without self-management programme would have constituted a clearer 
design. However, a comparison between our STG and a CG receiving no intervention 
at all would probably have led to similar conclusions with regard to cost-effectiveness, 
since the favourable effects of the intervention would probably have increased further. 
Furthermore, the costs of the self-management programme (€112) were very low and 
avoiding them would therefore have saved little. 
 Similar to other studies (including COPE-I) (15), our data showed a significantly 
higher reported use of courses prednisolone and antibiotics in the STG. But since the 
number of reported courses in the STG was still lower than the actual number of exac-
erbations reported in the diaries, we are convinced that the between-group difference 
in courses is due to a underreporting of respiratory complaints to the chest physician 
by patients in the CG, rather than a reflection of overtreatment in the STG. This under-
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reporting has also been observed in several other studies (1;3;16).  
 No effects were found on HRQoL and lung function. Associations between exacer-
bation frequency and HRQoL (1;17;18) and between severity of exacerbations and 
HRQoL (17) have been demonstrated by others. Since we found no effect on exacerba-
tion frequency, a relation with changes in HRQoL or lung function was no longer 
expected.  
 In this study, change from baseline was used to define symptoms and therefore 
exacerbation severity. This method was introduced because almost all COPD patients 
always experience at least some symptoms in stable state. Using health care consump-
tion (courses of prednisolone / antibiotics) instead of this change from baseline in 
symptoms, leads to a lower number of exacerbations in both study groups. On the 
other hand, using symptoms from the diaries, but only as presence or absence (instead 
of change relative to baseline) would most likely lead to the detection of more (and 
more severe) exacerbations. Whether the use of these other definitions would also affect 
the estimates of treatment effects remains to be studied.  
 Using a 2-by-2 factorial design confers the theoretical risk of interaction between 
both interventions. However, in our opinion there are no reasons to assume an interac-
tion of a physiotherapeutic exercise program and ST of exacerbations with regard to the 
different outcomes. Since the proportion of patients receiving physiotherapy was the 
same in the CG and STG, possible (additional) effects of the COPE-active program will 
have affected both study groups and will thereby not directly influence the between-
group differences.  
 The dominance of the ST strategy was largely caused by the lower probability for 
hospitalisation in the intervention group. As expected, no significant between-group 
differences in hospital admissions were found, since this study was not at all powered 
to detect a difference in hospital admissions.  
 In summary, we conclude that ST incorporated in a self-management programme 
in COPD patients leads to less exacerbation days at lower costs, while not leading to 
overtreatment. Given the rise in prevalence of COPD, and the costs associated with 
treatment, we suggest to start implementation programmes incorporating careful in-
structions on ST as a part of self-management programmes. 
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Abstract  
Little is known about effects of community-based physiotherapeutic exercise pro-
grammes incorporated in COPD self-management programmes. In a randomised trial, 
the effect of such a programme (COPE-active) on exercise capacity and various secon-
dary outcomes including daily activity as a marker of behaviour change was evaluated.  
 All patients attended four two-hour self-management sessions. In addition the in-
tervention group participated in the COPE-active programme, consisting of a 6-month 
“compulsory” period (3 sessions/week) and subsequently a 5-month “optional” period 
(2 sessions/week). Because COPE-active was intended to change behaviour with regard 
to exercise, one session/week in both periods consisted of unsupervised home-based 
exercise training.  
 Of 153 patients, 74 intervention and 68 control patients completed the one-year fol-
low-up. Statistically significant between-group differences in incremental shuttle walk 
test-distance (35.1 meters), daily activity (1190 steps/day), and Chronic Respiratory 
Questionnaire dyspnoea-score (0.33 points) were found in favour of the intervention 
group. A (non-significant) difference of 145.8 meters was measured with the endurance 
shuttle walk test. No differences were found for other secondary outcomes.  
 This study demonstrates that a community-based physiotherapeutic exercise pro-
gramme incorporated in a self-management programme improves exercise capacity 
and the level of daily activity in COPD-patients after one year.    
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Introduction 
The natural course of COPD includes a progressive decline in functional capacity and 
health-related quality of life (HRQoL) (1) and imposes a significant burden in terms of 
disability (2) and of costs (3). Therefore, optimisation of treatment is an important goal. 
Treatment currently consists of pharmacological interventions complemented by hospi-
tal-based pulmonary rehabilitation, oxygen therapy in the more severe patients, and 
attempts at life-style interventions. Self-management programmes are regularly offered 
to COPD patients (4). These programmes are directed towards behaviour change and 
can reduce COPD-related hospital admissions (4). However, the appropriate content 
and effects of the various components of self-management programmes, education, 
skills training (e.g., inhalation technique), self-treatment of exacerbations, but also 
physiotherapeutic exercise programmes, are still unclear. Whereas there is now a firm 
evidence base for hospital-based multi-disciplinary rehabilitation programmes (5), far 
less is known about the effects of community-based physiotherapeutic exercise pro-
grammes (programmes executed by local physiotherapists of private physiotherapy 
practices). Very few of these programmes have been evaluated in randomised con-
trolled trials and therefore this intervention has not yet been demonstrated to be 
effective (6;7). An important advantage of community-based physiotherapeutic exercise 
programmes is the accessibility near home. Adequately designed and effective com-
munity-based physiotherapeutic exercise programmes would fit perfectly into self-
management programmes. The goal of community-based physiotherapeutic exercise 
programmes within self-management programmes should not only be physical pro-
gress, but also behavioural change towards exercise in daily life. So, besides having an 
adequate content with respect to intensity and frequency of the training sessions, we 
hypothesised that the training period should be long enough to make the shift from 
exercising under guidance of a physiotherapist to unsupervised exercise at home and 
that home exercise sessions should be part of these physiotherapeutic exercise pro-
grammes. We performed a randomised controlled trial of a community-based 
physiotherapeutic exercise programme (COPE-active) incorporated in a self-
management programme, compared to self management only. Effects on exercise ca-
pacity and several secondary measurements, including HRQoL and daily activity, were 
assessed after one year of follow-up.  
 
Material and methods  
Patients 
From November 2004 through July 2006, 159 patients were recruited from the outpa-
tient pulmonary clinic of Medisch Spectrum Twente hospital at Enschede, The 
Netherlands. Patients had to meet the following criteria; 1) a clinical diagnosis of COPD 
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according to the GOLD criteria (1); 2) no exacerbation in the month prior to enrolment; 
3) > 3 exacerbations, defined as respiratory problems that required a course of oral cor-
ticosteroids and/or antibiotics, or one hospitalisation for respiratory problems in the 
two years preceding study entry; 4) (ex) smoker; 5) age 40-75 years; 6) post-
bronchodilator FEV1 25% - 80% of predicted; 7) able to understand and read Dutch; 
and 8) written informed consent from the subject prior to participation. Patients were 
excluded if they had: 1) serious other disease with a low survival rate; 2) other diseases 
influencing bronchial symptoms and/or lung function (e.g., cardiac insufficiency, sar-
coidosis); 3) severe psychiatric illness; 4) uncontrolled diabetes mellitus during a COPD 
exacerbation in the past or a hospitalisation for diabetes mellitus in the two years pre-
ceding the study; 5) need for regular oxygen therapy (> 16 hours per day or  pO2<7.2 
kPa); 6) maintenance therapy with antibiotics; 7) known α1-antitrypsine deficiency; 8) 
disorders or progressive disease seriously influencing walking ability (e.g., amputation, 
paralysis, progressive muscle disease). The hospital’s medical ethics committee ap-
proved the study.  
 
Study design 
A two-by-two factorial design was used, meaning that two independent interventions 
(self-treatment of exacerbations and a community-based physiotherapeutic exercise 
programme) were evaluated using one design (see online repository). This paper com-
pares the effect of a self-management programme including COPE-active (intervention 
group) with a self-management programme only (control group). Patients receiving 
guidelines for self-treatment of exacerbations were equally distributed over the inter-
vention and control group. It was assumed that both interventions would not interact 
with each other. Patients were randomised into two study groups, using a minimisa-
tion program (8), minimising differences between groups in gender, current smoking, 
FEV1 predicted (< or > 50%), use of inhaled corticosteroid, and current participation in 
a regular physiotherapy programme. In the month after the baseline measurements 
self-management courses were offered to all patients, followed by the start of the 
COPE-active programme in the intervention group in the second month. During the 
whole study period, patients in the control group were allowed to attend regular 
physiotherapy sessions if this was prescribed as part of regular care. Measurements 
were performed at baseline, and after 7 and 12 months.  
 
Self-management sessions 
Smokers were offered a three month smoking cessation programme prior to the group-
allocation (9). After randomisation, all patients and their partners were offered four 
weekly two-hour small-group (approximately 5 patients) self-management sessions 
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given by a respiratory nurse and a physiotherapist. The intention was to change pa-
tient’s disease behaviour by increasing their knowledge, confronting them with 
consequences of specific behaviour, and supplying them with skills to deal with differ-
ent components of their disease. Four, 13, and 26 weeks after the last course, the 
respiratory nurse contacted the patients by phone with the goal to recall the items ad-
dressed during the self-management courses. Patients were supplied with a booklet 
with the content of the courses.  
 
COPE-active programme 
For the development of the COPE-active programme the most problematic activities of 
a sample of 15 COPD patients were identified with help of the Canadian Occupational 
Performance Measure (10) and subsequently incorporated in the programme: bicycling, 
walking, climbing stairs, and lifting weights. Exact descriptions of the different training 
activities and the used training schemes can be found in the online repository (see 
online repository). Home exercises included: walking or cycling, and strength exercises 
for the upper and lower extremities.  
 The 16 participating private physiotherapy practices were situated in the catchment 
area of our hospital. All physiotherapists had already attended a national COPD course 
prior to the COPE-II study and were experienced in caring for COPD patients. As start 
of this study, they had to participate in an addition three-session course (11 hours in 
total) to refresh their knowledge about COPD in general and to standardise the content 
of the COPE-active-program. At baseline, we provided detailed information about the 
individual patient to the respective physiotherapist: results of the incremental maximal 
cycle ergometry test, incremental shuttle walk test, lung function, and fat free mass. In 
this way, training intensity of the COPE-active programme could be tailored to the in-
dividual.  
 The 11-month training period per patient was divided in two parts: a ‘compulsory’  
6-month and a subsequent optional but recommended 5-month period. Besides im-
provement of physical condition in the first period and preservation of these gains in 
the second period, behaviour change towards exercise was strived for during the whole 
period. Frequency of training sessions (first period: 3 times/week; second period: 
2 times/week) and intensity of the exercises within the programme are in line with the 
latest rehabilitation recommendations (11). We replaced one training session under 
guidance of the physiotherapist by an unsupervised home-based exercise training ses-
sion to facilitate behaviour change towards exercise. Training was given in small 
groups (2-3 patients). 
 For the home-based sessions, a diary including training information and illustra-
tions of how to perform the exercises was provided to increase the patient’s compliance 
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with the programme. Patients had to record whether they had executed these exercises, 
their feelings during the exercises, and their fatigue afterwards. Besides evaluation of 
the appropriateness of the training intensity of the different home-based exercises, 
physiotherapists went through the diaries with the patients every week.  
 
Outcome measures 
The primary outcome was maximal exercise capacity measured with the incremental 
shuttle walk test according to the protocol of Singh et al (12) using a 10-minute course. 
A practice walk was performed before the baseline measurement. The minimal impor-
tant difference for individual change is 47.5 meters (13).  
 Endurance capacity was measured with the endurance shuttle walk test using a 
10-minute course (14) and a walking speed of 85% of the maximal incremental test 
walking speed. HRQoL was measured with help of the self-administered Chronic Res-
piratory Questionnaire standardised (CRQ-SAS) (15). The minimal important 
difference for individual change is 0.5 per domain (dyspnoea, fatigue, emotional func-
tioning, mastery) (16). Health status was evaluated by the self-administrated Clinical 
COPD Questionnaire (CCQ) (17). A change of  0.4 represents the minimal important 
difference at individual level (18). Anxiety and depression was measured with the 
Hospital Anxiety and Depression Scale (HADS) (19). This instrument produces sepa-
rate scores for anxiety and depression ranging from 0-21. A score over 10 is judged to 
be a predictor of a clinical diagnosis of anxiety and depression. Body composition was 
estimated using single-frequency bioelectrical impedance analysis (Bodystat 1500, 
Bodystat Ltd., Douglas, Isle of Man, UK). Fat free mass was calculated from COPD- and 
gender specific regression equations (20). Finally, daily activity was assessed by the 
Yamax Digi-Walker SW-200 (Tokyo, Japan) during 7-day periods at baseline, 7, and 
12 months.   
    
Statistical analyses 
We calculated that 64 evaluable patients per treatment group would be required to de-
tect a difference of 50 meters (SD 100 m) on the incremental shuttle walk test between 
both groups with 80% power and a two-sided 0.05 α-level test. All analyses were per-
formed on an intention-to-treat principle. Between-group differences in continuous 
variables over time were assessed by analysis of repeated measurements using the 
SPSS procedure for mixed models (version 12.0). Baseline values were subtracted from 
follow-up values to correct for baseline differences. Additional analyses were per-
formed using Chi-square statistics for categorical variables. 
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Results 
Of the 421 eligible patients, 159 patients were assigned to the intervention (n=80) or the 
control group (n=79) (Figure 1). Between the inclusion and the baseline measurements 
three patients dropped out in each study group (Figure 1). Table 1 shows the baseline 
characteristics of the remaining 153 patients. The study groups were similar with re-
spect to all measured prognostic factors. During the year after the baseline 
measurements, three patients dropped out in the intervention group, as did eight pa-
tients in the control group (see Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
Figure 1  Flow diagram of subject progress through the COPE-II study 
The three patients who dropped out of the intervention group during the one-year fol-
low-up all dropped out directly after the baseline measurements before the start of 
COPE-active. In addition seven patients assigned to the intervention group refused to 
participate in the COPE-active programme (transport problems (n=2); too busy (n=3); 
disagreement with protocol (n=1); co-morbidity (n=1)) but they completed the follow-
up measurements. So, 67 patients (87.0%) participated in the COPE-active programme. 
After the first period of 6 months, 11 patients decided not to continue with COPE-active 
as was allowed according to the protocol. Therefore, 56 patients (72.7%) completed the 
whole training period of 11 months. Twenty-five patients (32.9%) in the control group 
received usual care physiotherapy (non-standardised) during the 12-month follow-up.   
 Results of the repeated measurements analysis of the incremental shuttle walk test 
are presented in Figure 2 and Table 2. During the first 7 months of the follow-up pe-
riod, the intervention group showed a slight increase in walking distance that remained  
Eligible patients: n=421 Excluded: n=262 
Refused to participate (n=130)
Participation in other research 
projects (n=33)
Transport problems (n=22)
Other reasons (n=77)Randomisation
Withdrawn: n=3
- Co-morbidity; n=2
- Too busy; n=1
Withdrawn: n=3
- Co-morbidity; n=1
- Too busy; n=2
COPE-active group: n=80 Control group: n=79
Baseline measurement: n=76Baseline measurement: n=77
Withdrawn: n=8
- Too busy; n=1
- Death; n=2
- Failure to return; n=4
- Co-morbidity; n=1
One-year follow-up: n=68
Withdrawn: n=3
- Too busy; n=1
- Death; n=2
One-year follow-up: n=74
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Table 1  Baseline characteristics of the two treatment groups 
Number of patients 
 
COPE-active 
n=77 
Control 
n=76 
Age (mean ± sd; years) 62.9 ± 8.1 63.9 ± 7.8 
Male (%) 58.4 57.9 
Body Mass Index (mean ± sd; kg/m2)* 26.1 ± 5.0 26.8 ± 4.4 
Medical Research Council dyspnoea scale (mean ± sd) 2.25 ± 1.05 2.50 ± 1.15 
Smokers (%) 35 34 
Lung function post bronchodilation (mean ± sd) 
     FEV1 (L) 
     FEV1 % predicted value 
     VC (L)      
 
1.43 ± 0.54 
49.6 ± 14.2 
3.78 ± 1.05 
 
1.40 ± 0.53 
50.5 ± 17.0 
3.47 ± 0.84 
Inhaled corticosteroid use (%) 85.7 88.2 
Incremental Shuttle Walk Test (mean ± sd; meters)** 388 ± 164.5 341 ± 152.4 
Endurance Shuttle Walk Test (mean ± sd; meters)** 679 ± 553.1 630 ± 554.1 
* Mean values were based on 77 and 75 patients in the COPE-active and control group respectively 
** Mean values were based on 77 and 74 patients in the COPE-active and control group respectively 
stable until the end of the one-year follow-up period. Conversely, the control group 
showed a steady decline in walking distance over the whole follow-up period. A sig-
nificant between-group difference of 35.1 meters was found after 12 months (Table 2). 
 The probability of an improved walking distance by 47.5 meters (the minimal im-
portant difference) or more after one year was 1.91 times higher (95% CI 0.97-3.78) in 
the intervention group compared to the control group. Similarly, the probability of a 
decreased walking distance by 47.5 meters or more after one year was 1.56 times higher 
(95% CI 0.92-2.70) in the control group compared to the intervention group.  
 In addition, a per protocol analysis was performed, for which 26 patients (34%) 
were omitted because of an attendance of less than 70% of the physiotherapeutic ses-
sions (11-month period: < 50 sessions; 6-month period: < 36 sessions). The major 
reasons for this lack of attendance were not starting COPE-active (n=10) and new co-
morbidity (n=4). With this analysis a between-group difference of 48.9 meter was found 
(p<0.01) (Figure 2). 
 Results of the secondary outcomes are presented in Table 2. The COPE-active 
group showed an improvement of daily activity (steps per day) after 7 months that in-
creased further during the second period. Daily activity of the control group decreased 
progressively. The mean between-group difference over the whole period was 
877 steps per day (p=0.028), the between-group difference at 12 months was even 
higher (1190 steps per day). An increase in the endurance shuttle walk test in compari-
son with baseline was seen at 7 and 12 months in the intervention group. The walking 
distance of the control group diminished progressively over the whole follow-up. A 
non-significant between-group difference of 145.8 meters was found after 12 months 
(p=0.11). The CRQ dyspnoea-score was 0.33 points higher in the COPE-active group 
compared to control (p=0.04). No between-group differences were found in the other 
CRQ-components and CCQ (sub)-scores, the HADS scores, and percentage of fat free 
mass.  
Physiotherapeutic exercise in COPD patients 
 - 77 - 
 
Ta
b
le
 2
 M
e
a
n
 (
S
D
) 
b
a
se
lin
e
 s
c
o
re
s,
 t
h
e
 m
e
a
n
 d
if
fe
re
n
c
e
s 
(S
E
) 
fr
o
m
 b
a
se
lin
e
 a
t 
7
 m
o
n
th
s 
a
n
d
 1
2
 m
o
n
th
s 
a
ft
e
r 
b
a
se
lin
e
, 
th
e
 b
e
tw
e
e
n
-g
ro
u
p
 d
if
fe
re
n
c
e
 a
t 
1
2
 m
o
n
th
s,
 a
n
d
 t
h
e
 o
v
e
ra
ll 
m
e
a
n
 d
if
fe
re
n
c
e
 
b
e
tw
e
e
n
 b
o
th
 s
tu
d
y
 g
ro
u
p
s 
w
it
h
 t
h
e
 c
o
rr
e
sp
o
n
d
in
g
 9
5
%
 c
o
n
fi
d
e
n
c
e
 i
n
te
rv
a
l 
(9
5
%
 C
I)
 o
f 
th
e
 i
n
c
re
m
e
n
ta
l 
sh
u
tt
le
 w
a
lk
 t
e
st
 (
IS
W
T)
, 
e
n
d
u
ra
n
c
e
 s
h
u
tt
le
 w
a
lk
 t
e
st
 (
E
S
W
T)
, 
c
h
ro
n
ic
 r
e
sp
ir
a
to
ry
 q
u
e
st
io
n
n
a
ir
e
 
(C
R
Q
),
 c
lin
ic
a
l 
C
O
P
D
 q
u
e
st
io
n
n
a
ir
e
 (
C
C
Q
),
 h
o
sp
it
a
l 
a
n
x
ie
ty
 a
n
d
 d
e
p
re
ss
io
n
 s
c
a
le
 (
H
A
D
S
),
 p
e
d
o
m
e
te
rs
, 
a
n
d
 p
e
rc
e
n
ta
g
e
 o
f 
fa
t 
fr
e
e
 m
a
ss
 (
F
F
M
).
 
 
 
C
O
P
E
-a
c
ti
v
e
 
C
o
n
tr
o
l 
 
  
 
 
D
if
fe
re
n
c
e
 w
it
h
 b
a
se
li
n
e
* 
 
D
if
fe
re
n
c
e
 w
it
h
 b
a
se
li
n
e
* 
Tr
e
a
tm
e
n
t 
e
ff
e
c
t 
 C
O
P
E
-a
c
ti
v
e
-c
o
n
tr
o
l 
 
 
B
a
se
li
n
e
 
M
e
a
n
 (
S
D
) 
7
 m
o
n
th
s 
M
e
a
n
 (
S
E
) 
1
2
 m
o
n
th
s 
M
e
a
n
 (
S
E
) 
B
a
se
li
n
e
 
M
e
a
n
 (
S
D
) 
7
 m
o
n
th
s 
M
e
a
n
 (
S
E
) 
1
2
 m
o
n
th
s 
M
e
a
n
 (
S
E
) 
∆
 1
2
 
m
o
n
th
s 
9
5
%
 C
I 
(∆
 a
t 
1
2
 m
o
n
th
s)
  
 
∆
 o
v
e
ra
ll
* 
9
5
%
 C
I 
(∆
 o
v
e
ra
ll
) 
* 
 
 
 
 
 
 
 
 
 
 
 
 
N
r 
o
f 
p
a
ti
e
n
ts
 
n
=
7
7
 
n
=
6
8
 
n
=
6
9
 
n
=
7
4
 
n
=
6
0
 
n
=
6
6
 
 
 
 
 
 IS
W
T 
D
is
ta
n
c
e
 (
m
e
te
rs
) 
3
8
7
.7
 (
1
6
4
.5
) 
 
1
2
.2
 (
1
0
.6
) 
1
1
.1
 (
1
0
.6
) 
3
4
1
.4
 (
1
5
2
.4
) 
-1
2
.1
 (
8
.4
) 
-2
4
.0
 (
8
.2
) 
3
5
.1
 
8
.4
; 
6
1
.8
 
3
0
.4
 
5
.1
; 
5
5
.7
 
 
 
 
 
 
 
 
 
 
 
 
 
N
r 
o
f 
p
a
ti
e
n
ts
 
n
=
7
7
 
n
=
6
8
 
n
=
6
8
 
n
=
7
4
 
n
=
6
0
 
n
=
6
6
 
 
 
 
 
 E
S
W
T 
D
is
ta
n
c
e
 (
m
e
te
rs
) 
6
7
8
.9
 (
5
5
3
.1
) 
1
0
6
.1
 (
6
7
.4
) 
5
3
.3
 (
6
7
.4
) 
6
2
9
.5
 (
5
5
4
.1
) 
-1
5
.9
 (
5
5
.6
) 
-9
2
.5
 (
5
4
.5
) 
1
4
5
.8
 
-2
6
.2
; 
3
1
7
.8
 
1
3
4
.5
 
-2
9
.0
; 
2
9
8
.0
 
 
 
 
 
 
 
 
 
 
 
 
 
N
r 
o
f 
p
a
ti
e
n
ts
 
n
=
7
7
 
n
=
6
8
 
n
=
7
1
 
n
=
7
6
 
n
=
6
3
 
n
=
6
8
 
 
 
 
 
D
y
sp
n
o
e
a
 
4
.4
0
 (
1
.4
4
) 
0
.3
7
 (
0
.1
3
) 
0
.3
0
 (
0
.1
3
) 
4
.5
2
 (
1
.3
8
) 
0
.0
4
 (
0
.1
2
) 
-0
.0
2
 (
0
.1
2
) 
0
.3
2
 
-0
.0
3
; 
0
.6
7
 
0
.3
3
 
0
.0
1
; 
0
.6
4
 
Fa
ti
q
u
e
 
4
.5
5
 (
1
.2
4
) 
0
.1
5
 (
0
.1
5
) 
0
.1
5
 (
0
.1
5
) 
4
.1
3
 (
1
.2
8
) 
0
.0
3
 (
0
.1
7
) 
0
.0
6
 (
0
.1
6
) 
0
.0
9
 
-0
.3
4
; 
0
.5
2
 
0
.1
0
 
-0
.2
9
; 
0
.5
0
 
E
m
o
ti
o
n
a
l 
F
u
n
c
ti
o
n
 
5
.1
4
 (
1
.1
9
) 
-0
.0
2
 (
0
.1
1
) 
0
.1
8
 (
0
.1
1
) 
4
.9
0
 (
1
.0
2
) 
-0
.0
5
 (
0
.1
2
) 
0
.0
8
 (
0
.1
2
) 
0
.1
0
 
-0
.2
2
; 
0
.4
2
 
0
.0
7
 
-0
.2
1
; 
0
.3
4
 
 C
R
Q
 
M
a
st
e
ry
 
5
.3
5
 (
1
.1
5
) 
0
.1
3
 (
0
.1
2
) 
0
.3
3
 (
0
.1
2
) 
5
.3
0
 (
1
.0
9
) 
0
.1
4
 (
0
.1
2
) 
0
.2
2
 (
0
.1
1
) 
0
.1
1
 
-0
.2
1
; 
0
.4
3
 
0
.1
2
 
-0
.1
8
; 
0
.4
1
 
 
 
 
 
 
 
 
 
 
 
 
 
N
r 
o
f 
p
a
ti
e
n
ts
 
n
=
7
7
 
n
=
6
7
 
n
=
7
0
 
n
=
7
4
 
N
=
6
0
 
n
=
6
6
 
 
 
 
 
S
y
m
p
to
m
s 
2
.3
5
 (
1
.0
2
) 
-0
.0
6
 (
0
.1
2
) 
-0
.1
1
 (
0
.1
2
) 
2
.9
2
 (
1
.2
2
) 
-0
.0
6
 (
0
.1
4
) 
-0
.1
7
 (
0
.1
4
) 
0
.0
6
 
-0
.3
0
; 
0
.4
2
 
0
.0
3
 
-0
.2
9
; 
0
.3
4
 
Fu
n
c
ti
o
n
a
l 
st
a
te
 
2
.1
4
 (
1
.1
7
) 
0
.0
3
 (
0
.1
2
) 
-0
.0
6
 (
0
.1
2
) 
2
.3
3
 (
1
.2
9
) 
-0
.0
3
 (
0
.1
2
) 
0
.0
6
 (
0
.1
2
) 
0
.0
0
 
-0
.4
6
; 
0
.2
2
 
-0
.0
3
 
-0
.3
4
; 
0
.2
8
 
M
e
n
ta
l 
st
a
te
 
0
.9
3
 (
0
.9
8
) 
-0
.0
6
 (
0
.1
1
) 
-0
.1
4
 (
0
.1
1
) 
1
.0
3
 (
1
.0
9
) 
0
.0
8
 (
0
.1
5
) 
-0
.1
2
 (
0
.1
4
) 
-0
.0
2
 
-0
.3
7
; 
0
.3
3
 
-0
.0
8
 
-0
.4
0
; 
0
.2
3
 
 C
C
Q
 
To
ta
l 
1
.8
0
 (
0
.8
9
) 
-0
.0
3
 (
0
.0
8
) 
-0
.1
0
 (
0
.0
8
) 
2
.0
9
 (
0
.9
5
) 
-0
.0
1
 (
0
.1
0
) 
-0
.0
8
 (
0
.1
0
) 
-0
.0
2
 
-0
.2
7
; 
0
.2
3
 
-0
.0
3
 
-0
.2
6
; 
0
.2
0
 
 
 
 
 
 
 
 
 
 
 
 
 
N
r 
o
f 
p
a
ti
e
n
ts
 
n
=
7
6
 
n
=
6
7
 
n
=
6
9
 
n
=
7
6
 
n
=
6
2
 
n
=
6
8
 
 
 
 
 
A
n
x
ie
ty
 
4
.2
6
 (
3
.7
4
) 
-0
.1
7
 (
0
.3
2
) 
-0
.6
6
 (
0
.3
2
) 
5
.3
8
 (
3
.6
0
) 
-0
.2
8
 (
0
.3
8
) 
-0
.6
1
 (
0
.3
6
) 
0
.0
5
 
-1
.0
0
; 
0
.9
0
 
0
.0
2
 
-0
.7
9
; 
0
.8
4
 
 H
A
D
S
 
D
e
p
re
ss
io
n
 
3
.9
6
 (
3
.6
6
) 
-0
.3
7
 (
0
.3
3
) 
-0
.7
1
 (
0
.3
3
) 
5
.2
4
 (
3
.8
7
) 
-0
.4
8
 (
0
.3
2
) 
-0
.3
0
 (
0
.3
1
) 
-0
.4
1
 
-1
.3
1
; 
0
.4
9
 
-0
.1
6
 
-0
.9
4
; 
0
.6
2
 
 
 
 
 
 
 
 
 
 
 
 
 
N
r 
o
f 
p
a
ti
e
n
ts
 
n
=
6
2
 
n
=
5
9
 
n
=
5
5
 
n
=
6
5
 
n
=
5
2
 
n
=
5
5
 
 
 
 
 
 P
e
d
o
m
e
te
r 
S
te
p
s 
(p
e
r 
d
a
y
) 
4
4
7
2
 (
2
7
1
5
) 
4
7
8
.1
 (
3
4
8
.5
) 
8
1
5
.6
 (
3
5
8
.6
) 
5
2
2
4
 (
3
4
6
4
) 
-8
7
.3
 (
3
1
3
.6
) 
-3
7
4
.8
 (
3
0
6
.4
) 
1
1
9
0
.4
 
2
5
5
.6
; 
2
1
2
5
.2
 
8
7
6
.6
 
9
5
.4
; 
1
6
5
7
.7
 
 
 
 
 
 
 
 
 
 
 
 
 
N
r 
o
f 
p
a
ti
e
n
ts
 
n
=
7
7
 
n
=
6
8
 
n
=
7
0
 
n
=
7
5
 
n
=
6
2
 
n
=
6
7
 
 
 
 
 
 F
F
M
 
Fa
t 
fr
e
e
 m
a
ss
 (
%
) 
3
4
.7
 (
7
.3
2
) 
1
.1
 (
0
.4
4
) 
0
.8
 (
0
.4
3
) 
3
5
.2
 (
6
.2
8
) 
-0
.1
 (
0
.4
0
) 
0
.2
 (
0
.3
9
) 
0
.6
 
-0
.5
5
; 
1
.7
5
 
0
.1
 
-0
.5
; 
0
.6
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
In
te
n
ti
o
n
 t
o
 t
re
a
t 
a
n
a
ly
se
s:
 r
e
su
lt
s 
w
e
re
 o
b
ta
in
e
d
 w
it
h
 r
e
p
e
a
te
d
 m
e
a
su
re
m
e
n
ts
 a
n
a
ly
se
s 
(S
P
S
S
) 
 
 
Chapter 4 
 - 78 - 
 
ISWT: intention to treat analysis
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ISWT: per protocol analysis
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Figure 2  Mean change (SE) from baseline in incremental shuttle walk test (ISWT) walking distance (meters) at 
7 and 12 months after baseline measurements of the COPE-active (▲) and control (■) group using an inten-
tion to treat analysis (number of patients at baseline: COPE-active: 77; control: 74) and a per protocol 
analysis (number of patients at baseline: COPE-active: 51; control: 74) 
 
Discussion 
This randomised controlled trial evaluated the effects of a one-year community-based 
physiotherapeutic exercise programme (COPE-active) incorporated in a self-manage-
ment programme compared to self management alone. The intervention group showed 
an improved maximal exercise capacity and a positive change in daily activity, which 
was used as a marker of behaviour change in comparison with the control group.  
 The COPE-active group experienced a clear improvement in maximal exercise ca-
pacity compared to the steady decline in the control group. A 35 meter larger mean 
shift in the intervention group than in the control group is rather impressive as a group 
level effect, knowing that there will always be patients who do not respond to exercise 
interventions (21). In fact, patients in the intervention group were almost twice as likely 
to improve their walking distance with a magnitude of at least the recently publicised 
MID of 47.5 meters (13). 
 It should be noted that, in contrast to many other studies (e.g. 22-25), we used an 
‘intention to treat’-principle for our primary analyses, meaning that all patients who 
were assigned to the intervention group at baseline were included in the analysis. As 
expected, applying a per protocol analysis (with potential bias due to incomparable 
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groups (26)) led in our study to a larger between-group difference in favour of the in-
tervention group.  
 The study population comprised relatively severe COPD patients with a median 
one-year exacerbation rate of 3 in both study groups. This relatively high exacerbation 
rate might explain the deterioration in exercise capacity in the control group and also 
the relatively small increase of exercise capacity in the intervention group because ex-
acerbations do not only lead to a reduced walking distance during an exacerbation, but 
walking distance remains reduced also after the exacerbation (27).   
 Besides the changes in exercise capacity, we intended to change behaviour with 
regard to exercise with our relatively long lasting program (28). The fact that only 11 of 
the 67 patients who started the training decided not to continue after the first 6-month 
training period seems to indicate at least a high motivation to continue exercising un-
der guidance of the physiotherapist. Moreover, we found a between-group difference 
(1190 steps/day) in daily activity in favour of the intervention group. Baseline scores of 
patients in the COPE-active and control group were 4472 and 5224 steps/day respec-
tively, which places the difference of almost 1200 steps in more perspective, i.e. an 
improvement of approximately 25%. We believe that these results indicate behavioural 
change with regard to levels of daily activity.  
 A positive trend, though not significant, was seen in endurance capacity. The 
change in endurance exercise capacity showed the same trend as the change in maxi-
mal (incremental) exercise capacity, but the substantial between-group difference at 12 
months of 145.8 meters did not reach significance. The latter is explained by a large 
standard deviation, and by a ceiling effect (i.e. 12 COPE-active and 14 controls already 
walked the maximum 20 minutes at baseline). 
 A statistically significant between-group difference of the CRQ-dyspnoea domain 
was found at 12 months. This is in line with our expectations, because desensitisation to 
dyspnoea seems to be an important mechanism in improving the exercise tolerance of 
COPD (6). Because no significant nor clinically relevant effects were detected in the 
other CRQ-domains, we can conclude that our HRQoL-results do not match results 
from the literature (29). Lack of power and relatively high CRQ-baseline scores are pos-
sible explanations. Finally, no changes in anxiety and depression were found, but 
average baseline scores were so low that expecting a further decrease might not be rea-
sonable.  
 It should be noted that the included patients were not “fresh” patients. The major-
ity of the patients was under supervision of our chest physicians for years already. So, 
aspects as for example the importance of exercising were brought to their attention 
many times before. Therefore, it is plausible that larger effects can be expected in other 
populations. More importantly, we assumed up front that an underestimation of possi-
Chapter 4 
 - 80 - 
ble effects of the exercise training would occur since patients in our control group were 
allowed to receive physiotherapy as part of their usual care. Actually, almost one third 
did (32.9%). We designed our study this way to document that the positive effects of a 
pro-active and mandatory training programme would surpass the effects of variable 
and less strict exercise programmes in usual care. Additionally, since our study evalu-
ated the addition of the exercise programme to a self-management programme 
compared to the self-management programme alone, all patients also received self 
management instructions on exercising as part of the life style advices. This design 
might have slightly diminished the room for improvement in the active arm compared 
to the control arm, even though the effects of self management in this sense have not 
been found to be very large (4).  
 In conclusion, this study demonstrated that a community-based physiotherapeutic 
exercise programme implemented in a self-management programme improved the ex-
ercise capability of COPD-patients and additionally their actual daily activities after 
one year, indicating real behaviour change with regard to daily exercise.  
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Abstract  
No information is available about the cost-effectiveness of different regularly used 
components of self-management programmes. In this randomised controlled trial, the 
cost-effectiveness was evaluated of the addition of a community-based physiotherapeu-
tic exercise programme (COPE-active) to a self-management programme.  
 All patients (intervention: n=77; control: n=76) attended four self-management ses-
sions. In addition the intervention group participated in COPE-active, consisting of a 
6-month ‘compulsory’ (3 sessions/week) and subsequently a 5-month ‘optional’ period 
(2 sessions/week). A decision analytical model with a 12-month time perspective was 
used to evaluate cost-effectiveness. Sensitivity analyses were used to evaluate the ro-
bustness of the findings. 
 Applying COPE-active costs additionally €735 per patient. In the COPE-active 
group the probability to improve walking distance > 47.5 meters was 0.29 compared to 
0.15 in the control group. The probability to prevent deterioration > 47.5 meters was 
0.23 in the intervention group versus 0.36 in the controls. This means that among eight 
patients offered COPE-active (costs 8 * €735: €5880), one will substantially improve and 
one will not substantially deteriorate. In addition COPE-active increased daily activity 
(NNT to gain 500 steps/day: 0.4) and prevented hospitalisations (NNT: 21.4).  
 We conclude that this community-based physiotherapeutic exercise programme is 
effective at limited extra costs.  
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Introduction 
Chronic obstructive pulmonary disease (COPD) prevalence and mortality vary across 
countries and across different groups within countries. Due to continued exposure to 
COPD risk factors and the changing age structure of the world’s population, the preva-
lence and burden of COPD are projected to increase in the coming decades (1). In the 
European Union, the total direct costs of respiratory disease are estimated to be ap-
proximately 6% of the total health care budget, with COPD accounting for 56% (€38.6 
billion) of these costs (2).  
 Besides pharmacologic treatment, oxygen therapy, and pulmonary rehabilitation, 
self-management programmes are regularly offered to COPD patients (3). With limited 
health care budgets, it is important to balance the costs of health care interventions 
against outcomes. Until now only two self-management studies (4;5) were evaluated 
with regard to cost-effectiveness and only one held promise for positive economic 
benefits (5). Whereas there is positive information available about the cost-effectiveness 
of multidisciplinary pulmonary rehabilitation programmes (6), no studies have been 
published about the cost-effectiveness of a community-based physiotherapeutic exer-
cise programme as a component of a self-management programme. 
 In a randomised controlled trial, the COPE-II study, the effect of a community-
based physiotherapeutic exercise programme (COPE-active) was evaluated within a 
self-management programme. The focus of this manuscript is to investigate whether 
COPE-active is a cost-effective component within a self-management programme in 
COPD patients. 
 
Material and methods  
In the COPE-II study, a randomised controlled trial, the effects of a self-management 
programme including COPE-active (intervention group; n=77) were compared with a 
self-management programme only (control group; n=76). All COPD patients were re-
cruited from the outpatient department of pulmonary medicine of Medisch Spectrum 
Twente at Enschede, the Netherlands. Patients, aged 40-75 years, had to have a clinical 
diagnosis of COPD according to the GOLD criteria (1), and > 3 exacerbations or one 
hospitalisation for respiratory problems in the two years preceding study entry. Pa-
tients were excluded if they had serious co-morbidity, including disorders or diseases 
seriously influencing walking ability. 
 In the first month after the baseline measurements four 2-hour self-management 
courses were offered to all patients by a respiratory nurse and physiotherapist, fol-
lowed by phone calls at 4, 13, and 26 weeks after the last course. The intention of the 
courses was to change patient’s disease behaviour by increasing their knowledge, con-
fronting them with consequences of specific behaviour, and supplying them with skills 
Chapter 5 
 - 86 - 
to deal with different components of their disease. The goal of the phone contacts was 
to recall the matters addressed during the self-management courses.  
 In the second month after baseline measurements, patients of the intervention 
group started the COPE-active programme. A detailed description of the different 
(home) training activities and the used training schemes can be found in the online re-
pository (see online repository). The 11-month training period per patient was divided 
into two parts: a ‘compulsory’ 6-month period and a subsequent optional but recom-
mended 5-month period. Besides improvement of physical condition in the first period 
and preservation of these gains in the second period, behaviour change towards exer-
cise was strived for during the whole period. Frequency of training sessions (first pe-
riod: 3 times/week; second period: 2 times/week) and intensity of the exercises within 
the programme are in line with the latest rehabilitation insights (6). One training ses-
sion with the physiotherapist was replaced by an unsupervised exercise session at 
home to facilitate behaviour change towards exercise. Training was given in small 
groups (2-3 patients).  
 During the whole study period, patients in the control group were allowed to at-
tend regular physiotherapy sessions if this was prescribed as part of regular care. The 
results described in this article are based on the 12-month follow-up.  
 
Outcomes 
Primary outcome for the base-case analysis (main analysis) was the probability to im-
prove or deteriorate more than the minimal important difference of 47.5 meters (7) on 
the incremental shuttle walk test in a period of 12 months. The incremental shuttle 
walk test is an externally paced walking test (via audio signal) using a 10-meter course 
(8). Daily physical activity was assessed by the Yamax Digi-Walker SW-200 (Tokyo, 
Japan) during 7-day periods at baseline at 12 months.   
 
Economic evaluation 
A decision analytical model with a time perspective of 12 months was developed to 
evaluate the cost effectiveness of a self-management programme including COPE-
active versus solely a self-management programme.  
 Table 1 presents the percentages, which are derived from the COPE-II study, for 
each step in the decision analytic model (Figure 1). Figure 1 shows, besides the percent-
ages of patients for each step, also the percentages of patients in the different branches. 
For example, the percentage of patients in the intervention group having at least one 
exacerbation (85.9%), one health care contact (100%), and one hospitalisation (20.0%) is 
17.2% (85.9% * 100% * 20.0%). The costs made by a patient in this branch are €7428. 
These costs consists of: the costs of COPE-active sessions (€1227), regular medication  
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Table 1 Base case values of percentages of COPD patients with an exacerbation, a hospitalisation and medica-
tion use for an exacerbation 
 Base case value (95% CI) 
 COPE-active Control 
 
Patients with an exacerbation (%) 
 
85.9 (78.1 to 93.7) 
 
 
88.7 (81.6 to 95.8) 
 
Patients with a hospitalisation when having an exacerbation 
and health care contact (%) 
20.0 (11.1 to 28.9) 
 
23.0 (13.5 to 32.5) 
 
 
Patients with medication use for an exacerbation when not 
hospitalised but having an exacerbation and a health care 
contact (%) 
81.0 (72.2 to 89.8) 
 
 
72.0 (61.9 to 82.1) 
 
 
 
 
costs (€688), health care contacts costs (€356) (Table 2), and the hospitalisation costs 
(€5157). In this branch medication for an exacerbation is incorporated in hospitalisation 
costs. The percentage of patients in each branch will finally determine the weight of the 
branch costs to the total costs / patient / study group (e.g., 17.2% * €7428). The costs of 
the self-management sessions were excluded from the base case analysis because these 
were equally divided in both groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Decision analytic model with percentages of patients with exacerbations, health care contacts, 
hospitalisations and medication for exacerbations for the COPE-active and control group 
11.3%
10.0%
20.0%
80.0%
14.1%
100.0%
Health care contacts
85.9%
Exacerbation
COPE II
Control
0.0%
100.0%
Health care contacts
88.7%
Exacerbation
23.0%
77.0%
55.7%
Hospitalisation
No 
hospitalisation
Medication for 
exacerbation
No medication for 
exacerbation
81.0%
17.2%
13.1%
19.0%
0.0%
49.2%
0.0%
COPE-active
No 
exacerbation
No health care 
contacts
0.0%
0.0%
100.0%
Health care contacts
No health care 
contacts 0.0%
14.1%
Hospitalisation
No medication for 
exacerbation
72.0%
20.4%
19.1%
28.0%
No 
hospitalisation
Medication for 
exacerbation
No health care 
contacts
100.0%
Health care contacts
No health care 
contacts 0.0%
11.3%
No 
exacerbation
0.0%
Chapter 5 
 - 88 - 
 
Table 2  Mean costs (€) per patient per year of COPD patients receiving a self-management 
programme with and without COPE-active using 2004 cost prices 
Costs per patient COPE-active 
(n=77) 
Control 
(n=76) 
Difference 
     Self-management courses 115.14 115.14 0.00 
     Physiotherapy per year* 1226.60 349.16 877.44 
     Regular medication per year† 688.01 634.84 53.17 
     Health care contacts per year‡ 
          patients with exacerbation 
          patients without exacerbation 
329.09 
     355.86 (85.9%) 
     166.03 (14.1%) 
302.21 
     326.89 (88.7%) 
     108.50 (11.3%) 
26.88 
     Hospitalisation costs§ 1001.37 1222.07 -220.70 
     Medication for exacerbations** 62.43  63.97 - 1.54 
 Total costs 3422.64 2687.39 €  735.25 
* Costs of a one-hour group session: €26.80; patients participating into physiotherapy programs: COPE-active: n=67 and con-
trol: n=25; mean number of visits of patients attending the physiotherapist: intervention: 52.6 and control: 39.6. 
† Includes €6 pharmacy cost and 6% VAT per prescription. 
‡ Includes (phone) consults with the physician and general practitioner, and emergency room visits. 
§ Costs per hospitalisation day: €337 (includes medication costs); mean of 10.4 and 10.6 hospitalisation days per admission and 
22 and 26 admissions for respectively the COPE-active and control group. The sum of €5157 for hospitalisation costs as men-
tioned in the text are the hospitalisation costs per intervention patient having at least one hospitalisation: mean costs of a 
hospitalisation x (total number of hospitalisations in the intervention group / total number of intervention patients with > one 
exacerbation). 
**Average of medically treated exacerbations per patient per year for respectively the COPE-active and control group: 
treatment with prednisolone and antibiotics: 1.79 versus 1.94 (€ 27,69 per exacerbation); treatment with solely prednisolone: 
0.91 versus 0.83 €7.79 per exacerbation); and treatment with solely antibiotics: 0.29 versus 0.19 (€19.90 per exacerbation). 
 
Base case cost effectiveness analyses were performed according to the US panel on cost 
effectiveness analysis guidelines (9;10). We took the perspective of the health care 
payer, meaning that indirect costs related to e.g., loss of productivity or reduced usual 
daily activities were not taken into account. The costs-effectiveness ratio was calculated 
as costs per patient to gain a clinical relevant distance (> 47.5 m) at the incremental 
shuttle walk test, or to prevent a similar loss in this test. In addition we estimate the 
costs per hospital admission prevented, and the costs to gain 500 steps in daily activity.  
 Sensitivity analyses (Monte Carlo simulation with 1000 iterations), in which cost 
parameters and probabilities were varied simultaneously over their ranges and associ-
ated 95% CI, were performed to evaluate the relative impact of the various parameters 
on the decision analytical model. For the costs of health care contacts and hospital ad-
missions a normal distribution was observed, while for the costs of the self-
management programme, the COPE-active programme, usual care physiotherapy, ex-
acerbations, and regular medication a triangular distribution (50% to 150% of the actual 
costs) was used. Logistic normal distributions were used for all probabilities.   
 
Resources and costs 
Health care resource use was prospectively recorded during the study by active follow 
up of the patients’ records (both inpatients and outpatients) with regard to hospital 
admissions, emergency room visits, scheduled and emergency outpatients visits, phone 
calls with physicians, consultations with the general practitioner, and information 
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about drug use. Also the attendance at physiotherapy sessions was collected for the 
cost-effectiveness analyses. 
 Resource uses (hospitalisations, emergency room visits, scheduled and emergency 
outpatients visits, and consultations with the GP) were multiplied by 2004 unit prices 
(11). The costs of the (un)scheduled health care contacts (outpatient, telephone consul-
tation, GP visits) included salary, travel, and parking costs, if applicable. Medication 
costs were based on market prices and included a €6 dispensing fee and 6% VAT for 
each prescription. The costs for physiotherapy sessions were also based on market 
prices. Because of the short-time perspective, costs and effects were not discounted for 
time preferences.  
 
Results 
Figure 2 shows the flow diagram of this study. 159 patients were assigned to either the 
intervention (n=80) or the control group (n=79). Between the inclusion and the baseline 
measurements three patients dropped out in each study group. Table 2 shows the base-
line characteristics of the remaining 153 patients. The study groups were similar with 
respect to all measured prognostic factors.  
 
 
Eligible patients: n=421 Excluded: n=262 
Refused to participate (n=130)
Participation in other research 
projects (n=33)
Transport problems (n=22)
Other reasons (n=77)Randomisation
Withdrawn: n=3
- Co-morbidity; n=2
- Too busy; n=1
Withdrawn: n=3
- Co-morbidity; n=1
- Too busy; n=2
COPE-active group: n=80 Control group: n=79
Baseline measurement: n=76Baseline measurement: n=77
Withdrawn: n=8
- Too busy; n=1
- Death; n=2
- Failure to return; n=4
- Co-morbidity; n=1
One-year follow-up: n=68
Withdrawn: n=3
- Too busy; n=1
- Death; n=2
One-year follow-up: n=74
 
                    Figure 2 Flow diagram of subject progress through the COPE II-study 
Three patients dropped out of the intervention group directly after the baseline 
measurements (before the start of COPE-active). In addition seven patients assigned to 
the intervention group refused to participate in the COPE-active programme. After the 
first period of 6 months, 11 patients decided not to continue with COPE-active as was 
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allowed according to the protocol. Therefore, 56 patients (72.7%) completed the whole 
training period of 11 months. Twenty-five patients (32.9%) in the control group re-
ceived usual care physiotherapy during the 12-month follow-up.   
 The primary outcome was exercise capacity measured by the incremental shuttle 
walk test. After 12 months, a significant between-group difference of 35.1 meters was 
found in favour of the intervention group (see Figure 3). The probability of an im-
proved walking distance equal or more than the minimal important difference of 47.5 
meters after one year was 1.91 times higher (95% CI 0.97-3.78) in the intervention group 
compared to the control group. Also, the probability of a decreased walking distance 
equal or more than 47.5 meters after one year was 1.56 times higher (95% CI 0.92-2.70) 
in the control group compared to the intervention group.  
-40.0
-30.0
-20.0
-10.0
0.0
10.0
20.0
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40.0
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Figure 3  Mean change (SE) from baseline in incremental shuttle walk test walking distance (meters) at 7 and 
12 months after baseline measurements of the intervention (▲) and control (■) group using an intention to 
treat analysis 
 The mean daily activity of the COPE-active group improved, while mean daily ac-
tivity of the control group decreased progressively over the 12 month-period, resulting 
in a significant overall between-group difference of 877 steps/day in favour of the in-
tervention group (95% CI 95; 1658).  
 
Base case cost effectiveness analysis of the trial  
The 12 month costs and effects are presented in table 2 and 4 respectively. The average 
patient in the COPE-active group generated €3422 in direct medical costs including the 
€1227 for the COPE-active sessions. The cost of the control group was €2687, including 
€349 for regular physiotherapy. So, applying COPE-active cost an additional €735 per 
patient.  
 The number needed to treat (NNT) to increase walking distance by more than 47.5 
meters in one patient was 7.1, while the NNT to prevent a deterioration of more than 
47.5 meters in one patient was 7.7. So, when eight patients were offered a COPE-active 
programme (8 * €735: €5880), one patient would achieve a minimal important differ-
ence of 47.5 meters and one patient would be prevented from deteriorating 47.5 meters 
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in comparison with the control group. The NNT to prevent one hospitalisation was 21.4 
(€15.729), and the NNT to gain 500 steps/day was 0.4 (€294). 
Table 4  Effects per patient per year of COPD patients receiving a self-management programme 
with and without COPE-active 
Effect per patient COPE-active Control Difference 
      
Probability of an improved incremental shut-
tle walk test distance by > 47.5 m 
 
 
0.29 
 
0.15 
 
0.14 
Probability of a decreased incremental shut-
tle walk test distance by > 47.5 m 
0.23 0.36 -0.13 
      
Number of hospitalizations / patient / year 
 
0.29 
 
0.34 
 
-0.05 
 
Sensitivity analysis of the decision analytical model 
The result of the sensitivity analyses with regard walking distance, daily activity (steps 
per day), and hospital admissions are shown in Figure 4. For an improvement of > 47.5 
meters on the incremental shuttle walk test, positive effects at increased costs were seen 
in 95.2% of the iterations. For preventing a deterioration of > 47.5 meters, positive ef-
fects at increased costs were seen in 89.4% of the iterations. An increase in steps at in-
creased costs was seen in 60.6% of the iterations, and finally for hospitalisations, posi-
tive effects at increased costs were seen in 67.0% of the iterations. 
  
Discussion 
This paper reports the economic evaluation of the COPE-active programme: a commu-
nity-based physiotherapeutic exercise programme. COPE-active was evaluated as a 
component of a COPD self-management programme in a randomised clinical trial: the 
COPE-II study. Offering the COPE-active programme to eight patients (at €735 per pa-
tient), results in one patient to gain substantially on the incremental shuttle walk test 
and in addition prevents one patient from deteriorating substantially after a one-year 
follow-up. Whereas the positive effect on daily activity was large (NNT to gain 500 
steps of 0.4), the reducing effect on hospitalisations was relatively small with an NNT 
of 21.4.  
 Patients included in this study exacerbated frequently with an average exacerba-
tion rate of 3.5 per year. Because exacerbations affect walking distance over time (12), 
the observed progressively reduced walking distance in the control group after one 
year is not surprising. Therefore, we did not only analyse the proportion of patients 
who relevantly improved their walking distance, but also patients who were kept from 
substantially deteriorating. Our data showed that an investment of €5880 (treatment of 
8 patients) led to a profit in walking distance in two patients. So, the costs to let one 
patient profit came to €2940. 
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 The shuttle walk test and the number of steps measured with the pedometers are 
both directed towards evaluation of activity but they are measuring two different con-
cepts; namely what the patient is able to do and what he really does. The COPE-active 
programme aimed to improve both parameters and it succeeded, against increased 
costs. Literature provides little evidence about the costs-effectiveness of self-
management programmes and their separate components. Bourbeau et al. (5) con-
cluded that their comprehensive self-management programme in patients previously 
hospitalised because of a COPD exacerbation held promise for positive economic bene-
fits. Because their self-management programme included several components among 
which management of exacerbations and an unsupervised home exercise programme, 
no conclusions could be drawn about the cost-effectiveness of the separate components. 
With regard to the cost-effectiveness of pulmonary rehabilitation, Griffiths et al. (13) 
conclude that their pulmonary rehabilitation programme (6 weeks, not explicitly di-
rected towards behavioural change) was cost-effective and beneficial to the health ser-
vices. However, their evaluation was done for more severe and costly patients (mean 
number of hospitalisation days in the control group 6.9 per year versus 3.6 in COPE-II), 
and therefore the room for improvement in hospitalisation rates was larger in their 
study, influencing directly the between-group difference in costs.  
 We could not demonstrate a favourable financial balance for the COPE-active in-
tervention. Because of the length of the intervention period and the low number of 
hospital admission days in the control group, this result is not surprising. However, if 
we really have succeeded in achieving behavioural change with regard to exercise, 
COPE-active will become profitable in the next years when no more intervention costs 
will be made. An example: The costs for one patients to gain the clinical relevant distance of 
47.5 meters are €5219 (number needed to treat (=7.1) * €735). Assuming that the remaining 
costs for both groups will stay the same in the next years, except for the costs associated with the 
self-management programme and the COPE-active intervention, and assuming that patients in 
both groups will preserve 75% of their original gain in walking distance every year, after 2 years 
the costs will be €1220 per year for one patient still having the clinically relevant gain (number 
needed to treat = 10.0), and after 3 years this would turn into a benefit of  €83 per patient, and 
offering COPE-active would have become the dominant strategy. 
 Whether the effects of the COPE-active programme are large enough to merit the 
costs, is subject to debate. It depends on how much we are prepared to pay for an effec-
tive intervention. Compared to the costs of for instance lung volume reduction surgery 
($35.000) (14), our costs are minor. We can probably further improve the cost-
effectiveness ratio by being more selective with the inclusion of patients. Predictors of 
success with regard to COPD exercise programmes might be very helpful in that con-
text. In addition, costs of COPE-active might be reduced by a shortening of the pro-
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gramme length, with a risk to diminish the effects simultaneously. Troosters et al. (15) 
evaluated a 6 months out-patient rehabilitation programme and showed persistent 
training effects till 18 months after starting the program, indicating room for reduction 
of the length (and costs) of COPE-active. Finally, it should be noted that several pa-
tients in the control group received usual care physiotherapy. This surely has led to 
increased costs in the control group, but it might also have led to a reduction of the ef-
fect size.  
 In summary, we can conclude that this community-based physiotherapeutic exer-
cise programme is effective at limited increased costs.  
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Abstract  
This paper presents a practical procedure to assess compliance of physiotherapists with 
an experimental protocol (EP) in a randomised trial. Also change in compliance over 
time and potential contamination bias were studied.  
 Patients were interviewed to examine to what extent the EP was implemented by 
their physiotherapist. In 2005, 24 patients (EP: n=14; regular physiotherapy (RP): n=10) 
and in 2006 27 patients (EP: n=18; RP: n=9) were interviewed. Nine characteristics were 
scored. Scores were converted into percentages (0%: no aspects of EP - 100%: full 
implementation of EP). 
 In both time periods compliance with the EP was high (median scores 96.8% and 
92.1%, respectively), and large contrasts in scores between EP and RP groups were 
found (2005: 96.8% versus 22.7%; 2006: 92.1% versus 25.0%). The scores of patients 
treated by six physiotherapists training patients of both study groups were similar to 
the scores of patients treated by physiotherapists who only treated patients of one 
study group. 
 The compliance with the EP was high, remained unchanged over time, and no 
obvious contamination bias has occurred. Moreover, we demonstrated that compliance 
of physiotherapists with an EP can be assessed effectively by interviewing patients. 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is a systemic disease characterised by 
the progressive development of irreversible airflow limitation, leading to impaired 
muscle strength and exercise capacity (1). Physiotherapeutic exercise programmes 
given by specialised physiotherapists are a well-established part of treatment of 
patients with COPD and are incorporated in rehabilitation programmes (2; 3), self-
management programmes (4-6) and in near home rehabilitation programmes (7). The 
reported effectiveness of these programmes, however, varies considerably. Besides the 
programme content, the lack of adherence by physiotherapists with the protocol may 
explain such variability in outcomes (8).   
 This paper addresses two methodological issues in (randomised controlled) trials 
that both can impede study quality: protocol non-compliance by care providers and 
contamination of control patients with (elements of) the experimental treatment. A 
practical procedure to assess to what extent these two issues occur, developed and 
tested in the COPE-II study, is outlined in this paper. The COPE-II study is a 
randomised controlled trial to assess the additional effect of an intensive, standardized 
community based physiotherapeutic exercise programme (COPE-active) within a self-
management programme in patients with COPD. The intervention group received 
COPE-active while the control group received usual care, which may include regular 
physiotherapy when indicated. The observed effectiveness of COPE-active will depend 
on how well physiotherapists comply with the protocol (9). Assessment of the 
effectiveness of the COPE-active protocol as designed requires a complete and correct 
application by the physiotherapists.  
 Contamination bias in the COPE-II study means that patients of the control group 
are (partly) exposed to COPE-active by their physiotherapist. In this study, 
contamination bias was a possible threat in control patients receiving regular 
physiotherapy as a part of usual care. Because randomisation was performed at patient 
level, some physiotherapists participating in the COPE-II study were treating patients 
of both the intervention group and the control group. Instructions with regard to the 
COPE-active protocol were provided and physiotherapists were instructed to treat 
control patients according to the standards that were applied prior the COPE-II study. 
So, physiotherapists were trained to use the new treatment, which they had to 
withhold knowingly, in case of control patients. If physiotherapists fail to do this, true 
effects of the intervention might be concealed.  
 Before conclusions can be drawn about the effectiveness of the COPE-active 
programme, compliance of physiotherapists with the new protocol, as well as with the 
usual treatment, should be assessed. Therefore, in this study a practical procedure is 
presented to evaluate care provider compliance with a protocol and to check whether 
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contamination bias has occurred. Because compliance and the amount of contamination 
bias might change during the study, the degree of compliance of physiotherapists with 
the COPE-active protocol and the presence of contamination bias were evaluated 
during two periods within the COPE-II study (May-August 2005 and July-September 
2006).  
 
Methods  
In the COPE-II study 160 out-patients were included during a period of 18 months 
(January 2005 - July 2006). Patients were aged between 40 and 75 and had a clinical 
diagnosis of ‘moderate to severe’ COPD as defined by the GOLD-criteria (10). All 
patients attended a self-management education course, but only patients of the 
intervention group participated in the COPE-active programme for a period of six 
months. After this 6-month period these patients had the opportunity to continue with 
the COPE-active programme for another five months on a voluntary basis. Patients in 
the control group were allowed to continue regular physiotherapy as a part of their 
usual care treatment. Initiation of prescribed regular physiotherapy was also allowed.  
 Patients instead of physiotherapists were interviewed to obtain information about 
compliance to avoid possible social desirability bias by physiotherapists (11). Fifty-
three patients receiving physiotherapy (either COPE-active or regular physiotherapy) 
between May and August 2005 or July and September 2006 were asked for an 
interview. With two patients (COPE-active: n=1; regular physiotherapy: n=1) no 
appointment for an interview could be made. Therefore, 51 patients were interviewed 
by one of two independent interviewers to examine to what extent the COPE-active 
protocol was applied by their physiotherapists. In the first period, 24 patients were 
interviewed (COPE-active: n=14; regular physiotherapy: n=10), whereas in the second 
period 27 patients (COPE-active: n=18; regular physiotherapy: n=9) were interviewed. 
The 51 included patients were trained by 18 physiotherapists, all working in different 
private physiotherapy practices in the catchment area of the department of Pulmonary 
Medicine of Medisch Spectrum Twente, a large teaching hospital in Enschede, the 
Netherlands. All patients were interviewed at home using identical, semi-structured 
questionnaires. They were blinded for the purpose of the study and were unaware of 
the intended content of the COPE-active protocol. To distinguish patient compliance 
from protocol compliance by the physiotherapists, patients were not asked what 
activities they were actually performing, but what they were instructed to do. A total of 
34 questions were scored. Although the questions were open in nature, a dichotomous 
score was attributed: 0) ‘not performed according to the COPE-active protocol’ or 
1) ‘performed according to the COPE-active protocol’. 
Adherence of physiotherapists 
 - 101 - 
 The 34 questions were classified in ten different categories. During the study it 
became clear that one category ‘the choice for duration or interval training’ could not 
be validly determined by only interviewing patients. Therefore, it was decided to 
determine the COPE-active score with nine (30 questions) aspects (Table 1). Adding 
together all aspect scores led to an overall score per patient ranging from 0 (no 
exposure to aspects of COPE-active) through 9 (full exposure to the COPE-active-
protocol). Because it is reasonable to assume that after six months of physiotherapy, the 
therapy is no longer aimed at improving exercise capacity and muscle strength but on 
maintaining the improvements achieved, it was decided to leave the two aspects 
regarding structural increase in intensity of the exercises (aspect 4 and 7) out of the 
overall score for patients with physiotherapy after six months. So, in these patients the 
overall score ranged from 0-7. Finally, all overall scores were converted into 
percentages, so scores of patients receiving physiotherapy for different lengths of time 
could be compared: 0% (no aspects of COPE-active) through 100% (full implementation 
of the COPE-active-protocol). 
Table 1  The nine aspects of the COPE-active programme, with number of items per aspect, the score per item, 
and the maximum score per aspect. 
Aspect Description  Number 
of items 
per 
aspect 
Score 
per item 
Maximum 
score per 
aspect 
1 Frequency of physiotherapeutic sessions (twice a week in 
the first 6 months; once a week thereafter) 
1 1 1 
2 Duration of physiotherapeutic sessions (60 minutes) 1 1 1 
3 Type of exercises in physiotherapeutic sessions 
(cycling, walking, walking stairs, lifting (optional: push/pull)) 
5 0.25 1* 
4† Increasing intensity of physiotherapeutic sessions  5 0.25 1* 
S Number of exercise sessions at home per week (at least 
one) 
1 1 1 
6 Type of exercises at home (one strength exercise of the 
lower extremities + one strength exercise of upper 
extremities + one exercise for endurance training: walking or 
cycling) 
7 
 
  
0.14 1 
7† Increasing intensity of exercises at home 7 0.14 1 
8 Within muscle strength training session: three repeating 
series  
2 0.5 1 
9 Use of  BORG- scores  1 1 1 
 Total 30  9 
* extra exercises (aspect 3: push/pull; aspect 4:  push/pull, rowing etc.) could be scored, resulting in a surplus value of 0.25;  
final aspect score can not exceed ’1’    
†  in patients receiving physiotherapy for more than 6 months these aspects have been excluded because they are no longer 
applicable 
 
Data analysis 
Data analyses were performed using SPSS 12.0. Descriptive statistics were used to 
compare the scores of the two study groups at two different periods in time and the 
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scores per physiotherapist. When applicable between-group differences were tested 
with the Mann-Whitney U test.  
 
Results  
In both time periods (May-August 2005 and July-September 2006) patients in the 
COPE-active groups reported very high scores on protocol aspects (median scores 
96.8% and 92.1%, respectively) (Figure 1). A small and insignificant reduction could be 
observed over time (p=0.44). Combining scores of the two periods, all but two COPE-
active patients scored between 80% and 100%. The two patients scoring below 80% 
(78.7% and 61.9%) were both trained in the second time period. In both periods there 
was a clear and significant difference between the COPE-active group (median scores 
96.8% and 92.1%, respectively) and the group receiving regular physiotherapy (median 
scores 22.7% and 25.0%, respectively) (p<0.001) (Figure 1).  
 
 
 
 
 
 
 
 
 
 
   
    
 
 
 
  Figure 1  The median, 25th and 75th percentile of total scores and outliers (•) of  
  patients receiving regular physiotherapy and COPE-active in two different time  
  periods within the COPE-II study. 
 
 In figure 2 all the individual patients’ scores (n=51) are linked to the corresponding 
physiotherapists (n=18). No overlap was detected between the COPE-active group and 
patients receiving regular physiotherapy. Seven physiotherapists (1, 4, 5, 6, 7, 11, and 
12) trained patients of both study groups. The median scores of patients treated by 
these physiotherapists (COPE-active (n=17): 91.7%; regular physiotherapy (n=13): 
23.1%) did not deviate from the scores of patients treated by physiotherapists who only 
treated patients of one study group (COPE-active (n=18): 100.0%; regular physiothe-
rapy (n=7): 26.4%). 
 Regular           COPE-active  Regular         COPE-active 
 Physiotherapy   Physiotherapy 
 
          May – August 2005                                                July – September 2006 
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 The contribution of the different aspects to the total scores of both study groups for 
two sub samples (patients with < 6 months physiotherapy and patients with > 6 months 
physiotherapy at the time of the assessment for the current analyses) is presented in 
Figure 3. In both sub samples of COPE-active patients, all aspects contributed to the 
total score. In the regular physiotherapy group, the contribution of the different aspects 
to the score was less consistent over time.    
 
  
    
   Figure 2  Individual patients’ scores of the COPE-active group (○) and the  
   group receiving regular physiotherapy (∆) per physiotherapist. Six physio- 
   therapists (1, 5, 6, 7, 11, and 12) trained patients of both study groups 
 
Discussion  
This study suggests that the COPE-active protocol was appropriately performed by the 
physiotherapists in patients of the COPE-active group, and that they maintained this 
high level of compliance during the study. Furthermore, the difference between the 
scores of the COPE-active group and the group receiving regular physiotherapy was 
apparent and did not diminish during the COPE-II study. Finally, we demonstrated 
that compliance of physiotherapists with an active intervention can effectively be 
assessed by interviewing the patients participating in the trial.  
 The reason for not achieving the maximum score of 100% in the COPE-active group 
was mostly due to home work sessions, which of all COPE-active aspects are most 
likely to be biased by patient report (i.e. patient non-compliance). It is possible that 
patients claim that no instructions for exercise at home were given, because they did 
not act on these instructions. This is underlined by the fact that one patient that scored 
obviously low on aspects referring to exercises at home (and with an overall score of 
Physiotherapists 
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less than 80%), was trained in the same practice as another COPE-active patient who 
scored 100%. So, the actual compliance of physiotherapists could have been better  
 
   * 1) number of physiotherapeutic sessions per week; 2) duration of a physiotherapeutic  
 session; 3) type of exercises in physiotherapeutic sessions; 4) increasing intensity of  
 physiotherapeutic sessions; 5) number of exercise sessions at home; 6) type of exercises  
 at home; 7) increasing intensity of exercises at home; 8) number of repeating sessions in  
training; 9) use of Borg-scores.  
 
 
 
 
 
than showed by the results. In this study it was attempted to prevent socially desirable 
answers of patients by creating a non-condemning and confidential atmosphere by the 
independent interviewer, and by not asking questions about whether exercises were 
really performed.  
 With regard to contamination bias in this trial, exposure of patients in the usual 
care group to the COPE-active treatment was largely limited to two aspects: ‘duration 
of physiotherapeutic session’ and ‘type of exercises within physiotherapeutic sessions’. 
This was not unexpected because training aimed at improvement of exercise capacity in 
patients with COPD will frequently last 60 minutes and regularly incorporates walking 
and/or cycling. Therefore, these two aspects seemed not to be very unique for the 
COPE-active programme and retrospectively it can be concluded that they did not 
contribute to the contrast between COPE-active and regular physiotherapy. The 
negligible exposure of usual care patients to the other seven COPE-active aspects as 
Figure 3  Relative contribution (%) of each of the nine aspects constituting 
the (mean) COPE-active score, for both the COPE-active patients and those 
receiving regular physiotherapy. Data are divided in patients receiving less 
than six months (maximal contribution of 9 items) and more than six months 
(maximal contribution of 7 items) of physiotherapy. 
Adherence of physiotherapists 
 - 105 - 
well as the low and relatively stable overall COPE-active score of these patients over 
time, underline the absence of contamination bias. Moreover, the difference in scores 
between both study groups was as obvious in practices treating patients of both study 
groups, in which the risk of contamination would be higher, as in practices treating 
patients of only one of the two study groups. 
 In this study patients were interviewed instead of physiotherapists to avoid social 
desirability. Patients were blinded for the purpose of the study and were unaware of 
the content of the COPE-active protocol. Therefore, although some measurement error 
will have occurred, it is unlikely that respondents in this study provided biased 
reports. It should be noted that the interviewer in this study was not blinded for the 
study group allocation of patients. Interviewer bias (intentional or unintentional 
prompting by the interviewer, which affects the patient’s response) therefore might 
have occurred, but can never explain the vast contrast between both study groups.  
 These results imply that the compliance of physiotherapists with the studied 
protocol was excellent and that no obvious contamination bias had occurred. The 
method applied seems suitable to assess how well treatments (both the experimental 
and the control) are adhered to in randomised controlled trials.  
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Abstract 
Many definitions of COPD exacerbations are reported. The choice for a definition 
determines the number of exacerbations observed. However, the effect of different 
definitions on the effect sizes of randomized controlled trials is unclear.  
 This paper provides an overview of the large variation of definitions of COPD 
exacerbations from the literature. Furthermore, the effect of using different definitions 
on effect sizes (relative risk and hazard ratio) was investigated in a randomized 
controlled discontinuation trial of inhaled corticosteroids (COPE study). The following 
definitions were applied: 1) unscheduled medical attention; 2) a course of oral 
corticosteroids/antibiotics; 3) deterioration in two major or one major and one minor 
symptom according to Anthonisen; 4) a change in >1 symptom; 5) change in >2 
symptoms; 6) combination of 2) and 4). Relative risks for the exacerbation rate ranged 
from 1.19 - 1.49, and hazard ratios for time to first exacerbation from 1.36-1.84 for the 
various definitions, varying from non-significant to significant.  
 Since the definition of a COPD exacerbation has an impact on the effect size of 
interventions, there is an urgent need for concerted attempts to reach agreement on a 
definition of an exacerbation. Also, the exact definition to be used in a study should be 
specified in the protocol. 
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Opinion paper 
Until quite recently, almost all major studies in Chronic Obstructive Pulmonary Disease 
(COPD) used FEV1 as the main outcome parameter (1-3). The advantage of FEV1 is that 
it is easily measurable, reproducible, and everyone knows the exact definition of FEV1. 
Unfortunately, this highly valued outcome parameter is not very closely related to 
patient centered outcomes (symptoms, quality of life, exercise capacity). More recently, 
exacerbations have become an additional primary outcome in many clinical trials on 
COPD next to conventional outcomes such as FEV1 (1), quality of life (4), 
hospitalizations (5), and mortality (6). Exacerbations are closely associated with quality 
of life, impose a great burden to the patient, and cause a considerable economic burden 
to society (7). Unfortunately, unlike FEV1, measuring an exacerbation is not 
straightforward and highly variable definitions exist. This is reflected in the medical 
literature when research studies report on exacerbations. This paper provides an 
overview of the range of definitions encountered, which would even have been broader 
if we would also have asked patients how they define an exacerbation (8).  
 One of the earliest and most quoted definitions of an exacerbation is the symptom 
based definition of Anthonisen et al (9). Since then many definitions have been 
reported in the literature (10), among which is the frequently used definition based on 
episodes for which oral corticosteroids and/or antibiotics are prescribed (1;2;6). One of 
the latest attempts has been described by Rodriguez-Roisin with an expert panel (11) 
that defined an exacerbation as ‘a sustained worsening of the patient’s condition from 
the stable state and beyond normal day to day variations, that is acute in onset and 
necessitates change in regular medication in a patient with underlying COPD’. So, 
several attempts have been made to achieve consensus about the definition of an 
exacerbation, but until today no single definition has been broadly accepted, nor has 
one of these definitions have ever been validated (including, contrary to popular belief 
the one by Anthonisen et al). There is a clear lack of a gold standard.  
 One of the main reasons for the diversity of definitions is probably the 
heterogeneous nature of exacerbations. Exacerbations can arise as a result of bacterial 
infections, viral infections, environmental triggers and/or co-morbidities and about one 
third of exacerbations have no identifiable cause. Consequently, the clinical 
manifestations of the exacerbations are diverse and very difficult to capture in one 
definition. Preferences for a specific definition of an exacerbation are likely also 
influenced by the aim of studies (e.g. studies assessing effects of antibiotics will prefer a 
different definition than self-management studies). Also the choice for a specific 
definition might be restricted by the design of a study. For instance, the estimation of 
the number of exacerbations from databases in a retrospective study is often limited to 
health care use.  
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 The lack of consensus and the variability in definitions used make it hard to com-
pare the results of studies. It is obvious that some definitions give rise to a much higher 
incidence of exacerbations whereas other more strict definitions will lead to a lower 
incidence. This has been demonstrated in a study of Seemungal et al (12) where pa-
tients had to report symptoms in a daily diary. There were half as many exacerbations 
when a definition was used based on whether a medical doctor would actually pre-
scribe additional treatment, compared to a symptom based exacerbation derived from 
the diaries.  
 Though it is clear that no agreement exists for the definition of an exacerbation, and 
it is both intuitive and shown in analyses that the use of different definitions affects the 
incidence of exacerbations, it still remains to be established whether these differences 
actually influence the estimates of treatment effects in randomized controlled trials and 
their statistical significance. In other words the question is whether a particular inter-
vention A would be superior over intervention B using one definition, while A and B 
would be equally effective using another definition? If so, interpreting the literature to 
decide on effective treatment policies for COPD will be very difficult. Moreover, re-
searchers and companies performing clinical studies might be tempted to choose a 
definition of an exacerbation that suits their data best at the end of the study. To pro-
vide an idea of the impact of fitting definitions to the data observed, this paper 
discusses the impact and relevance of different outcome definitions on study results. 
  
How have exacerbations been defined in study reports?  
One hundred and thirty one articles were identified in a MEDLINE search (January 
1987 – May 2007; [[chronic obstructive pulmonary disease [tw] OR pulmonary disease, 
chronic obstructive [MeSH] OR COPD] AND exacerbation* [tw] AND Randomized 
Controlled Trial [pt] AND English [la] NOT review [pt]] in which only journals with a 
citation index ≥ 3 in 2006 were included (Figure 1). Only 53% of these studies provided 
a definition of an exacerbation. In most of the studies in which no definition of an exac-
erbation was given, the variable ‘exacerbation’ was used as an inclusion criterion (87%). 
In studies using ‘exacerbation’ as a primary or secondary outcome, a definition of an 
exacerbation was given more frequently (88%, Figure 1).  
 In 69 studies, a definition of an exacerbation was provided (see Table E1 in the 
online data supplement). The various items used to define an exacerbation are summa-
rised in Table 1. Remarkably, only one of the definitions included the variable ‘lung 
function’. A ‘change in symptoms’ was used in 54 studies, but in 14 of these studies no 
description of the specific symptoms was provided. In 26 studies the definition of an 
exacerbation was based completely on this change in symptoms. More recent studies 
based the definition less frequently on symptoms alone (1987-1999: 68.5% (11 out of  
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Figure 1  Flow chart of the search strategy. Of the included articles, the context in which the variable  
‘exacerbation’ was used is specified and it is noted whether a definition of an ‘exacerbation’ was defined.  
 
Table 1  Summary of the items used to define an exacerbation (n=69)  
Variables  Number of studies % of total 
(n=69) 
   
Change in symptoms  54 78.3 
     Dyspnoea          36      52.2 
     Sputum production      35      50.7 
     Cough      30      43.5 
     Sputum purulence      27      39.1 
     Wheezing      15      21.7 
     Fever      10      14.5 
     Sore throat        7      10.1 
     Nasal discharge        7      10.1 
     No specific symptoms mentioned      14      20.3 
Respiratory rate and/or heart rate   5 7.2 
Change in use of medication 29 42.0 
     Bronchodilators      13      18.8 
     Course of oral corticosteroids and/or antibiotics      27      39.1 
Use of a specific time factor (e.g. 24 hours) 22 31.9 
Hospitalization 15 21.7 
Unscheduled medical attention 10 14.5 
Clinical diagnosis (not further defined)   9 13.0 
Emergency room visits   3 4.3 
Chest problems   5 7.2 
Chest X-ray   5 7.2 
Physical examination   3 4.3 
Arterial blood gases   1 1.4 
Lung function   1 1.4 
 
16 studies) versus 2003-2007: 20% (7 out of the 32 studies)). From 2000 onwards, the 
combination of ‘a change in symptoms’ and ‘a short course of oral corticosteroids 
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and/or antibiotics’ was encountered more frequently (n=16).  In definitions (partly) 
based on symptoms, the number and type of symptoms varied considerably. Symp-
toms most frequently used were dyspnoea, sputum production, cough, and sputum 
purulence. Changes in the use of medication (bronchodilators and courses of oral corti-
costeroids or antibiotics) were incorporated in 29 definitions. Three studies, all 
published after 2002, defined an exacerbation solely by prescription of a course of oral 
corticosteroids and/or antibiotics. Whereas the variable ‘a clinical diagnosis of an exac-
erbation’ was mostly incorporated in studies using exacerbation as an inclusion criteria 
(7 out of 9 studies), the variable ‘unscheduled medical attention’ was mainly used 
when exacerbations were used as an outcome measure (9 out of 10 studies). No other 
clear distinctions were found between definitions applied in studies in which ‘exacer-
bation’ was used as either an outcome measure or inclusion criterion. A time period 
(e.g. 24 hours) during which the change in symptoms had to be persistent was pro-
vided in 22 studies. More recent studies applied this ‘time period’ as frequently as older 
ones. Finally, a classification in severity of exacerbations based on health care utilisa-
tion (mild – moderate – severe) was used in 14 studies; 11 of these studies were 
published after 2000.  
 
What is the impact of different definitions of exacerbation on effect size estimation 
in randomized controlled trials? 
Using data from the COPE-study (a randomized, double blind, placebo controlled trial 
on discontinuation of inhaled corticosteroids (ICS)) (13), we were able to assess the po-
tential impact of exacerbation definition on size and significance of treatment effect. 
Therefore, six definitions of exacerbations (see Table 2) and two effect parameters that 
are commonly used in the literature (‘exacerbation rate (=number of exacerbations per 
year)’ and ‘time to first exacerbation’) were selected for the analyses. As Aaron (14), we 
believe that a good analysis for reduction of exacerbations of COPD due to any inter-
vention is to use an adjusted poisson regression. However, this analysis was relatively 
seldom used in the studies of our literature search. In line with the mainstream of this 
literature of COPD exacerbations we analysed exacerbation rate as a dichotomous vari-
able (0 exacerbations per patient per year versus 1 or more exacerbations). In this way, 
relative risks (RR), defined as the proportion of patients with 1 or more exacerbations in 
the placebo group compared to the proportion of patients with 1 or more exacerbations 
in the intervention group, were calculated. Differences between groups were assessed 
by cross-tables and Chi-square statistics. Cox regression analyses were performed to 
calculate hazard ratios with accompanying confidence intervals for time to first exacer-
bation from the start of the blinded study period. 
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* Relative Risk of one or more exacerbations of the placebo group (P) compared to the intervention group (I)  
† Hazard Ratio for time to first exacerbation for the risk of the placebo group (P) compared to the 
intervention group (I) 
 
 The results of the analyses of the COPE-data are presented in Table 2. To be able to 
compare the results of the analyses on all six definitions, we had to perform these 
analyses on the same set of patients. This resulted in the removal of 20 randomized pa-
tients because they had missing information on at least one variable (intervention n=11; 
placebo n=9); analyses were performed on 228 patients (intervention: n=116 and pla-
cebo: n=112). Applying the different definitions of exacerbations to the COPE-data, the 
relative risks ranged from 1.19 to 1.49 and from statistically non-significant to statisti-
cally significant, whereas the hazard ratios ranged from 1.36 to 1.84, also from non-
significant to significant. Use of the definition ‘change in at least one symptom’ resulted 
in a non-significant relative risk and hazard ratio, while application of the definition 
‘unscheduled medical attention’ resulted in a non-significant relative risk and a signifi-
cant hazard ratio. The highest (statistically significant) relative risks and hazard ratios 
were found with the definitions based on ‘treatment with a short course of oral corti-
costeroids and/or antibiotics’ and ‘exacerbation according to Anthonisen’.  
 
Table 2  Impact of using different definitions of exacerbations in a randomised controlled trial (COPE-study) 
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116 
 
54 
 
1.19  
 
1.47  
Unscheduled medical attention  
P 
 
112 
 
62 
 
(0.92-1.54) 
 
(1.02 - 2.12) 
          
I 
 
116 
 
41 
 
1.44  
 
1.84  Course of oral corticosteroids  
and/or antibiotics 
P 
 
112 
 
57 
 
(1.06-1.96) 
 
(1.23 - 2.75) 
          
I 
 
116 
 
39 
 
1.49  
 
1.66  Exacerbation according   
to Anthonisen  
P 
 
112 
 
56 
 
(1.09-2.04) 
 
(1.10 - 2.51) 
          
I 
 
116 
 
41 
 
1.42  
 
1.65  At least one symptom and a course 
of prednisolone or antibiotics  
P 
 
112 
 
56 
 
(1.04-1.93) 
 
(1.10 - 2.47) 
          
I 
 
116 
 
49 
 
1.23  
 
1.36  
At least one symptom 
  P 
 
112 
 
58 
 
(0.93-1.62) 
 
(0.93 - 1.99) 
          
I 
 
116 
 
41 
 
1.42  
 
1.58  At least two symptoms 
  
P 
 
112 
 
56 
 
(1.04-1.93) 
 
(1.05 - 2.37) 
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Implications for randomized controlled trials 
We demonstrated that different definitions of an exacerbation led to substantially 
different effect sizes and hence different conclusions about the effect of withdrawing 
inhaled steroids in patients with COPD. Thus it really matters which definition of an 
exacerbation is chosen. Considerably larger relative risks and hazard ratios were found 
with the ‘Anthonisen definition’, that specifically identifies major and minor symptoms 
(aimed at bacterial exacerbations), but also with the definition incorporating ‘a short 
course of oral corticosteroids and/or antibiotics’. Two definitions of exacerbations did 
not lead to statistically significant effect sizes: ‘unscheduled medical attention’ and 
‘change in at least one symptom’. With regard to the definition ‘unscheduled medical 
attention’, a possible explanation for the lack of significance might be that data were 
collected in a study-setting. Participation in the COPE study might have increased the 
patients’ focus on their COPD, hence symptoms related to other diseases might more 
often have been interpreted as a COPD exacerbation. As a result, substantially more 
self-reported, false positive ‘exacerbations’ might have appeared in both the 
intervention and the control group. Consequently, the effect size will change in the 
direction of ‘the null’ (no effect). The fact that also ‘change in at least one symptom’ did 
not result in a statistically significant relative risk and hazard ratio, suggests that more 
symptomatic change is needed for a definition of an exacerbation. Indeed when 
defining an exacerbation by at least two symptoms as opposed to one, this led to 
statistically significant results.  
 We were interested whether the effect of the use of various definitions in the 
COPE-study, was also true in another study. Therefore, we performed the same 
analyses on the data of the COSMIC-database (1), also a placebo controlled ICS 
discontinuation trial (data not shown). The authors of the COSMIC-study reported 
statistically significant treatment effects only for mild exacerbations, whereas no effects 
were observed for moderate and severe exacerbations. Varying the definitions did not 
lead to obvious differences in relative risks and hazard ratios. All effect sizes were 
around ‘the null’, and none of them reached significance. Because the selected 
definitions were not directed towards mild exacerbations (change in the number of 
inhalations of short-acting B2-agonist), effect sizes did not deviate from ‘the null’, 
simply because of the absence of an effect for moderate and severe exacerbations. 
The rationale of this paper is not to recommend a specific definition for 
exacerbations to be used in studies on the effects of interventions in COPD. Rather we 
wrote this paper to show the great variety in the definition of exacerbations in the 
literature, and its impact on results and inferences. The results suggest that the 
currently popular definition ‘use of courses antibiotics and/or oral corticosteroids’ leads 
to the largest effect estimates, although we did not formally test the differences. A 
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maximum effect size is preferred, both for reasons of efficiency and of ethics, provided 
that measuring the specific outcome does not lead to increased costs or burden for the 
patients. This is the case when registering courses of antibiotics and/or oral 
corticosteroids.  
 In addition to the caveat we have discussed here, i.e. whether different definitions 
of exacerbations matter, the methods for counting and analysing them can also result in 
major differences in the magnitude of the treatment effect, as recently demonstrated by 
Aaron et al (14). Our data also shows that the use of different analysis techniques can 
lead to different effect sizes. Hazard ratios are higher than the corresponding relative 
risks, probably due to the inclusion of information on the time to the exacerbation in 
the former effect measure.  
 Researchers may be tempted for various reasons to perform several analyses with 
various definitions of exacerbations and various outcome estimates and choose the one 
that best serves their purpose. Such an approach would obviously lead to more false 
positive statements on treatment effects. We think that it is of paramount importance 
that prior to a study, both the exact definition of an exacerbation and the intended 
analyses should be reported. Major journals at current only require registering a study 
in one of the worldwide trial registers. We believe this is not sufficient, because many 
details of studies do not yet need to be defined. In the context of exacerbations: specific 
definitions of exacerbations and description of the specific analyses are not yet 
mandatory. This should be clearly defined in complete protocols prior to the study, and 
we plead for uploading the complete protocol and amendments to the public domain 
registration sites. Additionally and in the meantime, the medical community, 
researchers and clinicians, should put great, joint effort in reaching consensus on one or 
two preferred definitions. The recently frequently cited number of courses of systemic 
steroids and/or antibiotics performed well in our analyses in this paper and should 
remain an important candidate consensus definition for trials. At the same time, 
consensus on analysis methods needs to be reached. 
 
Conclusions 
We have shown that distressingly many definitions of COPD exacerbation exist, and 
that the definition and analysis technique chosen to assess the treatment effect have a 
major impact. This could potentially lead to opportunistic presentation of results from 
clinical trials. These results stress the need for concerted attempts to reach consensus 
about definitions and analysis methods of COPD exacerbations to be used in future 
randomized controlled trials.  
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Abstract 
Little is known about effects of immediate reactivation in COPD-patients hospitalised 
for an acute exacerbation. In a semi-randomised trial, the effect of an immediate 
reactivation programme (PULMOFIT-MST) on length of stay in the hospital was 
evaluated.  
 Directly after admission patients were allocated to an intervention (n=29) or control 
ward (n=29). All patients received usual care. In addition, intervention patients 
received PULMOFIT-MST: they had to exercise three times a day for at least 15 minutes 
with increasing intensity.  
 No difference in the length of hospital stay was found (intervention: 8.7 ± 5.3 days 
versus control: 8.4 ± 5.6 days; hazard ratio 0.96 (95% CI: 0.56 – 1.62)). After the first four 
days a greater recovery of walking distance (3 minute walking test) was found in the 
intervention group, which increased further to the day of medical discharge (p=0.018). 
No between-group differences were found on dyspnoea, health status, activities of 
daily living, and relapse rate.  
 Although no effect was detected on length of hospital stay, a clinically relevant 
change in walking distance was achieved. So, patients were discharged in a better 
condition and we submit that a better starting point was created for (outpatient) 
reactivation. 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of disability and 
mortality worldwide (1;2). Morbidity and mortality among COPD-patients are strongly 
related to acute exacerbations. Exacerbations may lead to hospital admissions and have 
a major impact on disease evolution and costs (3). 
 In patients hospitalised because of an exacerbation, muscle weakening occurs, 
which is still detectable three months after hospitalisation (4). This weakening can be 
caused by several factors, including the increased inflammatory state at the time of the 
acute exacerbation (4). Inactivity during hospitalisation will lead to further decrease of 
condition and strength (5;6). Because of feelings of illness and shortness of breath, 
inactivity is the rule rather than the exception (7). After discharge, condition and 
strength can be optimised by participation in a rehabilitation programme (8). However, 
by implementing immediate reactivation during hospitalisation, in-hospital decline in 
exercise capacity and strength might be prevented. Only two studies have been 
published in which the effects of early reactivation are studied in COPD-patients 
hospitalised for an exacerbation (9;10). These programmes did not start immediately, 
but 3-8 days after admission and positive effects on exercise capacity were reported 
(9;10). No difference in length of hospital stay was seen (9).  
 We developed an immediate reactivation programme starting within 24 hours after 
admission: PULMOFIT-MST. We hypothesised that it could reduce the length of 
hospital stay by preventing loss of muscle strength and exercise capacity and thereby 
initiating a faster recovery of activities of daily living. We evaluated the effect of the 
programme on length of hospital stay and in addition on walking distance, activities of 
daily living, dyspnoea, health status, and number of readmissions.  
 
Material and methods  
Patients 
Patients were recruited from February 2006 through January 2007 and had to meet the 
following criteria; 1) a clinical diagnosis of COPD according to the global initiative for 
COPD (GOLD) criteria (11); 2) a clinical diagnosis of an exacerbation for which 
hospitalisation was required; 3) (ex-) smoker; 4) age >40 years; 5) a life expectancy > 3 
months; 6) able to understand and read Dutch; and 7) an informed consent prior to 
participation. Patients were excluded if they had: 1) pneumonia; 2) fever (>38.5 C°); 3) 
severe confusion; 4) severe heart failure, New York Heart Association class III or IV; or 
5) relevant co-morbidity seriously influencing mobility. The hospital’s medical ethical 
committee approved this study.  
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Study design 
Patients presenting themselves to their chest physician or the emergency room of 
Medisch Spectrum Twente Hospital with an acute COPD exacerbation for which 
hospitalisation was required, were asked to participate. Two respiratory wards were 
designated as an intervention and control ward. We used a semi-randomised design. 
When beds were available on both wards, patients were balanced over the two wards 
using a minimization programme (12) with regard to GOLD stage (11). When a bed 
was available on only one of the two wards, the patient was assigned to this specific 
ward. So also in these cases, assignment of the patient to one of the two wards could no 
be influenced by the researcher or physician. All patients received usual care treatment, 
meaning treatment patients receive regardless of the study. For patients in the 
intervention group the PULMOFIT-programme was added. If indicated by the chest 
physician, physiotherapy was also prescribed to control patients. The content of these 
physiotherapeutic sessions was very heterogeneous. Besides breathing and 
mobilization exercises, they sometimes included exercise training, however on no 
account in the same structure, intensity and frequency as PULMOFIT-MST.  
 
PULMOFIT-MST 
A multi-disciplinary task group (chest physicians, nurses, physiotherapists, and human 
movement scientists) developed the PULMOFIT-MST protocol based on latest evidence 
(13). It included both endurance and strength training and was tailored for hospital 
admitted patients. The PULMOFIT-MST protocol aimed at an active role of COPD 
patients during their stay in the hospital. Patients were asked to perform three daily 
training sessions of 15 minutes each. One session was assisted by a physiotherapist. 
PULMOFIT-MST consists of four levels of increasing difficulty (Figure 1). Within four 
hours after admission, the programme was started by the nurse who instructed the first 
exercises and distributed the workbook with a description of exercises and space for 
physiotherapists en patients to note exercise intensities and daily experiences, 
respectively. Within 24 hours after admission, the physiotherapist continued the 
programme by choosing the appropriate follow-up level and determining exercise 
intensities. Every day the physiotherapist evaluated the exercises and the 
appropriateness of the training level and training intensity. Peripheral muscle strength 
training using weight bands was performed in three series of 8 repetitions. The training 
started at 70% of the one repetition maximum (maximum weight with which they 
could perform one well-coordinated move) for each muscle group (biceps, triceps and 
quadriceps). During the endurance training an intensity of minimal 60% of the peak 
work rate was strived for. In absence of an incremental maximal cycle ergometry test or 
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6MWT (usually the case during hospitalisations for an exacerbation), the intensity was 
determined and adjusted based on clinical appearance and performance.  
 
    
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  The four levels of the immediate reactivation programme: PULMOFIT-MST 
 
Outcome measures  
The primary outcome measure was length of stay, defined as number of days between 
day of admission and day of medical discharge. It was determined by the chest 
physicians and distinguished from the actual day of discharge because some patients 
remain in hospital longer than medically necessary (e.g. waiting time before referral to 
a nursing home). Secondary outcomes were walking distance, dyspnoea, health status, 
activities of daily living, and readmissions due to an exacerbation. All measurements 
were done on the same time on day 0, day 4 and day of medical discharge. For patients 
admitted after 5 p.m., the next day was defined as day 0.  
 Walking distance was assessed by means of the 3 minute walking test (3MWT) 
with standardised encouragement (14) instead of the more widely used 6 minute 
walking test (6MWT). On the day of admission it was only achievable to perform the 
shorter and less exhausting 3MWT in these severe ill patients. Physiotherapists were 
trained in executing the 3MWT. Patient’s dyspnoea in rest was quantified with the 
BORG-score ranging from 0 (no shortness of breath) to 10 (worst imaginable degree of 
shortness of breath) (15). Health status was evaluated by the self-administrated 24-hour 
version of the Clinical COPD Questionnaire (CCQ) (16). The total score was calculated 
by adding the separate scores (0: no limitation - 6: totally limited) of the ten questions 
and dividing that number by ten. A change of  ≥ 0.4 represents the minimal clinical 
LEVEL I: 
Exercises on chair; instructed by nurse
Three simple exercises for the upper and 
lower extremities 
LEVEL II: 
Exercises on chair
Muscle strength upper and 
lower extremities
LEVEL III: 
Exercises on side of bed
Muscle strength upper and 
lower extremities
Patient is able to walk 
around the room without 
help
Patient is able to walk in the 
corridors and to perform level 
III exercises independently
LEVEL IV: 
Progressive training of 
walking and cycling plus 
exercises level III
NO YES
YES
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important difference (MCID) (17). Activities of daily living were evaluated by means of 
the Barthel Index (18) that is frequently used in frail elderly people and stroke patients 
(19), and some COPD-studies (20). Nurses had to answer ten questions about the 
patient’s daily performance (e.g. feeding, mobility, bathing) on 2- and 3-point scales, 
resulting in a score from 0 (completely dependent) to 20 (completely independent). A 
change of ≥ 1.85 represents the MICD in stroke patients (21). Finally, readmission due 
to an exacerbation within 28 days after discharge was defined as a relapse.  
 
Statistical analyses 
A difference of 2.5 days in length of stay between both groups was deemed clinically 
relevant. Forty patients per group were required to detect this difference with 80% 
power and a type I error probability of 5%. Power calculations were based on the 
assumption that all patients would survive the hospital admission. In reality one 
patient died during hospital admission, therefore Cox proportional hazards analysis 
was used to analyse duration of hospital stay and Kaplan Meier Graphs were 
constructed instead of the pre-planned t-tests or Wilcoxon tests. All statistical analyses 
were performed on an intention-to treat basis using SPSS version 12.0. The effect of 
PULMOFIT-MST on walking distance, dyspnoea, health status, and activities of daily 
living was assessed by repeated measurements analysis using the SSPS procedure for 
mixed models. Baseline values were subtracted from follow-up values to correct for 
baseline differences. Between-group difference in readmission rate was analysed with a 
Chi-square test. 
 
 
 
 
 
 
 
 
    Figure 2  Flow diagram of subject progress during the PULMOFIT-study 
 
Results 
Of the 149 patients assessed for eligibility, 58 patients were assigned to the intervention 
(n=29) and control group (n=29) (Figure 2). One patient, assigned to the control group, 
died during follow-up due to hospital acquired pneumonia. Patient characteristics and 
baseline values are shown in Table 1. No between-group differences in baseline 
characteristics were found. Twenty-five patients (86.2%) of the control group received 
usual care physiotherapy.  
Assessed for eligibility: n=149
Balanced: n=58
PULMOFIT-MST group (n=29)
Control group (n=29)
Excluded: n=91 
Not meeting inclusion criteria (n=57)
Refused to participate (n=14)
Other reasons (n=20)
Withdrawn during follow-up: n=1
Control group (n=1: dead)
Follow-up till discharge: 
PULMOFIT-MST group: n=29
Follow-up till discharge: 
Control group: n=28
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Table 1  Baseline characteristics of the two study groups, data are presented as 
mean (SD) or numbers 
 Intervention group  
(N=29) 
Control group 
(N=29) 
Age (yrs)  68.4 (9.6) 69.6 (10.2) 
Gender (M/F) 15/14  14/15  
GOLD stage (I+II/ III+IV) 7/22  6/23  
3 Minute Walking Test (meters)  96.3 (37.8) 107.1 (42.3) 
Borg-score  3.0 (1.4) 3.8 (2.0) 
Clinical COPD Questionnaire  3.2 (0.8) 3.1 (1.0) 
Barthel Index  17.4 (2.7) 15.3 (4.4) 
 
 The mean length of hospital stay was 8.7 ± 5.3 days for the intervention group 
versus 8.4 ± 5.5 days for the control group (hazard ratio 0.96 (95% confidence interval: 
0.56 – 1.62)) (Figure 3). Also no difference was found using the actual day of discharge 
(9.8 ± 5.5 days for the intervention group versus 9.4 ± 5.6 days for the control group). 
 
    Figure 3  Time to hospital discharge curve (Cox regression)   
  
The secondary outcomes walking distance, dyspnoea, health status, and activities of 
daily living are plotted in Figure 4. In both study groups, these outcomes improved 
significantly over the study period (p<0.05), with the exception of dyspnoea. However, 
the between-group difference was only significant for walking distance (p=0.018). The 
intervention group showed a greater recovery of walking distance compared to the 
control group after de first 4 days (8 meters), which increased to 17 meters at the day of 
medical discharge (see Figures 4-5). The remaining secondary outcome measures did 
not reach significant between-group differences. Finally, three patients in the 
intervention group and four patients in the control group were readmitted within 
28 days.  
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Figure 4  Mean change from baseline in walking distance (3MWT), dyspnoea  
score (BORG-scale), health status (CCQ), and activities of daily living (Barthel Index),  
at day 4 and day of medical discharge of the intervention (■) and control group(▲) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
   Figure 5  Change in walking distance (3MWT) of both study groups 
   at day 4 and day of discharge compared with baseline (day 0)  
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Discussion 
This study showed that immediate reactivation did not reduce the length of 
hospitalisation, dyspnoea, health status and activities of daily living in patients with an 
acute COPD exacerbation. However, a significant improvement in walking distance 
was found. The intervention group showed a greater recovery of walking distance 
compared with the control group after de first four days, which increased further to the 
day of medical discharge.  
 As in the study of Nava (9), no effect on length of hospital stay was found. One of 
the most likely explanations for this lack of effect could be the complex processes and 
circumstances that influence discharge from the hospital. Besides medical recovery, 
factors such as age (22), presence of co-morbidities (22), availability of community 
resources (23), and attitudes of a multidisciplinary team with regard to discharge, 
might also play a role. In our study, no between-group differences in age were detected 
and patients with co-morbidity seriously influencing mobility were excluded. To 
overcome problems related to delayed discharge due to e.g. a scarcity of community 
resources, we have chosen for the concept of “medical discharge” instead of the date of 
the “real discharge”. Because early discharge was not actively promoted in our study, 
routines around discharging patients remained unaltered on both wards. These 
routines might be so rigid that length of hospital stay is difficult to affect by a change in 
medical recovery alone.  
 At the day of discharge, a significant improvement in walking distance in favor of 
the intervention group was detected. This result was also found in the studies by 
Kirsten and Nava (9;10). However, these studies investigated early instead of 
immediate reactivation (programmes started respectively 6-8 and 3-5 days after 
admission) and continued for a longer period (11 and ±30 days respectively). The 
difference in walking distance of 17 meters found in our study was already achieved 
after approximately 8.5 days and although it did not reach half of the MCID of the 
6MWT (=27 meters), an effect size of 0.47 (mean difference (=17.0) / pooled standard 
deviation (=36.1)) was found. This effect size is defined as moderate by Cohen and is 
large enough to be visible to the naked eye (24). Obviously, immediate reactivation can 
visibly improve walking distance in a short period of time. Therefore, a better starting 
point for an (outpatient) reactivation programme might be created, in which further 
improvements can be strived for (25).  
 Between group differences might have been diminished by the fact that most 
patients in the control group (86.2%) also received physiotherapy as part of usual care, 
although these sessions did by no means reach the intensity and frequency of 
PULMOFIT-MST. Insufficient group sizes might thereby have influenced the 
significance of the results, but not the size of the effects. Besides another explanation 
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namely that simply no between groups differences in these secondary outcomes exist, 
other explanations should be considered. Breathlessness was measured at rest because 
this could easily be standardised. Retrospectively, this might not have been the best 
choice because breathlessness is associated with some level of activity in most COPD-
patients, resulting in a relatively low average baseline score with little room for 
improvement. Activities of daily living and health status significantly improved within 
each study group, but no differences between the study groups were found. The 
relatively short length of hospital stay together with the presence of a fast natural 
recovery in both groups might have limited measurable effects of PULMOFIT-MST. 
Although no (significant) difference in relapse rate between both groups was found, we 
suggest to incorporate this outcome again in future studies (with larger sample sizes) 
because there is evidence for a strong association between physical activity and 
reduced risk of readmission in the hospital (1).  
 Randomisation or minimisation of all patients was not possible, because no 
continuously free beds on both wards could be arranged. Whereas no differences in 
known baseline characteristics were found, we can not rule out another currently 
unknown bias. Furthermore, because all measurements were performed by 
physiotherapists and nurses who were also responsible for the intervention, 
information bias and an overestimation of the effects could have been occurred. Using 
the shorter and less exhausting 3MWT (compared to the 6MWT), we were still able to 
register walking distance in these often very ill patients at the day of admission. 
Because of the severe physical condition it was not feasible to perform an extra practice 
3MWT at the day of admission. The lack of practice test might have led to an 
overestimation of the increase in walking distance within both study groups over time 
(26). However, this will not influence the validity of the observed between-group 
difference. Additionally, a lack of practice test increases variability, thereby increasing 
the risk for a type II error (false negative result), but we still found significant between-
groups differences. 
 PULMOFIT-MST assumed an active role of the patient. This is in conflict with the 
traditional view that ill patients have to rest. It might need more time and effort to 
reverse this traditional view both in hospital staff as well as in patients to reach the 
maximum intervention effect of this novel approach. Since it was not feasible to do an 
incremental maximal cycle ergometry test or 6MWT prior to the start of level IV in our 
setting, the determination of the intensity for endurance training was guided by clinical 
appearance and performance of patients. This might sometimes have led to a 
suboptimal training intensity. Therefore the inclusion of (sub)-maximal tests should be 
strived for in future programmes to guarantee a more optimal training intensity. 
Further studies are needed to learn more about the most optimal training intensity and 
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safety of immediate reactivation programmes. The results and conclusions with regard 
to effectiveness and safety of this study are not generalisable to all patients hospitalised 
with a COPD-exacerbation, because patients with serious co-morbidities were 
excluded.  
 The results of this study demonstrate that patients hospitalised with an acute 
exacerbation are well trainable. Although no effects were detected in the length of 
hospital stay, a clinically relevant change in walking distance was achieved without 
any sign of adverse reaction to the training. We conclude that PULMOFIT-MST 
improves the patients’ condition at discharge and creates a better starting point for 
subsequent (outpatient) reactivation programmes. More and larger studies are needed 
to optimise and evaluate immediate in hospital reactivation programmes, preferably 
directly followed by an out-patient exercise programme.  
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General Discussion 
This thesis describes the results of the COPE-II study on the effectiveness and costs of 
two components of self-management programmes, namely, self-treatment of exacerba-
tions and a community-based physiotherapeutic exercise programme (COPE-active). 
This is of major importance as the literature so far is still inconclusive and major con-
cerns are raised with respect to costs and adverse side effects (e.g., overtreatment). In 
this final chapter we will put the results into the wider context of self-management 
programmes, discuss some methodological issues and elaborate on the impact of these 
findings for COPD care and for further research.  
 
Self-management programmes  
Self-management programmes are comprehensive, i.e., directed both at optimising 
physiological functioning and at optimising adaptation to the illness. Self-management 
programmes therefore aim at structural behavioural change. Though literature on 
comprehensive self-management programmes in COPD is still scarce and inconclusive, 
these programmes hold promise for yielding good results (1). Disentangling the rela-
tive contributions of individual components as ‘self-treatment of exacerbations’ and 
‘community-based physiotherapeutic exercise programmes’ is necessary to design ef-
fective and efficient self-management strategies for (the individual) COPD patients 
within the continuum of disease.  
 
Self-treatment of exacerbations 
Guidelines for the self-treatment of exacerbations, summarised in personalised action 
plans, are considered to be an essential component of self-management. The COPE-II 
study showed that self-treatment of exacerbations leads to fewer exacerbation days in 
combination with an increase in the use of courses of prednisolone and antibiotics. 
Cost-effectiveness analyses showed that a self-management strategy including self-
treatment is favourable compared to a self-management strategy without self-
treatment, resulting in fewer hospitalisations, fewer health care contacts and lower 
costs (Chapter 3). Thus, our results support the notion that self-treatment leads to a 
reduction in unscheduled health care needs (1;2). Because the intervention itself is 
rather inexpensive, a self-management strategy including self-treatment of exacerba-
tions indeed leads to cost-savings. However, a major concern is whether self-treatment 
of exacerbations leads to overtreatment when applied in daily practice. Earlier studies 
showed an increase in the use of courses of prednisolone and/or antibiotics in patients 
treating themselves (3;4), but whether this is an indication of overtreatment by the in-
tervention group or a reflection of undertreatment in the control group has remained 
unclear thus far. The COPE-II data showed that the reported number of courses in the 
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self-treatment group was substantially lower than the reported number of exacerba-
tions in this group, indicating that underreporting of respiratory complaints by COPD 
patients to their chest physicians is more likely an issue than overtreatment in patients 
who are thoroughly trained in self-treatment. Several other studies support this notion 
of undertreatment of COPD in regular care (5-7). Setting aside concerns about over-
treatment, the reduction in unscheduled need for health care, in combination with a 
reduction in costs, argues for implementation of programmes incorporating careful 
instructions on self-treatment. Indeed, an effective self-management programme is 
mandatory when introducing self-treatment of exacerbations because patients need to 
learn about the disease, the recognition of exacerbations and the negative effects of 
treatment. Through the self-management programme, patients will become familiar 
with the concept and practice of self-treatment, receive actual training including feed-
back on first experiences and become aware of their ability to adequately manage their 
own disease. Without sufficient attention to these issues, the self-treatment option will 
be used insufficiently, and the whole self-management programme will be less effec-
tive. Such a phenomenon has also been described for asthma patients (8). 
 A major priority in self-management training is to teach patients to recognise and 
evaluate the early signs of an exacerbation. Because most COPD patients experience 
symptoms every day, even in stable state, we have used a symptom diary that focuses 
on change from baseline, instead of using the mere occurrence of symptoms with 
graded severity. We defined the start of an exacerbation as ‘an evident negative change 
in two of the major symptoms or one major and one minor symptom from baseline, for 
at least two consecutive days’. Our diary choice makes it difficult to compare our re-
sults with other studies. However, by focussing on change instead of state, and 
incorporating a minimum duration of two days, we believe that we reduced the risk of 
overdiagnosis of exacerbations and therefore overtreatment. For the purpose of obtain-
ing valid data, it should be noted that our diary data were remarkably complete 
(approximately 85% of the data of all patients), given the recording period of 12 
months. The setup of our diary likely contributed to the completeness of the data. 
When no symptom changes with regard to baseline were experienced, patients could 
just check ‘no change in symptoms’.  
 
Community-based physiotherapeutic exercise physiotherapy 
Exercise programmes for COPD patients given by specialised physiotherapists have 
been shown to be beneficial at first (9-12), but the effects gradually disappear over time 
(13) because patients stop the exercises after completion of the programme. A physio-
therapeutic programme within a self-management programme therefore should aim 
not only at physical progress but also at sustained behavioural change towards exercise 
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in daily life. The COPE-active programme, offered by local, COPD-specialised physio-
therapists, particularly emphasised the shift from exercising with the physiotherapist to 
exercising at home. Indeed, the intervention group showed not only improved maximal 
exercise capacity but also substantially increased daily activity (measured by pedome-
ters) at the end of the 12-month follow-up period (Chapter 4). Despite the intensity of 
training, the additional costs of this part of the programme were limited (Chapter 5). It 
should be emphasised that the compliance of patients (Chapter 4) and physiotherapists 
(Chapter 6) with the exercise programme was high, demonstrating both the skills of the 
physiotherapists and the level of acceptance by the patients. 
 We did not adequately measure process variables of behavioural change (e.g., self-
efficacy), nor could we use more sophisticated instruments to measure daily activity 
(e.g., multi-axial accelerometers) (14). It is tempting to speculate that, with such instru-
ments, we would have learned more about the nature of the change in exercise 
behaviour. However, our choice with regard to the measurements does not have a 
negative effect on the internal validity of our study.  
 Community-based physiotherapeutic exercise programmes are already frequently 
used and reimbursed in COPD patients in several countries, including the Netherlands. 
The content, frequency, intensity and cost-effectiveness of these programmes vary con-
siderably. We recommend the design and implementation of standardised community-
based physiotherapeutic exercise programmes with proven effectiveness, offered by 
properly trained community-based physiotherapists who specialise in COPD. We also 
recommend periodic updating and monitoring of the skills of these physiotherapists. 
Future studies should elucidate which factors predict long-term success, with respect to 
the programme content, the organisational context and the characteristics of the pa-
tients included in these programmes.  
 
Other components of self-management programmes 
Self-management programmes must be tailored individually and should include a mix-
ture of elements to teach disease knowledge, promote physical activity and optimise 
medication and compliance to medication. Training should also cover themes such as 
problem solving, decision making, resource use and formation of a patient-provider 
partnership.  
 Structural behavioural change is crucial for sustained success of a self-management 
programme. A highly effective tool to achieve behavioural change is cognitive-
behavioural therapy (15-17). ´Operant conditioning’ is a fundamental psychological 
mechanism from cognitive-behavioural principles (18), meaning that a particular be-
haviour is likely to re-occur if one actually experiences positive effects from this 
behaviour. This will ultimately motivate the COPD patient to follow self-management 
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instructions. Actual experience of positive effects from new adaptive behaviour will 
reinforce the continued adoption of this behaviour. Health care providers involved in 
coaching COPD patients within self-management programmes should be trained in 
cognitive behavioural intervention techniques as we have done. This includes encour-
aging patients to take more responsibility for their own health.  
It should be noted that COPD patients are generally older and not well educated. Liter-
acy and numeracy, i.e., the ability to understand and act on numerical directions, might 
present problems in self-management programmes (19;20). Many patients have diffi-
culties in understanding abstract concepts and interpreting percentages, risks and 
information about scheduled appointments (21;22). Material for self-management 
should be easy to interpret, and the programme should encourage patients to recite 
back the facts that they have learned. Pictorial representations may be helpful in getting 
the message across (23). 
 Aside from self-treatment of exacerbations and physiotherapy programmes, the 
following specific components may be added as needed:  
- Smoking cessation programmes: effective smoking cessation has been found to pro-
long the life of COPD patients and postpone invalidation at all stages of the disease 
(24). 
- Nutritional programmes: Poor nutritional status is associated with increased morbid-
ity and mortality in patients with moderate to severe COPD (25). Although, 
according to a review by Ries (26), studies have not proven the effectiveness of die-
tary interventions in COPD patients, actions to improve nutritional status (e.g. 
behavioural weight management) might nevertheless be valuable in some patients 
with COPD.   
- Management of breathlessness: Breathlessness is inherent to COPD but may increase 
over time due to progression of the disease, de-conditioning, an exacerbation, or 
comorbidity, such as chronic heart failure. Teaching the patient how to discrimi-
nate between causes of increased dyspnoea and how to take appropriate action is 
essential. Energy-saving strategies, breathing regulation training (27;28), and miti-
gation of concomitant anxiety are important interventions (29). 
 
Recommendations for future research 
1. Optimising self-management programmes 
It is a priority is to optimise self-management programmes and properly assess the 
costs and effects of these programmes. Taking into account the lessons learned from the 
COPE-II study and the latest developments in the field of self-management in COPD, 
the following recommendations can be made with regard to the content of the self-
management programmes: 1) implementation of self-treatment guidelines in combina-
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tion with symptom diaries that focus on change from baseline to avoid overtreatment; 
2) implementation of standardised (community-based) physiotherapeutic exercise pro-
grammes with proven effectiveness, offered by properly trained community-based 
physiotherapists specialising in COPD; 3) incorporation of extra psychological compo-
nents (e.g., cognitive behavioural therapy) to more efficiently achieve behavioural 
change. Aside from the assessment of effects of different components of self-
management programmes, patient factors that predict success of the different pro-
gramme components should be determined so that better individual tailoring of 
programmes will be possible. Furthermore, consensus on desired outcomes and how to 
measure these outcomes is needed. Ultimately, these studies should lead to interna-
tionally accepted evidence-based guidelines. 
 
2. Moving toward a consensus on the definition and criteria for exacerbations 
Many definitions of exacerbations have been used in the literature, incorporating a 
wide range of parameters. The lack of consensus and the variability in definitions used 
make it hard to compare the results of studies (30). We demonstrated that different 
definitions of an exacerbation might lead to substantially different estimates of effec-
tiveness of interventions (Chapter 7). In the COPE-II study we used a symptom-based 
definition based on the reports of Seemungal et al (6). However, we used ‘change in 
symptoms’ instead of ‘presence of symptoms’, and we have added ‘evident’ to the 
definition: ‘an evident negative change in two of the major symptoms or one major and 
one minor symptom from baseline, for at least two consecutive days’. This specific 
definition fit with our action plan for self-treatment of exacerbations.  
There is a definite need for concerted attempts to reach a consensus about the definition 
of COPD exacerbations and about the specific criteria to measure exacerbations as out-
comes in study protocols.  
 
3. Immediate in-hospital reactivation of patients with an exacerbation of COPD 
As part of our studies, we developed an immediate reactivation programme (PUL-
MOFIT-MST) starting within 24 hours after admission. Although this reactivation did 
not reduce the length of hospitalisation, it led to greater gains in walking distance, 
which were sustained until hospital discharge (Chapter 8). We recommend further 
studies to improve the intervention and to combine it with a self-management pro-
gramme following discharge. Properly designed studies are needed to assess whether 
such a combination indeed leads to greater benefits with regard to exercise capacity 
and daily activity for patients recently hospitalised because of an exacerbation.  
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Final conclusions and recommendations 
In summary, our main conclusions and recommendations are as follows: 
Conclusions 
- Self-management programmes including instructions on self-treatment of exacerba-
tions lead to a reduction in need for unscheduled health care, reduction in costs and 
absence of overtreatment.  
- A standardised, community-based physiotherapeutic exercise programme follow-
ing the design of COPE-active as part of a self-management programme for COPD 
patients is effective on patient-relevant outcomes with only moderate costs. 
 
Recommendations  
- We believe that comprehensive COPD self-management programmes that include 
careful instructions on self-treatment of exacerbations should be implemented.  
- After consideration of the effects against the costs, we recommend implementation 
of the community-based physiotherapeutic exercise programme COPE-active in pa-
tients with COPD.  
- In our view, continuous evaluation of the costs and effects of high quality self-
management programmes in properly designed studies is needed to gain more evi-
dence for guidelines on comprehensive self-management in COPD management 
strategies. An international task force on COPD self-management is necessary to 
join forces and use available resources optimally.  
- Because the definition of an exacerbation has substantial impact on the assessment 
of intervention effects, there is an urgent need to reach an international consensus 
on the definition and operational criteria for COPD exacerbations.  
- More studies are needed to optimise and evaluate immediate in-hospital reactiva-
tion programs, preferably directly followed by an outpatient self-management 
programme, including an exercise programme such as COPE-active.  
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Summary 
Chronic obstructive pulmonary disease (COPD) is a disease with significant extra-
pulmonary effects that contribute to the disease burden on individual patients. Self-
management programmes play an increasingly important role in the management of 
COPD patients, but there is still no clarity about the exact definition, necessary content, 
and effectiveness of (components) of these programmes. The first COPE-study evalu-
ated a COPD self-management programme consisting of a self-management education 
course, guidelines for the self-treatment of exacerbations and a physical exercise pro-
gramme. The most striking result of the original COPE study was a twofold increase in 
the frequency of reported exacerbations in the intervention group. It remained unclear, 
however, whether or not the higher number of self-initiated courses of prednisolone 
and antibiotics in the intervention group indicated overtreatment in the intervention 
group or implied undertreatment in the control group. The original COPE study also 
included an exercise programme, but no effects on health-related quality of life and 
exercise capacity were detected. This lack of effect was likely due to the low frequency 
and intensity of the exercise programme compared to the current guidelines.  
 Against this background, we decided to undertake a new study with the objective 
of evaluating the costs and effects of two components of COPD self-management pro-
grammes: self-treatment of exacerbations and an intensive community-based 
physiotherapeutic exercise programme (COPE-active). In contrast with the original 
COPE study, only frequently exacerbating patients were included. We also assessed the 
compliance of the physiotherapists with the COPE-active protocol. In addition to the 
main research questions, we studied whether the choice of the definition of an exacer-
bation influences the outcome of a clinical trial in COPD. Finally, we took the 
opportunity to assess the effects of immediate in-hospital reactivation in patients hospi-
talised with a COPD exacerbation. 
 The COPE-II study is designed as a two-by-two factorial randomised clinical trial. 
This means that two independent interventions, self-treatment of exacerbations and a 
community-based physiotherapeutic exercise programme (COPE-active), were evalu-
ated in one study, under the assumption of no interaction. Patients were randomly 
allocated to one of four study groups. All patients received four self-management ses-
sions. The effect of a self-management programme including self-treatment of 
exacerbations was thus compared with the self-management programme alone. Pa-
tients receiving COPE-active were divided equally over the patients receiving 
guidelines for self-treatment of exacerbations and the control group. Similarly, the ef-
fect of COPE-active was assessed by comparing a self-management programme 
combined with COPE-active to the self-management programme alone. Patients who 
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were instructed to self-treat their exacerbations were divided equally over the COPE-
active group and the control group.  
 Patients in the self-treatment group received an action plan with the option to self-
initiate a course of prednisolone (with or without antibiotics) at exacerbation. During 
follow-up all participants kept a daily symptom diary from which exacerbation data 
were extracted. Patients assigned to the exercise intervention participated in the COPE-
active programme, consisting of a 6-month “compulsory” period (3 sessions/week), 
followed by a 5-month “optional” period (2 sessions/week). Because COPE-active was 
intended to change exercise behaviour, one session/week in both periods consisted of 
unsupervised home-based exercise training.  
 Before embarking upon the aforementioned study, we updated the Cochrane re-
view “Self-management education for patients with chronic obstructive pulmonary 
disease” (Chapter 2). We concluded that self-management is associated with a reduc-
tion in hospital admissions without detrimental effects on other outcome parameters. 
However, due to heterogeneity in interventions, study populations, follow-up time and 
outcome measures, data from studies published so far are insufficient to formulate 
clear recommendations regarding the form and content of COPD self-management 
education programmes. Before more conclusions can be drawn, more large randomised 
controlled trials with a long-term follow-up are needed. 
 In Chapter 3, we present the results of self-treatment of exacerbations on severity of 
exacerbations and costs within the COPE-II study. We conclude that self-treatment of 
exacerbations, incorporated into a self-management programme for COPD patients, 
leads to fewer exacerbation days and lower costs, while not leading to overtreatment. 
Given the rise in the prevalence of COPD, and the costs associated with treatment, we 
suggest starting implementation programmes that incorporate careful instructions on 
self-treatment as a part of self-management programmes. 
 In Chapter 4 we demonstrate that COPE-active, an intensive community-based 
physiotherapeutic exercise programme, when implemented in a self-management pro-
gramme, improved not only the exercise capacity of COPD patients but also their level 
of daily activities after one year, indicating real behaviour change with regard to daily 
exercise. Despite the intensity of training, the additional costs of this part of the pro-
gramme were limited (Chapter 5). In Chapter 6, we show that the compliance of 
physiotherapists with the study protocol was excellent and that no obvious contamina-
tion bias had occurred.  
 In Chapter 7, we give an overview of different definitions used for exacerbations 
and conclude that a wide variety of definitions of exacerbations has been used in the 
literature. We also demonstrate that the definition chosen to assess a treatment effect 
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has an impact on the outcome of a study. This stresses the need for concerted attempts 
to reach a consensus on one or two definitions of COPD exacerbations.   
 In Chapter 8, we present the results of an immediate reactivation programme in 
patients hospitalised because of a COPD exacerbation (PULMOFIT-MST). Although 
this reactivation did not reduce the length of hospitalisation, it did lead to an im-
provement in walking distance at hospital discharge. We recommend further studies to 
improve the intervention and to combine it with a self-management programme after 
discharge.  
 The major results of the studies in this thesis are discussed in Chapter 9. After put-
ting the results into the wider context of self-management programmes and 
consideration of some methodological issues, we present our recommendations.  
- We believe that comprehensive COPD self-management programmes that include 
careful instructions on self-treatment of exacerbations should be implemented.  
- After consideration of the effects against the costs, we recommend implementation 
of the community-based physiotherapeutic exercise programme COPE-active in pa-
tients with COPD.  
- Continuous evaluation of the costs and effects of high quality self-management 
programmes in properly designed studies is needed to produce evidence based 
guidelines on comprehensive COPD self-management strategies.  
- Maximal effort should be directed at reaching an international consensus on the 
definition and operational criteria for COPD exacerbations.  
- Optimisation and evaluation of immediate in-hospital reactivation programmes, 
which are preferably followed by out-patient self-management programmes includ-
ing community-based physiotherapeutic reactivation, is eagerly awaited. 
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COPD, Chronic Obstructive Pulmonary Disease , is een verzamelnaam voor chronische 
bronchitis en longemfyseem. COPD gaat gepaard met verschijnselen die de kwaliteit 
van leven van de patiënt ernstig reduceren. Bij de behandeling van patiënten met 
COPD worden zelfmanagementprogramma’s steeds belangrijker. Over de exacte defi-
nitie, de noodzakelijke inhoud en de effectiviteit van de (verschillende onderdelen) van 
zelfmanagementprogramma’s bestaat echter nog onvoldoende duidelijkheid. In een 
eerder onderzoek (COPE-I) werd een interventie bestaande uit een zelfmanagement 
educatie programma, richtlijnen voor zelfbehandeling en een bewegingsprogramma 
vergeleken met reguliere zorg. Het meest opvallende resultaat van deze studie was dat 
het aantal geregistreerde exacerbaties (min of meer acute verergering van de ziekte, in 
COPE-I geteld aan de hand van het aantal kuren prednisolon en/of antibiotica) in de 
interventie-groep verdubbelde ten opzichte van de controlegroep. Het bleef echter on-
duidelijk of deze verdubbeling verklaard kon worden door overbehandeling in de 
interventiegroep, of dat het duidde op onderbehandeling van exacerbaties in de contro-
legroep. Het ontbreken van enig effect van het bewegingsprogramma in COPE-I op 
gezondheidsgerelateerde kwaliteit van leven en uithoudingsvermogen was mogelijk te 
verklaren door de lage frequentie en intensiteit van het bewegingsprogramma in verge-
lijking met de huidige richtlijnen.  
 Op basis van deze resultaten werd een nieuwe studie (COPE-II) opgezet met als 
doel de effecten en kosten te evalueren van twee relevante  onderdelen van een COPD 
zelfmanagementprogramma: zelfbehandeling van exacerbaties en een intensief eerste-
lijns fysiotherapeutisch bewegingsprogramma (COPE-actief). In tegenstelling tot de 
eerste COPE studie, werden alleen frequent exacerberende patiënten in het onderzoek 
betrokken. Expliciet onderzochten we in hoeverre fysiotherapeuten het COPE-actief 
protocol volgden.  
 Alvorens te starten met het onderzoek is eerst de literatuur over effecten van zelf-
managementprogramma’s samengevat in de vorm van een update van een reeds 
eerder gepubliceerd ‘Cochrane’ review (hoofdstuk 2). We concludeerden dat zelfmana-
gement kan leiden tot minder ziekenhuisopnamen, zonder negatieve effecten op 
andere uitkomstmaten. Echter, door heterogeniteit in interventies, studiepopulaties, 
follow-up tijd en uitkomstmaten, waren de data ontoereikend om duidelijke aanbeve-
lingen te formuleren ten aanzien van de vorm en inhoud van zelfmanagement educatie 
programma’s. Daarvoor zijn meer grote gerandomiseerde studies met een lange follow-
up tijd noodzakelijk.  
 Binnen de gerandomiseerde COPE-II studie gebruikten we een twee bij twee facto-
rieel design. Dit betekent dat twee onafhankelijke interventies, zelfbehandeling van 
exacerbaties en een eerstelijns fysiotherapeutisch bewegingsprogramma (COPE-actief), 
zijn geëvalueerd binnen één studie, onder de aanname dat er geen interactie tussen de 
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beide interventies plaatsvindt. Patiënten werden willekeurig toegewezen aan één van 
de vier onderzoeksgroepen. Alle patiënten participeerden in vier zelfmanagement ses-
sies. Het effect van een zelfmanagementprogramma met zelfbehandeling van 
exacerbaties werd vergeleken met het effect van een zelfmanagementprogramma al-
leen. Patiënten die het COPE-actief programma ontvingen werden gelijk verdeeld over 
de groep die richtlijnen voor zelfbehandeling van exacerbaties ontving en de controle-
groep. Op dezelfde manier werden de effecten van het COPE-actief programma 
onderzocht.  
 Patiënten in de zelfbehandelingsgroep ontvingen een actieplan met instructies 
wanneer ze moesten starten met een kuur prednisolon (al dan niet gecombineerd met 
antibiotica). Tijdens de follow-up hielden alle patiënten in een dagboek hun klachten 
bij, waaruit aan het eind van de studie de exacerbatie-gegevens werden geëxtraheerd. 
Patiënten die de bewegingsinterventie toegewezen hadden gekregen, startten met het 
COPE-actief programma, bestaande uit een zes maanden lange verplichte periode 
(3 sessies per week), gevolgd door een vijf maanden lange vrijwillige periode (2 sessies 
per week). Aangezien COPE-actief opgezet was om gedragsverandering te initiëren, 
moest  gedurende de gehele trainingsperiode één trainingssessie per week zelfstandig 
thuis worden uitgevoerd.  
 In hoofdstuk 3 presenteren we de resultaten van de COPE-II studie, voor zover het 
gaat om het effect van zelfbehandeling op de ernst van exacerbaties en de hieraan gere-
lateerde kosten. We concluderen dat zelfbehandeling van exacerbaties als onderdeel 
van een zelfmanagementprogramma voor COPD patiënten, tot minder exacerbatieda-
gen en lagere kosten leidt.  
 In hoofdstuk 4 laten we zien dat COPE-actief, een intensief eerstelijns fysiothera-
peutisch bewegingsprogramma, als onderdeel van een zelfmanagementprogramma na 
een jaar deelname aan het programma niet alleen het uithoudingsvermogen van COPD 
patiënten verbetert maar ook hun dagelijkse activiteitenniveau. Dit laatste interpreteren 
wij als een indicatie van werkelijke gedragsverandering ten aanzien van hun dagelijkse 
activiteitenniveau. In relatie tot de hier boven vermelde positieve effecten zijn de hier-
mee gepaard gaande extra kosten beperkt (hoofdstuk 5). In hoofdstuk 6 laten we zien 
dat de betrokken fysiotherapeuten zich erg goed aan het studieprotocol hielden en dat 
het contrast met de controle-interventie gedurende het gehele onderzoek in stand is 
gebleven. 
 De antwoorden op twee aanvullende onderzoeksvragen zijn uitgewerkt in de 
hoofdstukken 7 en 8. Deze vragen betreffen de invloed van de keuze voor een bepaalde 
definitie van een exacerbatie op de uitkomst van een studie, en de effecten van een re-
activatieprogamma (PULMOFIT-MST) bij patiënten die met een exacerbatie van COPD 
in het ziekenhuis worden opgenomen.  
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 In hoofdstuk 7 geven we een overzicht van de verschillende in de literatuur ge-
bruikte definities van exacerbaties. We concluderen dat er een grote variëteit aan 
definities wordt gebruikt. We laten daarnaast zien dat de keuze van een definitie in-
vloed kan hebben op de uitkomst van een studie. Dit benadrukt de noodzaak te komen 
tot een eenduidige definitie voor COPD exacerbaties.  
 In hoofdstuk 8 presenteren we de resultaten van een reactivatieprogamma dat di-
rect na opname in het ziekenhuis werd ingezet bij patiënten met een COPD exacerbatie 
(PULMOFIT-MST). Hoewel dit programma niet de lengte van een opname verminder-
de, leidde het wel tot een verbetering van de loopafstand bij ontslag. Wij achten verder 
onderzoek naar verbetering van deze interventie noodzakelijk en raden aan dergelijke 
programma’s te laten aansluiten op een direct na ontslag te starten eerstelijns fysiothe-
rapeutisch bewegingsprogramma, zo mogelijk geïncorporeerd in een zelfmanagement-
programma.  
 De belangrijkste resultaten van de studies beschreven in dit proefschrift worden 
bediscussieerd in hoofdstuk 9. Nadat we onze resultaten hebben beschouwd in de bre-
dere context van zelfmanagementprogramma’s en enkele methodologische punten in 
acht hebben genomen, presenteren we onze aanbevelingen: 
- COPD zelfmanagementprogramma’s met zorgvuldige instructies voor zelfbehande-
ling van exacerbaties dienen te worden geïmplementeerd in de reguliere zorg voor 
COPD patiënten.  
- Gelet op de afweging van effecten en kosten, kan implementatie van het eerstelijns 
fysiotherapeutische bewegingsprogramma COPE-actief worden geadviseerd.  
- Continue evaluatie van kosten en effecten van kwalitatief goed opgezette en uitge-
voerde zelfmanagementprogramma’s is nodig om evidence based richtlijnen te 
kunnen formuleren voor wat betreft uitgebreide COPD zelfmanagement strategie-
en.  
- Internationale consensus over de definitie en operationele criteria van COPD exa-
cerbaties is hoogstnoodzakelijk.  
- Reactivatieprogramma’s voor patiënten die met een COPD exacerbatie zijn opge-
nomen dienen te worden geïmplementeerd en vervolgens geëvalueerd, bij voorkeur 
in combinatie met een eerstelijns fysiotherapeutisch bewegingsprogramma, al dan 
niet geïncorporeerd in een zelfmanagementprogramma, dat start na ontslag uit het 
ziekenhuis.  
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Two-by-two factorial design of the COPE-II study 
 
In the COPE-II study, a two-by-two factorial design was used (see Table 1), meaning 
that two independent interventions, self-treatment of exacerbations and a community-
based physiotherapeutic exercise programme (COPE-active), were evaluated in one 
study. Patients were randomly allocated to one of four study groups. All patients 
received four self-management sessions. The effect of a self-management programme 
including self-treatment of exacerbations was thus compared with a self-management 
programme only. Patients receiving COPE-active were divided equally over the group 
receiving guidelines for self-treatment of exacerbations and the control group. 
Similarly, the effect of COPE-active was assessed by comparing a self-management 
programme including COPE-active with a self-management programme only. Patients 
who were instructed to self-treat their exacerbations were divided equally over the 
patients receiving COPE-active and the control patients. It was assumed that the two 
interventions would not interact with one another.    
 
 
 
Table 1  Description of the design of the COPE-II study, including the two interventions (COPE-active 
and self-treatment of exacerbations) and the measurements at baseline, 7, and 12 months 
Time schedule Interventions Group 1 Group 2 Group 3 Group 4 
Month 0 Baseline measurements X X X X 
Month 1 Self-management courses X X X X 
Month 1 Self-treatment of exacerbations X X   
Month 2-7 COPE-active: ‘compulsory’  X  X  
Month 7 Measurement X X X X 
Month 8-12 COPE-active: ‘voluntary’ X  X  
Month 12 Measurement X X X X 
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COPE-active protocol  
 
General information 
COPE-active is assumed to be a functional training method. For the development of the 
COPE-active programme, the five most problematic activities of a sample of 15 COPD 
patients were identified with help of the Canadian Occupational Performance Measure 
(1). These activities, bicycling, walking, climbing stairs, lifting weights and the optional 
exercise: pushing and pulling (e.g., vacuuming, raking the garden), were incorporated 
in the COPE-active programme. The determination of the intensity and the change in 
intensity for most exercises were derived from the book of Gosselink et al. (2) and are in 
line with the latest rehabilitation recommendations (3). 
The training was given by physiotherapists from private physiotherapy practices 
situated in the catchment area of the Medisch Spectrum Twente Hospital in Enschede, 
the Netherlands. All physiotherapists had already attended a national COPD course 
prior to the COPE II-study and were experienced in caring for COPD patients. At the 
start of this study, they had to participate in an additional three-session course 
(11 hours in total) to refresh their knowledge about COPD in general and with regard 
to exercise (e.g., the role of hyperinflation), and to standardise the content of the COPE-
active-program. At baseline, we provided detailed information about the individual 
patient to the respective physiotherapist: results of the incremental maximal cycle er-
gometry test, incremental shuttle walk test, lung function, and fat free mass. In this 
way, training intensity of the COPE-active programme could be tailored to the individ-
ual.  
The 11-month training period per patient was divided in two parts: a ‘compulsory’ 
6-month period and a subsequent optional but recommended 5-month period. Besides 
improvement of physical condition in the first period and preservation of these gains in 
the second period, behaviour change towards exercise was strived for during the whole 
period. Frequency of training sessions during the first period was three times per week, 
while in the second period this was reduced to two times per week. One of these train-
ing sessions consisted of unsupervised home based exercise training to facilitate 
behaviour change towards exercise. Training was given in small groups (2-3 patients). 
 
Choice between endurance and interval training 
The choice for endurance or interval training in cycling and walking had to be deter-
mined by means of the results of the incremental maximal cycle ergometry test and a 
sub-maximal cycle test examined by the physiotherapist. During the sub-maximal cycle 
test the patient had to cycle for as long as possible, with a maximum of 30 minutes, us-
ing a standardised speed. For deciding whether or not interval training was indicated, 
a flow chart was used (Figure 1). 
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    Figure 1  Flow chart  for decision endurance or interval training 
Determination of the intensity 
The intensity of the exercises was determined by the physiotherapists. For this, they 
could use the information of the maximal cycle ergometry test and the incremental 
shuttle walk test. When required, they had to determine the 1 Repetition Maximums 
(1-RM; the maximum weight with which patients can perform one well-coordinated 
move) using the Holten graph (4). Training schemes, which were meant as a guideline, 
were provided. So, training intensity had to be adjusted if that fitted the individual pa-
tient better.  
Aside from the clinical judgement of the physiotherapists, Borg-scores for dysp-
noea and fatigue (5) were used for adjustment of the training intensity. When a patient 
indicated a low dyspnoea and/or fatigue score (< 4) at the end of the training, the inten-
sity of the training had to be reconsidered. If there was a discrepancy between both 
BORG-scores during successive training sessions, a low score on fatigue and a high 
score on dyspnoea, a switch from endurance to interval training had to be considered. 
When the patient was already on an interval scheme, the interval time could be re-
duced and the intensity could be increased.  
 
Exercises with the physiotherapist 
Week 1-2:  
• physiotherapeutic examination (anamnesis, physical examination) 
• the sub-maximal cycle test 
• general back posture education 
Week 2-3: 
• Getting used to the training activities and working up to the individually tailored 
training intensity  
Week 4 and further: 
• Protocols with training intensities for week 4-15 were provided. Physiotherapists 
had to determine for the individual patients if and how much they could increase 
the training intensity after week 15. The patient had the choice whether or not to 
stop after week 25. From week 25 (the 6th month), the intensity of the exercises in 
essence stayed the same.  
Cardiovascular 
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Exercise 1: Cycling 
The Wmax, determined by maximal cycle ergometry, was used to set the training in-
tensity.  
 
Table 1  Cycling: intensity and time settings for endurance training 
Week Intensity Time Week Intensity  Time 
4 55% Wmax 10 minutes 10 70% Wmax 16 minutes 
5 55% Wmax 12 minutes 11 70% Wmax 16 minutes 
6 60% Wmax 12 minutes 12 75% Wmax 16 minutes 
7 60% Wmax 14 minutes 13 75% Wmax 16 minutes 
8 65% Wmax 14 minutes 14 80% Wmax 16 minutes 
9 65% Wmax 16 minutes 15 80% Wmax 16 minutes 
 
 
 
 
 
 
 
 
 
Exercise 2: Walking 
The incremental shuttle walk test (ISWT) was used to determine the training intensity.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2  Cycling: intensity and time settings for interval training  
Week Intensity number  
of sets 
Week intensity number  
of sets  
4 60% Wmax 3 10 70% Wmax 5 
5 60% Wmax 4 11 70% Wmax 5 
6 60% Wmax 4 12 75% Wmax 5 
7 60% Wmax 5 13 75% Wmax 5 
8 65% Wmax 5 14 80% Wmax 5 
9 65% Wmax 5 15 80% Wmax 5 
Table 3  Walking: intensity and time settings for endurance training (treadmill) 
Week Intensity  
(% max  
speed ISWT) 
Time Week Intensity  
(% max  
speed ISWT) 
Time 
4 60%  8 minutes  10 85%  10 minutes 
5 60%  10 minutes 11 90%  10 minutes 
6 65%  10 minutes 12 95%  10 minutes 
7 70%  10 minutes 13 100%  10 minutes 
8 75%  10 minutes 14 100%  10 minutes 
9 80%  10  minutes 15 100%  10 minutes 
Table 4  Walking: intensity and time settings for interval training (treadmill) 
Week Intensity  
(% max  
speed ISWT) 
number  
of sets 
Week Intensity  
(% max  
speed ISWT) 
number  
of sets 
4 60%  3 10 70%  5 
5 60%  4 11 70%  5 
6 60%  4 12 75%  5 
7 60%  5 13 75% 5 
8 65%  5 14 75%  5 
9 65%  5 15 80%  5 
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Exercise 3: Walking stairs  
Within the exercise form ‘walking stairs’ four training forms could be used. Which ex-
ercise suited the patient best was decided by the physiotherapist and was also 
dependent on the training aids that were present in the private physiotherapy practice:  
1. Step on and off a footrest 
2. Walking a three-step stair 
3. Walking normal stairs 
4. Isolated training of the m. quadriceps 
 
Training form 1, 2, 3: 
For stepping on and off a footrest, walking a three-step stair and walking up normal 
stairs, three different training methods: 1) exercising for two minutes without rest; 2) 
two times one minute of exercise, after exercise one minute rest; 3) three times 30 sec-
onds of exercise, after exercise 30 seconds rest (see below), could be chosen. The 
physiotherapist had to decide which method suited the patient best. When necessary, 
the physiotherapist had to shift between different methods (e.g., to increase the inten-
sity).  
Intensity could be boosted by increasing the speed and by increasing the time. The first 
choice was to increase the speed but when coordination was the limiting factor and/or 
the patient became pulmonary limited, speed had to be maintained and time had to be 
increased.   
 
• Exercising for 2 minutes without rest 
The patient was asked to perform maximal with regard to the number of repeti-
tions within two minutes. Every week the number of repetitions was increased 
with 6% (Table 5). 
 
Table 5  Intensity for walking stairs exercises: 1 * 2 minutes 
Week Intensity Week Intensity 
4 100% of total number of repetitions 10 136% of total number of repetitions 
5 106% of total number of repetitions 11 142% of total number of repetitions 
6 112% of total number of repetitions 12 148% of total number of repetitions 
7 118% of total number of repetitions 13 154% of total number of repetitions 
8 124% of total number of repetitions 14 160% of total number of repetitions 
9 130% of total number of repetitions 15 166% of total number of repetitions 
 
• Two times one minute of exercise, after exercise one minute rest 
If the patient was not able to fulfil the first exercise-form, this exercise form could 
be chosen. First, the number of repetitions in one minute had to be counted (the pa-
tient was asked to perform maximal). The number of repetitions per minute was 
increased every week (Table 6). 
 
• Three times 30 seconds of exercise, after exercise 30 seconds rest 
If the patient was not able to exercise for two minutes or for two times one minute, 
this exercise form could be chosen. The number of repetitions in 30 seconds had to 
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be counted (the patient was asked to perform maximal). The number of repetitions 
per 30 seconds was increased every week (Table 6). 
 
Table 6  Intensity for walking stairs exercises: 2*1 minute / 3*0.5 minute 
Week Intensity Week Intensity 
4 80% of total number of repetitions 10 116% of total number of repetitions 
5 86% of total number of repetitions 11 122% of total number of repetitions 
6 92% of total number of repetitions 12 128% of total number of repetitions 
7 98% of total number of repetitions 13 136% of total number of repetitions 
8 104% of total number of repetitions 14 142% of total number of repetitions 
9 110% of total number of repetitions 15 148% of total number of repetitions 
 
Training form 4: 
This exercise should be used when the patient was: 
- not able to complete one of the other exercise forms for at least three times  
30 seconds  
- oxygen saturation dropped to less than 87% during one of the other exercises  
 
Quadriceps training could be performed in sit using a pulley, with help of a leg press, 
etc. The 1-RM had to be determined first (4) and then the following training scheme 
had to be used as a guide. Three sessions of 8 repetitions were used (Table 7).  
 
Table 7  Intensity for isolated strength training of the m. quadriceps 
Week Intensity Sets Week Intensity Sets 
4 70% of the 1-RM 3 * 8 10 100% of the 1-RM 3 * 8 
5 70% of the 1-RM 3 * 8 11 106% of the 1-RM 3 * 8 
6 76% of the 1-RM 3 * 8 12 112% of the 1-RM 3 * 8 
7 82% of the 1-RM 3 * 8 13 118% of the 1-RM 3 * 8 
8 88% of the 1-RM 3 * 8 14 124% of the 1-RM 3 * 8 
9 94% of the 1-RM 3 * 8 15 130% of the 1-RM 3 * 8 
 
 
Exercise 4: Lifting weights  
For this exercise the pulley was used. After the general 
back posture education courses, given in the first two 
weeks, the 1-RM was determined (4). Exercise had to be 
performed as shown on the pictures. 
The exercise should be performed in three sets of 
eight repetitions. Between the sets a rest of maximal 30 
seconds was allowed. In Table 8 guidelines for increasing the intensity are given. When 
the patient was performing very well, a faster increase of the weights was allowed.  
If during the training a weight of 18 kilos or more was needed to achieve the cor-
rect intensity, the exercise was changed to duration training. The same exercise form 
was used. A new 1-RM had to be set, and the exercise had to be performed in three sets 
of 30 repetitions (Table 9). 
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Table 8  Intensity for lifting weights (3 sets of 8 repetitions) 
Week Intensity Sets Week Intensity Sets 
4 70% of the 1-RM 3 * 8 11 100% of the 1-RM 3 * 8 
5 70% of the 1-RM 3 * 8 12 106% of the 1-RM 3 * 8 
6 76% of the 1-RM 3 * 8 13 112% of the 1-RM 3 * 8 
7 82% of the 1-RM 3 * 8 14 118% of the 1-RM 3 * 8 
8 88% of the 1-RM 3 * 8 15 124% of the 1-RM 3 * 8 
9 94% of the 1-RM 3 * 8 16 130% of the 1-RM 3 * 8 
 
Table 9  Intensity for lifting weights (3 sets of 30 repetitions) 
Week Intensity Sets Week Intensity Sets 
4 50% of the 1-RM . 3 * 30 10 80% of the 1-RM 3 * 30 
5 50% of the 1-RM 3 * 30 11 86% of the 1-RM 3 * 30 
6 56% of the 1-RM 3 * 30 12 92% of the 1-RM 3 * 30 
7 62% of the 1-RM 3 * 30 13 98% of the 1-RM 3 * 30 
8 68% of the 1-RM 3 * 30 14 104% of the 1-RM 3 * 30 
9 74% of the 1-RM 3 * 30 15 110% of the 1-RM 3 * 30 
 
 
An optional exercise: pushing and pulling 
This exercise could be incorporated in the programme when there 
was time left after performing the other exercises. For this exercise 
special training material was developed (see picture). This material 
had to be used on a smooth surface. Two lines had to be drawn with 
a space of one meter in between. The 1-RM was determined with 
help of the Holten graph (4). After putting the right amount of 
weights in the box, the patient had to push and pull the box for-
wards and backwards between the lines. During this exercise the 
back should be kept stable under supervision of the physiotherapist. The exercise had 
to be performed in three sets of 30 repetitions (Table 10). 
 
Table 10  Intensity for pushing and pulling 
Week Intensity Sets Week Intensity Sets 
4 50% of the 1-RM . 3 * 30 10 80% of the 1-RM 3 * 30 
5 50% of the 1-RM 3 * 30 11 86% of the 1-RM 3 * 30 
6 56% of the 1-RM 3 * 30 12 92% of the 1-RM 3 * 30 
7 62% of the 1-RM 3 * 30 13 98% of the 1-RM 3 * 30 
8 68% of the 1-RM 3 * 30 14 104% of the 1-RM 3 * 30 
9 74% of the 1-RM 3 * 30 15 110% of the 1-RM 3 * 30 
 
Home-based exercise training 
The patient had to execute one home-based training session a week. At the start of the 
training period, the physiotherapists had to discuss at what day this session had to take 
place. It was recommended that a rest day was planned after every training day.  
 
The home-based exercise programme consisted of three components: 
1. walking or cycling 
2. resistance training for the lower extremities (one exercise) 
3. resistance training for the upper extremities (one exercise) 
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Before the start of the training period, the patient decided whether he was going to 
walk or cycle. However, when interval training was indicated and the patient did not 
have a home-trainer, walking was recommended. In addition, the physiotherapists se-
lected the resistance exercises that most suited the patient. The patients were instructed 
in the exercises by the physiotherapist who also determined the intensity. A training 
diary with standardised instructions for the exercises was supplied to the patient. After 
each training the patient had to note: 1) whether or not he had executed the exercises; 2) 
the weather circumstances; and 3) to what extent he experienced fatigue. Every week, 
the physiotherapist and patient reviewed this diary. The physiotherapists noted on the 
study forms whether or not the home exercises were executed. Every other week the 
physiotherapists evaluated one of the two resistance training exercises to check the 
training intensity. At that moment, the physiotherapist had to decide whether the cho-
sen exercise form was still the most appropriate. 
 
Cycling: endurance 
The patient was instructed to reach the fatigue that he also experienced during the cy-
cling training with the physiotherapist. If this was not the case, the physiotherapist had 
to instruct the patient: 1) to increase the speed; 2) to extend the exercise time; or in case 
of a home trainer 3) to increase the resistance. At the start of the training period, weekly 
evaluations were necessary to properly determine cycling intensity. So, table 11 was 
just used as a guideline. 
  
Table 11  Home-based cycle training (endurance) 
Week Duration Week Duration 
4 Minimal 10 minutes 10 Minimal 16 minutes 
5 Minimal 12 minutes 11 Minimal 18 minutes 
6 Minimal 12 minutes 12 Minimal 18 minutes 
7 Minimal 14 minutes 13 Minimal 20 minutes 
8 Minimal 14 minutes 14 Minimal 20 minutes 
9 Minimal 16 minutes 15 Minimal 22 minutes 
 
Cycling: interval 
Interval training was only possible if the patient had a home trainer. The patient was 
instructed to reach the fatigue that he also experienced during the cycling training with 
the physiotherapist. The patient had to cycle in sets of two minutes, with two minutes 
rest in between (Table 12). When the fatigue was lower than the fatigue with the 
physiotherapist, the resistance had to be increased. When the patients experienced par-
ticularly dyspnoea and almost no fatigue, the length of the intervals had to be reduced 
and the resistance increased. Therefore weekly evaluations were necessary to deter-
mine the intensity properly 
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Walking: endurance 
The patient had to try to increase the walking time to 30 minutes. At the start, the 
physiotherapist asked the patient to measure how long he was able to walk without a 
rest. The patient had to try to walk one minute longer every week.  
When the patient was able to walk for 30 minutes, the speed was increased with 
help of a pedometer. The patient had to increase the total number of steps within 30 
minutes (increase of 5% per week). Therefore, the physiotherapist had to note the 
amount of steps the patient had to reach after 7.5, 15, and 22.5 minutes. During walk-
ing, the patient had to check whether he was on schedule and, when necessary, had to 
adjust his walking speed. When it was not longer possible to increase the walking 
speed, the speed was stabilised and the length of walking was increased with 2 minutes 
per week (number of steps after 7.5, 15, 22.5, 30… were again noted by the physio-
therapist).  
 
Walking: interval 
The physiotherapist determined the number of steps the patient was able to achieve in 
two minutes. The number of steps was kept the same (with help of a pedometer). In-
tensity was increased using table 13. If there was a discrepancy between the level of 
fatigue and dyspnoea, reduction of the exercise time and an increase of the speed (us-
ing pedometers) had to be considered. 
 
 
 
 
 
 
 
 
Resistance training: lower extremities 
Exercise 1: walking stairs 
Similar to walking stairs with the physiotherapist, patients 
used only the first step of the stairs: left foot on the step, 
right foot on the step, left foot on the ground, right foot on 
the ground. The physiotherapist had to choose the optimal 
form: exercising for two minutes; two times one minute of 
Table 12 Home-based cycle training (interval) 
Week Number of sets  Week Number of sets 
4 3 * 2 minutes 10 6 * 2 minutes 
5 4 * 2 minutes 11 6 * 2 minutes 
6 4 * 2 minutes 12 6 * 2 minutes 
7 5 * 2 minutes 13 6 * 2 minutes 
8 5 * 2 minutes 14 7 * 2 minutes 
9 5 * 2 minutes 15 7 * 2 minutes 
Table 13  Home-based walk training (interval) 
Week Number of sets  Week Number of sets 
4 3 * 2 minutes 10 6 * 2 minutes 
5 4 * 2 minutes 11 6 * 2 minutes 
6 4 * 2 minutes 12 6 * 2 minutes 
7 5 * 2 minutes 13 6 * 2 minutes 
8 5 * 2 minutes 14 7 * 2 minutes 
9 5 * 2 minutes 15 7 * 2 minutes 
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exercise, after exercise one minute rest; three times 30 seconds of exercise, after exercise 
30 seconds rest. For intensity: see Tables 5 and 6. 
 
Exercise 2: getting up out of a chair 
Initially, the patient was asked to get up and sit down as of-
ten as he could. The number of repetitions was taken as 
baseline. The training intensity was set at 3 sets of 70% of this 
baseline. For this exercise different forms could be used: 
hands on the knees, hands on the arm rests, use of a 
higher/lower chair. 
 
Exercise 3: training of m. quadriceps with help of a dyna-band 
The maximum number of repetitions for both legs was de-
termined. The training consisted of 3 sets for each leg (Table 
14). 
 
  
 
Table 14  Home-based training of the m. quadriceps 
Week Intensity Sets Week Intensity Sets 
4 70% of max repetitions 3 * 8 11 100% of max repetitions 3 * 8 
5 70% of max repetitions 3 * 8 12 106% of max repetitions 3 * 8 
6 76% of max repetitions 3 * 8 13 112% of max repetitions 3 * 8 
7 82% of max repetitions 3 * 8 14 118% of max repetitions 3 * 8 
8 88% of max repetitions 3 * 8 15 124% of max repetitions 3 * 8 
9 94% of max repetitions 3 * 8 16 130% of max repetitions 3 * 8 
 
 
Resistance training: upper extremities 
Exercise 1: training m. biceps brachii with help of the dyna-band 
For performance: see pictures. Intensity: see Table 7 
 
 
 
Exercise 2: press-ups from the wall 
The patient faced the wall. The physiotherapist decided which 
distance was used between the feet and the wall. The hands 
were are placed at the same height as the shoulders. The back 
had to be stabilised. For intensity: see Table 7 
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 Context in which the term   
 exacerbations is used *1 
 Exacerbation outcome units *2 
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 Change in condition: >24 hours 
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 Dyspnoea 
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E
4
5
) 
S
 
1
+
2
+
4
 
  
  
X
 
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
  
  
  
  
  
  
X
 
X
 
X
 
X
 
R
e
n
k
e
m
a
 1
9
9
6
 (
E
4
6
) 
S
 
5
+
9
 
  
X
 
  
X
 
  
  
X
 
X
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
R
e
n
n
a
rd
 2
0
0
6
 (
E
4
7
) 
S
 
1
+
6
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
X
 
  
  
  
  
X
 
X
 
X
 
X
 
X
 
R
e
n
n
a
rd
 2
0
0
7
 (
E
4
8
) 
S
 
1
 
  
X
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X
 
  
X
 
X
 
R
ic
e
1
9
8
7
 (
E
4
9
) 
I 
  
  
X
 
X
 
  
X
 
  
X
 
X
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X
 
  
R
ic
e
 2
0
0
0
 (
E
5
0
) 
P
 
2
 
  
X
 
  
X
 
X
 
  
X
 
X
 
  
  
  
X
 
  
  
  
X
 
X
 
  
  
  
  
  
X
 
  
  
  
R
o
d
ri
g
u
e
z-
R
o
is
in
 2
0
0
0
 
(E
5
1
) 
 
O
 
  
  
X
 
X
 
X
 
X
 
  
X
 
  
  
  
  
  
X
 
  
  
X
 
X
 
X
 
  
  
  
  
  
  
  
  
S
a
c
h
s 
1
9
9
5
 (
E
5
2
) 
I 
  
  
X
 
X
 
  
  
  
X
 
  
  
  
  
  
  
  
X
 
  
  
  
  
  
  
  
  
  
  
  
S
e
e
m
u
n
g
a
l 
1
9
9
8
 (
E
5
3
) 
O
 
  
  
X
 
X
 
X
 
X
 
  
X
 
X
 
X
 
X
 
X
 
X
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
S
e
th
i 
2
0
0
5
 (
E
5
4
) 
I 
  
  
X
 
  
X
 
X
 
  
X
 
X
 
X
 
X
 
X
 
X
 
  
X
 
  
  
  
  
  
  
  
  
  
  
  
  
S
p
e
n
c
e
r 
2
0
0
4
 (
E
5
5
) 
O
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
X
 
  
  
  
  
  
  
  
  
S
to
c
k
le
y
 2
0
0
6
 (
E
5
6
) 
P
 
1
+
4
 
  
X
 
  
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
X
 
  
  
  
  
  
  
  
X
 
X
 
S
u
zu
k
i 
2
0
0
1
 (
E
5
7
) 
P
 
1
+
4
 
  
X
 
X
 
  
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
  
  
  
  
  
  
  
  
X
 
S
za
fr
a
n
sk
i 
2
0
0
3
 (
E
5
8
) 
P
 
2
+
4
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
X
 
  
  
  
  
  
  
  
X
 
X
 
Th
o
m
p
so
n
 1
9
9
6
 (
E
5
9
) 
I 
  
  
X
 
X
 
  
  
  
X
 
X
 
  
  
  
  
  
  
  
  
  
  
  
  
 
X
 
  
  
  
  
Th
y
s 
2
0
0
2
 (
E
6
0
) 
I 
  
  
X
 
  
  
  
  
  
X
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 Context in which the term   
 exacerbations is used *1 
 Exacerbation outcome units *2 
 Lung function 
 Change in symptoms  
 Change in condition: >24 hours 
 Sputum production 
 Sputum purulence  
 Positive Gram stain 
 Dyspnoea 
 Cough 
 Sore throat 
 Nasal discharge 
 Fever 
 Wheezing 
 Bronchial retention 
 Respiratory rate and heart rate 
 Bronchodilator therapy 
 Oral corticosteroids 
 Antibiotics 
 Chest problems 
 Chest radiograph 
 Arterial blood gases 
 Physical examination 
 Clinical diagnosis  
 Unscheduled medical 
  attention  
 ER-visit 
 Hospitalization 
 Classification in severity of   
 exacerbations 
V
a
n
 d
e
r 
V
a
lk
 2
0
0
2
 
(E
6
1
)*
3
 
P
 
3
 
  
X
 
  
  
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
  
  
  
  
X
 
  
  
  
  
V
a
n
 N
o
o
rd
 2
0
0
0
 (
E
6
2
) 
S
 
1
 
  
X
 
  
  
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
  
  
  
  
  
  
  
X
 
  
V
a
rg
a
s 
2
0
0
5
 (
E
6
3
) 
I 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X
 
  
X
 
X
 
  
  
  
  
V
e
st
b
o
 1
9
9
9
 (
E
6
4
) 
S
 
4
 
  
X
 
  
X
 
  
  
  
X
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
V
in
c
k
e
n
 2
0
0
2
 (
E
6
5
)*
3
 
S
 
1
+
3
+
9
 
  
X
 
X
 
X
 
X
 
  
X
 
X
 
  
  
  
X
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
W
ill
a
e
rt
 2
0
0
2
 (
E
6
6
) 
I 
  
  
X
 
X
 
X
 
X
 
  
X
 
X
 
  
  
  
X
 
  
  
  
  
  
  
  
  
  
  
X
 
  
  
  
W
o
u
te
rs
 2
0
0
5
 (
E
6
7
) 
S
 
2
+
3
 
  
  
X
 
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
X
 
  
  
  
  
X
 
  
  
X
 
X
 
Y
a
su
d
a
 2
0
0
6
 (
E
6
8
) 
O
 
  
  
X
 
X
 
  
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
  
  
  
  
  
  
  
  
  
Z
u
 W
a
lla
c
k
 2
0
0
1
 (
E
6
9
) 
S
 
4
 
  
X
 
  
  
  
  
  
  
  
  
  
  
  
  
  
X
 
X
 
  
  
  
  
  
  
  
  
  
*1
) 
P
: 
p
ri
m
a
ry
 o
u
tc
o
m
e
; 
S
: 
se
c
o
n
d
a
ry
 o
u
tc
o
m
e
; 
I:
 i
n
c
lu
si
o
n
 c
ri
te
ri
a
; 
O
: 
o
th
e
r.
 
*2
) 
1
: 
N
u
m
b
e
r 
o
r 
p
e
rc
e
n
ta
g
e
 o
f 
p
a
ti
e
n
ts
 w
it
h
 ≥
 o
n
e
 e
x
a
c
e
rb
a
ti
o
n
; 
2
: 
N
u
m
b
e
r 
o
f 
e
x
a
c
e
rb
a
ti
o
n
s 
p
e
r 
p
a
ti
e
n
t 
o
r 
ti
m
e
 u
n
it
; 
3
: 
Ti
m
e
 t
o
 f
ir
st
 e
x
a
c
e
rb
a
ti
o
n
; 
4
: 
N
u
m
b
e
r 
o
f 
 
e
x
a
c
e
rb
a
ti
o
n
s 
p
e
r 
g
ro
u
p
; 
5
: 
M
e
d
ia
n
 n
u
m
b
e
r 
o
f 
e
x
a
c
e
rb
a
ti
o
n
s 
p
e
r 
p
a
ti
e
n
t 
o
r 
ti
m
e
 u
n
it
; 
6
: 
N
u
m
b
e
r 
o
f 
p
a
ti
e
n
ts
 f
re
e
 o
f 
e
x
a
c
e
rb
a
ti
o
n
s;
 7
:N
u
m
b
e
r  
o
f 
e
x
a
c
e
rb
a
ti
o
n
s 
p
e
r 
tr
e
a
tm
e
n
t 
d
a
y
s;
 8
: 
N
u
m
b
e
r 
n
e
e
d
e
d
 t
o
 t
re
a
t;
 9
: 
N
u
m
b
e
r 
o
f 
e
x
a
c
e
rb
a
ti
o
n
s 
d
a
y
s 
p
e
r 
p
a
ti
e
n
t 
p
e
r 
y
e
a
r;
 1
0
: 
N
u
m
b
e
r 
o
f 
d
a
y
s 
p
e
r 
e
x
a
c
e
rb
a
ti
o
n
s.
 
*3
) 
M
o
re
 t
h
a
n
 o
n
e
 a
rt
ic
le
 o
f 
th
is
 s
tu
d
y
 h
a
s 
tu
rn
e
d
 u
p
 w
it
h
in
 li
te
ra
tu
re
 s
e
a
rc
h
 
   R
e
fe
re
n
c
e
s
 
E
1
 
A
a
ro
n
 S
D
, 
V
a
n
d
e
m
h
e
e
n
 K
L,
 H
e
b
e
rt
 P
, 
D
a
le
s 
R
, 
S
ti
e
ll 
IG
, 
A
h
u
ja
 J
, 
e
t 
a
l. 
O
u
tp
a
ti
e
n
t 
o
ra
l 
p
re
d
n
is
o
n
e
 a
ft
e
r 
e
m
e
rg
e
n
c
y
 t
re
a
tm
e
n
t 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 
p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
N
 E
n
g
l 
J
 M
e
d
 2
0
0
3
 J
u
n
 2
6
;3
4
8
(2
6
):
2
6
1
8
-2
5
. 
E
2
 
A
a
ro
n
 S
D
, 
V
a
n
d
e
m
h
e
e
n
 K
L,
 F
e
rg
u
ss
o
n
 D
, 
M
a
lt
a
is
 F
, 
B
o
u
rb
e
a
u
 J
, 
G
o
ld
st
e
in
 R
, 
e
t 
a
l. 
Ti
o
tr
o
p
iu
m
 in
 c
o
m
b
in
a
ti
o
n
 w
it
h
 p
la
c
e
b
o
, 
sa
lm
e
te
ro
l,
 o
r 
fl
u
ti
c
a
so
n
e
-
sa
lm
e
te
ro
l 
fo
r 
tr
e
a
tm
e
n
t 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
: 
a
 r
a
n
d
o
m
iz
e
d
 t
ri
a
l. 
A
n
n
 I
n
te
rn
 M
e
d
 2
0
0
7
 A
p
r 
1
7
;1
4
6
(8
):
5
4
5
-5
5
. 
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E
3
 
A
lb
e
rs
 M
, 
S
c
h
e
rm
e
r 
T,
 v
a
n
 d
e
n
 B
G
, 
A
k
k
e
rm
a
n
s 
R
, 
v
a
n
 S
c
h
a
y
c
k
 C
, 
v
a
n
 H
e
rw
a
a
rd
e
n
 C
, 
e
t 
a
l.
 E
ff
ic
a
c
y
 o
f 
in
h
a
le
d
 s
te
ro
id
s 
in
 u
n
d
ia
g
n
o
se
d
 s
u
b
je
c
ts
 a
t 
h
ig
h
 r
is
k
 
fo
r 
C
O
P
D
: 
re
su
lt
s 
o
f 
th
e
 d
e
te
c
ti
o
n
, 
in
te
rv
e
n
ti
o
n
, 
a
n
d
 m
o
n
it
o
ri
n
g
 o
f 
C
O
P
D
 a
n
d
 a
st
h
m
a
 p
ro
g
ra
m
. 
C
h
e
st
 2
0
0
4
 D
e
c
;1
2
6
(6
):
1
8
1
5
-2
4
. 
E
4
 
A
lle
g
ra
 L
, 
K
o
n
ie
tz
k
o
 N
, 
Le
o
p
h
o
n
te
 P
, 
H
o
si
e
 J
, 
P
a
u
w
e
ls
 R
, 
G
u
y
e
n
 J
N
, 
e
t 
a
l.
 C
o
m
p
a
ra
ti
v
e
 s
a
fe
ty
 a
n
d
 e
ff
ic
a
c
y
 o
f 
sp
a
rf
lo
x
a
c
in
 i
n
 t
h
e
 t
re
a
tm
e
n
t 
o
f 
a
c
u
te
 
e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
: 
a
 d
o
u
b
le
-b
lin
d
, 
ra
n
d
o
m
is
e
d
, 
p
a
ra
lle
l,
 m
u
lt
ic
e
n
tr
e
 s
tu
d
y
. 
J
 A
n
ti
m
ic
ro
b
 C
h
e
m
o
th
e
r 
1
9
9
6
 M
a
y
;3
7
 
S
u
p
p
l 
A
:9
3
-1
0
4
. 
E
5
 
A
lv
a
re
z-
M
o
n
 M
, 
M
ir
a
v
it
lle
s 
M
, 
M
o
re
ra
 J
, 
C
a
llo
l 
L,
 A
lv
a
re
z-
S
a
la
 J
L.
 T
re
a
tm
e
n
t 
w
it
h
 t
h
e
 i
m
m
u
n
o
m
o
d
u
la
to
r 
A
M
3
 i
m
p
ro
v
e
s 
th
e
 h
e
a
lt
h
-r
e
la
te
d
 q
u
a
lit
y
 o
f 
lif
e
 o
f 
p
a
ti
e
n
ts
 w
it
h
 C
O
P
D
. 
C
h
e
st
 2
0
0
5
 A
p
r;
1
2
7
(4
):
1
2
1
2
-8
. 
E
6
 
A
n
th
o
n
is
e
n
 N
R
, 
M
a
n
fr
e
d
a
 J
, 
W
a
rr
e
n
 C
P
, 
H
e
rs
h
fi
e
ld
 E
S
, 
H
a
rd
in
g
 G
K
, 
N
e
ls
o
n
 N
A
. 
A
n
ti
b
io
ti
c
 t
h
e
ra
p
y
 i
n
 e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
A
n
n
 I
n
te
rn
 M
e
d
 1
9
8
7
 F
e
b
;1
0
6
(2
):
1
9
6
-2
0
4
. 
E
7
 
B
a
rd
i G
, 
P
ie
ro
te
llo
 R
, 
D
e
si
d
e
ri
 M
, 
V
a
ld
is
se
rr
i L
, 
B
o
tt
a
i M
, 
P
a
lla
 A
. 
N
a
sa
l 
v
e
n
ti
la
ti
o
n
 i
n
 C
O
P
D
 e
x
a
c
e
rb
a
ti
o
n
s:
 e
a
rl
y
 a
n
d
 l
a
te
 r
e
su
lt
s 
o
f 
a
 p
ro
sp
e
c
ti
v
e
, 
c
o
n
tr
o
lle
d
 
st
u
d
y
. 
E
u
r 
R
e
sp
ir
 J
 2
0
0
0
 J
a
n
;1
5
(1
):
9
8
-1
0
4
. 
E
8
 
B
e
llo
n
e
 A
, 
S
p
a
g
n
o
la
tt
i L
, 
M
a
ss
o
b
ri
o
 M
, 
B
e
lle
i E
, 
V
in
c
ig
u
e
rr
a
 R
, 
B
a
rb
ie
ri
 A
, 
e
t 
a
l.
 S
h
o
rt
-t
e
rm
 e
ff
e
c
ts
 o
f 
e
x
p
ir
a
ti
o
n
 u
n
d
e
r 
p
o
si
ti
v
e
 p
re
ss
u
re
 i
n
 p
a
ti
e
n
ts
 w
it
h
 a
c
u
te
 
e
x
a
c
e
rb
a
ti
o
n
 o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
 a
n
d
 m
ild
 a
c
id
o
si
s 
re
q
u
ir
in
g
 n
o
n
-i
n
v
a
si
v
e
 p
o
si
ti
v
e
 p
re
ss
u
re
 v
e
n
ti
la
ti
o
n
. 
In
te
n
si
v
e
 C
a
re
 M
e
d
 2
0
0
2
 
M
a
y
;2
8
(5
):
5
8
1
-5
. 
E
9
 
B
o
u
rb
e
a
u
 J
, 
J
u
lie
n
 M
, 
M
a
lt
a
is
 F
, 
R
o
u
le
a
u
 M
, 
B
e
a
u
p
re
 A
, 
B
e
g
in
 R
, 
e
t 
a
l.
 R
e
d
u
c
ti
o
n
 o
f 
h
o
sp
it
a
l 
u
ti
liz
a
ti
o
n
 i
n
 p
a
ti
e
n
ts
 w
it
h
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
: 
a
 d
is
e
a
se
-s
p
e
c
if
ic
 s
e
lf
-m
a
n
a
g
e
m
e
n
t 
in
te
rv
e
n
ti
o
n
. 
A
rc
h
 I
n
te
rn
 M
e
d
 2
0
0
3
 M
a
r 
1
0
;1
6
3
(5
):
5
8
5
-9
1
. 
E
1
0
 
B
ru
sa
sc
o
 V
, 
H
o
d
d
e
r 
R
, 
M
ir
a
v
it
lle
s 
M
, 
K
o
rd
u
c
k
i L
, 
To
w
se
 L
, 
K
e
st
e
n
 S
. 
H
e
a
lt
h
 o
u
tc
o
m
e
s 
fo
llo
w
in
g
 t
re
a
tm
e
n
t 
fo
r 
si
x
 m
o
n
th
s 
w
it
h
 o
n
c
e
 d
a
ily
 t
io
tr
o
p
iu
m
 c
o
m
p
a
re
d
 
w
it
h
 t
w
ic
e
 d
a
ily
 s
a
lm
e
te
ro
l 
in
 p
a
ti
e
n
ts
 w
it
h
 C
O
P
D
. 
Th
o
ra
x
 2
0
0
3
 M
a
y
;5
8
(5
):
3
9
9
-4
0
4
. 
E
1
1
 
B
u
rg
e
 P
S
, 
C
a
lv
e
rl
e
y
 P
M
, 
J
o
n
e
s 
P
W
, 
S
p
e
n
c
e
r 
S
, 
A
n
d
e
rs
o
n
 J
A
, 
M
a
sl
e
n
 T
K
. 
R
a
n
d
o
m
is
e
d
, 
d
o
u
b
le
 b
lin
d
, 
p
la
c
e
b
o
 c
o
n
tr
o
lle
d
 s
tu
d
y
 o
f 
fl
u
ti
c
a
so
n
e
 p
ro
p
io
n
a
te
 i
n
 
p
a
ti
e
n
ts
 w
it
h
 m
o
d
e
ra
te
 t
o
 s
e
v
e
re
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
: 
th
e
 I
S
O
LD
E
 t
ri
a
l.
 B
M
J
 2
0
0
0
 M
a
y
 1
3
;3
2
0
(7
2
4
5
):
1
2
9
7
-3
0
3
. 
E
1
2
 
B
u
rg
e
 S
, 
W
e
d
zi
c
h
a
 J
A
. 
C
O
P
D
 e
x
a
c
e
rb
a
ti
o
n
s:
 d
e
fi
n
it
io
n
s 
a
n
d
 c
la
ss
if
ic
a
ti
o
n
s.
 E
u
r 
R
e
sp
ir
 J
 2
0
0
3
;2
1
(S
u
p
p
l.
4
1
):
4
6
S
-5
3
S
. 
E
1
3
 
C
a
lv
e
rl
e
y
 P
, 
P
a
u
w
e
ls
 R
, 
V
e
st
b
o
 J
, 
J
o
n
e
s 
P
, 
P
ri
d
e
 N
, 
G
u
ls
v
ik
 A
, 
e
t 
a
l.
 C
o
m
b
in
e
d
 s
a
lm
e
te
ro
l 
a
n
d
 f
lu
ti
c
a
so
n
e
 i
n
 t
h
e
 t
re
a
tm
e
n
t 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 
d
is
e
a
se
: 
a
 r
a
n
d
o
m
is
e
d
 c
o
n
tr
o
lle
d
 t
ri
a
l.
 L
a
n
c
e
t 
2
0
0
3
 F
e
b
 8
;3
6
1
(9
3
5
6
):
4
4
9
-5
6
. 
E
1
4
 
C
a
lv
e
rl
e
y
 P
M
, 
A
n
d
e
rs
o
n
 J
A
, 
C
e
lli
 B
, 
F
e
rg
u
so
n
 G
T,
 J
e
n
k
in
s 
C
, 
J
o
n
e
s 
P
W
, 
e
t 
a
l.
 S
a
lm
e
te
ro
l 
a
n
d
 f
lu
ti
c
a
so
n
e
 p
ro
p
io
n
a
te
 a
n
d
 s
u
rv
iv
a
l 
in
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 
p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
N
 E
n
g
l 
J
 M
e
d
 2
0
0
7
 F
e
b
 2
2
;3
5
6
(8
):
7
7
5
-8
9
. 
E
1
5
 
C
a
sa
b
u
ri
 R
, 
M
a
h
le
r 
D
A
, 
J
o
n
e
s 
P
W
, 
W
a
n
n
e
r 
A
, 
S
a
n
 P
G
, 
Z
u
W
a
lla
c
k
 R
L,
 e
t 
a
l.
 A
 l
o
n
g
-t
e
rm
 e
v
a
lu
a
ti
o
n
 o
f 
o
n
c
e
-d
a
ily
 in
h
a
le
d
 t
io
tr
o
p
iu
m
 i
n
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 
p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
E
u
r 
R
e
sp
ir
 J
 2
0
0
2
 F
e
b
;1
9
(2
):
2
1
7
-2
4
. 
E
1
6
 
C
a
sa
n
o
v
a
 C
, 
C
e
lli
 B
R
, 
To
st
 L
, 
S
o
ri
a
n
o
 E
, 
A
b
re
u
 J
, 
V
e
la
sc
o
 V
, 
e
t 
a
l.
 L
o
n
g
-t
e
rm
 c
o
n
tr
o
lle
d
 t
ri
a
l 
o
f 
n
o
c
tu
rn
a
l 
n
a
sa
l 
p
o
si
ti
v
e
 p
re
ss
u
re
 v
e
n
ti
la
ti
o
n
 i
n
 p
a
ti
e
n
ts
 w
it
h
 
se
v
e
re
 C
O
P
D
. 
C
h
e
st
 2
0
0
0
 D
e
c
;1
1
8
(6
):
1
5
8
2
-9
0
. 
E
1
7
 
C
o
lle
t 
J
P
, 
S
h
a
p
ir
o
 P
, 
E
rn
st
 P
, 
R
e
n
zi
 T
, 
D
u
c
ru
e
t 
T,
 R
o
b
in
so
n
 A
. 
E
ff
e
c
ts
 o
f 
a
n
 i
m
m
u
n
o
st
im
u
la
ti
n
g
 a
g
e
n
t 
o
n
 a
c
u
te
 e
x
a
c
e
rb
a
ti
o
n
s 
a
n
d
 h
o
sp
it
a
liz
a
ti
o
n
s 
in
 p
a
ti
e
n
ts
 
w
it
h
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
Th
e
 P
A
R
I-
IS
 S
tu
d
y
 S
te
e
ri
n
g
 C
o
m
m
it
te
e
 a
n
d
 R
e
se
a
rc
h
 G
ro
u
p
. 
P
re
v
e
n
ti
o
n
 o
f 
A
c
u
te
 R
e
sp
ir
a
to
ry
 I
n
fe
c
ti
o
n
 b
y
 a
n
 
Im
m
u
n
o
st
im
u
la
n
t.
 A
m
 J
 R
e
sp
ir
 C
ri
t 
C
a
re
 M
e
d
 1
9
9
7
 D
e
c
;1
5
6
(6
):
1
7
1
9
-2
4
. 
E
1
8
 
C
o
tt
o
n
 M
M
, 
B
u
c
k
n
a
ll 
C
E
, 
D
a
g
g
 K
D
, 
J
o
h
n
so
n
 M
K
, 
M
a
c
G
re
g
o
r 
G
, 
S
te
w
a
rt
 C
, 
e
t 
a
l.
 E
a
rl
y
 d
is
c
h
a
rg
e
 f
o
r 
p
a
ti
e
n
ts
 w
it
h
 e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 
p
u
lm
o
n
a
ry
 d
is
e
a
se
: 
a
 r
a
n
d
o
m
iz
e
d
 c
o
n
tr
o
lle
d
 t
ri
a
l.
 T
h
o
ra
x
 2
0
0
0
 N
o
v
;5
5
(1
1
):
9
0
2
-6
. 
E
1
9
 
D
a
v
ie
s 
L,
 W
ilk
in
so
n
 M
, 
B
o
n
n
e
r 
S
, 
C
a
lv
e
rl
e
y
 P
M
, 
A
n
g
u
s 
R
M
. 
"H
o
sp
it
a
l 
a
t 
h
o
m
e
" 
v
e
rs
u
s 
h
o
sp
it
a
l 
c
a
re
 i
n
 p
a
ti
e
n
ts
 w
it
h
 e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 
p
u
lm
o
n
a
ry
 d
is
e
a
se
: 
p
ro
sp
e
c
ti
v
e
 r
a
n
d
o
m
is
e
d
 c
o
n
tr
o
lle
d
 t
ri
a
l.
 B
M
J
 2
0
0
0
 N
o
v
 1
8
;3
2
1
(7
2
7
1
):
1
2
6
5
-8
. 
E
2
0
 
D
e
c
ra
m
e
r 
M
, 
R
u
tt
e
n
-v
a
n
 M
o
lk
e
n
 M
, 
D
e
k
h
u
ijz
e
n
 P
N
, 
Tr
o
o
st
e
rs
 T
, 
v
a
n
 H
e
rw
a
a
rd
e
n
 C
, 
P
e
lle
g
ri
n
o
 R
, 
e
t 
a
l. 
E
ff
e
c
ts
 o
f 
N
-a
c
e
ty
lc
y
st
e
in
e
 o
n
 o
u
tc
o
m
e
s 
in
 c
h
ro
n
ic
 
o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
 (
B
ro
n
c
h
it
is
 R
a
n
d
o
m
iz
e
d
 o
n
 N
A
C
 C
o
st
-U
ti
lit
y
 S
tu
d
y
, 
B
R
O
N
C
U
S
):
 a
 r
a
n
d
o
m
is
e
d
 p
la
c
e
b
o
-c
o
n
tr
o
lle
d
 t
ri
a
l.
 L
a
n
c
e
t 
2
0
0
5
 A
p
r 
3
0
;3
6
5
(9
4
7
0
):
1
5
5
2
-6
0
. 
E
2
1
 
D
o
m
p
e
lin
g
 E
, 
v
a
n
 S
c
h
a
y
c
k
 C
P
, 
M
o
le
m
a
 J
, 
F
o
lg
e
ri
n
g
 H
, 
v
a
n
 G
ru
n
sv
e
n
 P
M
, 
v
a
n
 W
e
e
l 
C
. 
In
h
a
le
d
 b
e
c
lo
m
e
th
a
so
n
e
 i
m
p
ro
v
e
s 
th
e
 c
o
u
rs
e
 o
f 
a
st
h
m
a
 a
n
d
 C
O
P
D
. 
E
u
r 
R
e
sp
ir
 J
 1
9
9
2
 S
e
p
;5
(8
):
9
4
5
-5
2
. 
E
2
2
 
D
u
ss
e
r 
D
, 
B
ra
v
o
 M
L,
 I
a
c
o
n
o
 P
. 
Th
e
 e
ff
e
c
t 
o
f 
ti
o
tr
o
p
iu
m
 o
n
 e
x
a
c
e
rb
a
ti
o
n
s 
a
n
d
 a
ir
fl
o
w
 i
n
 p
a
ti
e
n
ts
 w
it
h
 C
O
P
D
. 
E
u
r 
R
e
sp
ir
 J
 2
0
0
6
 M
a
r;
2
7
(3
):
5
4
7
-5
5
. 
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E
2
3
 
F
ri
e
d
m
a
n
 M
, 
S
e
rb
y
 C
W
, 
M
e
n
jo
g
e
 S
S
, 
W
ils
o
n
 J
D
, 
H
ill
e
m
a
n
 D
E
, 
W
it
e
k
 T
J
, 
J
r.
 P
h
a
rm
a
c
o
e
c
o
n
o
m
ic
 e
v
a
lu
a
ti
o
n
 o
f 
a
 c
o
m
b
in
a
ti
o
n
 o
f 
ip
ra
tr
o
p
iu
m
 p
lu
s 
a
lb
u
te
ro
l 
c
o
m
p
a
re
d
 w
it
h
 ip
ra
tr
o
p
iu
m
 a
lo
n
e
 a
n
d
 a
lb
u
te
ro
l 
a
lo
n
e
 i
n
 C
O
P
D
. 
C
h
e
st
 1
9
9
9
 M
a
r;
1
1
5
(3
):
6
3
5
-4
1
. 
E
2
4
 
G
u
e
ll 
R
, 
C
a
sa
n
 P
, 
B
e
ld
a
 J
, 
S
a
n
g
e
n
is
 M
, 
M
o
ra
n
te
 F
, 
G
u
y
a
tt
 G
H
, 
e
t 
a
l.
 L
o
n
g
-t
e
rm
 e
ff
e
c
ts
 o
f 
o
u
tp
a
ti
e
n
t 
re
h
a
b
ili
ta
ti
o
n
 o
f 
C
O
P
D
: 
A
 r
a
n
d
o
m
iz
e
d
 t
ri
a
l.
 C
h
e
st
 2
0
0
0
 
A
p
r;
1
1
7
(4
):
9
7
6
-8
3
. 
E
2
5
 
G
u
d
m
u
n
d
ss
o
n
 G
, 
G
is
la
so
n
 T
, 
Li
n
d
b
e
rg
 E
, 
H
a
lli
n
 R
, 
U
lr
ik
 C
S
, 
B
ro
n
d
u
m
 E
, 
e
t 
a
l.
 M
o
rt
a
lit
y
 i
n
 C
O
P
D
 p
a
ti
e
n
ts
 d
is
c
h
a
rg
e
d
 f
ro
m
 h
o
sp
it
a
l:
 t
h
e
 r
o
le
 o
f 
tr
e
a
tm
e
n
t 
a
n
d
 
c
o
-m
o
rb
id
it
y
. 
R
e
sp
ir
 R
e
s 
2
0
0
6
;7
:1
0
9
. 
E
2
6
 
H
a
n
a
n
ia
 N
A
, 
D
a
rk
e
n
 P
, 
H
o
rs
tm
a
n
 D
, 
R
e
is
n
e
r 
C
, 
Le
e
 B
, 
D
a
v
is
 S
, 
e
t 
a
l.
 T
h
e
 e
ff
ic
a
c
y
 a
n
d
 s
a
fe
ty
 o
f 
fl
u
ti
c
a
so
n
e
 p
ro
p
io
n
a
te
 (
2
5
0
 m
ic
ro
g
)/
sa
lm
e
te
ro
l 
(5
0
 m
ic
ro
g
) 
c
o
m
b
in
e
d
 i
n
 t
h
e
 D
is
k
u
s 
in
h
a
le
r 
fo
r 
th
e
 t
re
a
tm
e
n
t 
o
f 
C
O
P
D
. 
C
h
e
st
 2
0
0
3
 S
e
p
;1
2
4
(3
):
8
3
4
-4
3
. 
E
2
7
 
H
a
tt
o
tu
w
a
 K
L,
 G
iz
y
c
k
i M
J
, 
A
n
sa
ri
 T
W
, 
J
e
ff
e
ry
 P
K
, 
B
a
rn
e
s 
N
C
. 
Th
e
 e
ff
e
c
ts
 o
f 
in
h
a
le
d
 f
lu
ti
c
a
so
n
e
 o
n
 a
ir
w
a
y
 i
n
fl
a
m
m
a
ti
o
n
 i
n
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 
d
is
e
a
se
: 
a
 d
o
u
b
le
-b
lin
d
, 
p
la
c
e
b
o
-c
o
n
tr
o
lle
d
 b
io
p
sy
 s
tu
d
y
. 
A
m
 J
 R
e
sp
ir
 C
ri
t 
C
a
re
 M
e
d
 2
0
0
2
 J
u
n
 1
5
;1
6
5
(1
2
):
1
5
9
2
-6
. 
E
2
8
 
H
o
e
p
e
lm
a
n
 A
I,
 S
ip
s 
A
P
, 
v
a
n
 H
e
lm
o
n
d
 J
L,
 v
a
n
 B
a
rn
e
v
e
ld
 P
W
, 
N
e
v
e
 A
J
, 
Z
w
in
k
e
ls
 M
, 
e
t 
a
l.
 A
 s
in
g
le
-b
lin
d
 c
o
m
p
a
ri
so
n
 o
f 
th
re
e
-d
a
y
 a
zi
th
ro
m
y
c
in
 a
n
d
 t
e
n
-d
a
y
 c
o
-
a
m
o
x
ic
la
v
 t
re
a
tm
e
n
t 
o
f 
a
c
u
te
 l
o
w
e
r 
re
sp
ir
a
to
ry
 t
ra
c
t 
in
fe
c
ti
o
n
s.
 J
 A
n
ti
m
ic
ro
b
 C
h
e
m
o
th
e
r 
1
9
9
3
 J
u
n
;3
1
 S
u
p
p
l 
E
:1
4
7
-5
2
. 
E
2
9
 
J
o
n
e
s 
P
W
, 
W
ill
it
s 
LR
, 
B
u
rg
e
 P
S
, 
C
a
lv
e
rl
e
y
 P
M
. 
D
is
e
a
se
 s
e
v
e
ri
ty
 a
n
d
 t
h
e
 e
ff
e
c
t 
o
f 
fl
u
ti
c
a
so
n
e
 p
ro
p
io
n
a
te
 o
n
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
 
e
x
a
c
e
rb
a
ti
o
n
s.
 E
u
r 
R
e
sp
ir
 J
 2
0
0
3
 J
a
n
;2
1
(1
):
6
8
-7
3
. 
E
3
0
 
K
a
rd
o
s 
P
, 
W
e
n
c
k
e
r 
M
, 
G
la
a
b
 T
, 
V
o
g
e
lm
e
ie
r 
C
. 
Im
p
a
c
t 
o
f 
sa
lm
e
te
ro
l/
fl
u
ti
c
a
so
n
e
 p
ro
p
io
n
a
te
 v
e
rs
u
s 
sa
lm
e
te
ro
l 
o
n
 e
x
a
c
e
rb
a
ti
o
n
s 
in
 s
e
v
e
re
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 
p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
A
m
 J
 R
e
sp
ir
 C
ri
t 
C
a
re
 M
e
d
 2
0
0
7
 J
a
n
 1
5
;1
7
5
(2
):
1
4
4
-9
. 
E
3
1
 
K
a
rp
e
l 
J
P
. 
B
ro
n
c
h
o
d
ila
to
r 
re
sp
o
n
se
s 
to
 a
n
ti
c
h
o
lin
e
rg
ic
 a
n
d
 b
e
ta
-a
d
re
n
e
rg
ic
 a
g
e
n
ts
 i
n
 a
c
u
te
 a
n
d
 s
ta
b
le
 C
O
P
D
. 
C
h
e
st
 1
9
9
1
 A
p
r;
9
9
(4
):
8
7
1
-6
. 
E
3
2
 
K
im
 S
, 
E
m
e
rm
a
n
 C
L,
 C
y
d
u
lk
a
 R
K
, 
R
o
w
e
 B
H
, 
C
la
rk
 S
, 
C
a
m
a
rg
o
 C
A
. 
P
ro
sp
e
c
ti
v
e
 m
u
lt
ic
e
n
te
r 
st
u
d
y
 o
f 
re
la
p
se
 f
o
llo
w
in
g
 e
m
e
rg
e
n
c
y
 d
e
p
a
rt
m
e
n
t 
tr
e
a
tm
e
n
t 
o
f 
C
O
P
D
 e
x
a
c
e
rb
a
ti
o
n
. 
C
h
e
st
 2
0
0
4
 F
e
b
;1
2
5
(2
):
4
7
3
-8
1
. 
E
3
3
 
Ll
o
b
e
re
s 
P
, 
R
a
m
is
 L
, 
M
o
n
ts
e
rr
a
t 
J
M
, 
S
e
rr
a
 J
, 
C
a
m
p
is
to
l 
J
, 
P
ic
a
d
o
 C
, 
e
t 
a
l.
 E
ff
e
c
t 
o
f 
th
re
e
 d
if
fe
re
n
t 
b
ro
n
c
h
o
d
ila
to
rs
 d
u
ri
n
g
 a
n
 e
x
a
c
e
rb
a
ti
o
n
 o
f 
c
h
ro
n
ic
 
o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
E
u
r 
R
e
sp
ir
 J
 1
9
8
8
 J
u
n
;1
(6
):
5
3
6
-9
. 
E
3
4
 
Lo
d
e
 H
, 
E
lle
r 
J
, 
L
in
n
h
o
ff
 A
, 
Io
a
n
a
s 
M
. 
Le
v
o
fl
o
x
a
c
in
 v
e
rs
u
s 
c
la
ri
th
ro
m
y
c
in
 i
n
 C
O
P
D
 e
x
a
c
e
rb
a
ti
o
n
: 
fo
c
u
s 
o
n
 e
x
a
c
e
rb
a
ti
o
n
-f
re
e
 i
n
te
rv
a
l.
 E
u
r 
R
e
sp
ir
 J
 2
0
0
4
 
D
e
c
;2
4
(6
):
9
4
7
-5
3
. 
E
3
5
 
Lu
b
a
sc
h
 A
, 
Lu
c
k
 S
, 
Lo
d
e
 H
, 
M
a
u
c
h
 H
, 
Lo
re
n
z 
J
, 
B
o
lc
sk
e
i 
P
, 
e
t 
a
l.
 O
p
ti
m
iz
in
g
 c
e
ft
a
zi
d
im
e
 p
h
a
rm
a
c
o
d
y
n
a
m
ic
s 
in
 p
a
ti
e
n
ts
 w
it
h
 a
c
u
te
 e
x
a
c
e
rb
a
ti
o
n
 o
f 
se
v
e
re
 
c
h
ro
n
ic
 b
ro
n
c
h
it
is
. 
J
 A
n
ti
m
ic
ro
b
 C
h
e
m
o
th
e
r 
2
0
0
3
 M
a
r;
5
1
(3
):
6
5
9
-6
4
. 
E
3
6
 
M
a
lt
a
is
 F
, 
O
st
in
e
lli
 J
, 
B
o
u
rb
e
a
u
 J
, 
To
n
n
e
l 
A
B
, 
J
a
c
q
u
e
m
e
t 
N
, 
H
a
d
d
o
n
 J
, 
e
t 
a
l.
 C
o
m
p
a
ri
so
n
 o
f 
n
e
b
u
liz
e
d
 b
u
d
e
so
n
id
e
 a
n
d
 o
ra
l 
p
re
d
n
is
o
lo
n
e
 w
it
h
 p
la
c
e
b
o
 in
 t
h
e
 
tr
e
a
tm
e
n
t 
o
f 
a
c
u
te
 e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
: 
a
 r
a
n
d
o
m
iz
e
d
 c
o
n
tr
o
lle
d
 t
ri
a
l.
 A
m
 J
 R
e
sp
ir
 C
ri
t 
C
a
re
 M
e
d
 2
0
0
2
 M
a
r 
1
;1
6
5
(5
):
6
9
8
-
7
0
3
. 
E
3
7
 
M
a
rt
in
e
z 
F
J
, 
G
ro
ss
m
a
n
 R
F
, 
Z
a
d
e
ik
is
 N
, 
F
is
h
e
r 
A
C
, 
W
a
lk
e
r 
K
, 
A
m
b
ru
zs
 M
E
, 
e
t 
a
l.
 P
a
ti
e
n
t 
st
ra
ti
fi
c
a
ti
o
n
 i
n
 t
h
e
 m
a
n
a
g
e
m
e
n
t 
o
f 
a
c
u
te
 b
a
c
te
ri
a
l 
e
x
a
c
e
rb
a
ti
o
n
 o
f 
c
h
ro
n
ic
 b
ro
n
c
h
it
is
: 
th
e
 r
o
le
 o
f 
le
v
o
fl
o
x
a
c
in
 7
5
0
 m
g
. 
E
u
r 
R
e
sp
ir
 J
 2
0
0
5
 J
u
n
;2
5
(6
):
1
0
0
1
-1
0
. 
E
3
8
 
M
a
te
ra
 M
G
, 
Tu
fa
n
o
 M
A
, 
P
o
lv
e
ri
n
o
 M
, 
R
o
ss
i F
, 
C
a
zz
o
la
 M
. 
P
u
lm
o
n
a
ry
 c
o
n
c
e
n
tr
a
ti
o
n
s 
o
f 
d
ir
it
h
ro
m
y
c
in
 a
n
d
 e
ry
th
ro
m
y
c
in
 d
u
ri
n
g
 a
c
u
te
 e
x
a
c
e
rb
a
ti
o
n
 o
f 
m
ild
 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
E
u
r 
R
e
sp
ir
 J
 1
9
9
7
 J
a
n
;1
0
(1
):
9
8
-1
0
3
. 
E
3
9
 
M
o
n
n
in
k
h
o
f 
E
, 
v
a
n
 d
e
r 
V
a
lk
 P
, 
v
a
n
 d
e
r 
P
a
le
n
 J
, 
v
a
n
 H
e
rw
a
a
rd
e
n
 C
, 
Z
ie
lh
u
is
 G
. 
E
ff
e
c
ts
 o
f 
a
 c
o
m
p
re
h
e
n
si
v
e
 s
e
lf
-m
a
n
a
g
e
m
e
n
t 
p
ro
g
ra
m
m
e
 i
n
 p
a
ti
e
n
ts
 w
it
h
 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
E
u
r 
R
e
sp
ir
 J
 2
0
0
3
 N
o
v
;2
2
(5
):
8
1
5
-2
0
. 
E
4
0
 
N
a
ir
 S
, 
Th
o
m
a
s 
E
, 
P
e
a
rs
o
n
 S
B
, 
H
e
n
ry
 M
T.
 A
 r
a
n
d
o
m
iz
e
d
 c
o
n
tr
o
lle
d
 t
ri
a
l 
to
 a
ss
e
ss
 t
h
e
 o
p
ti
m
a
l 
d
o
se
 a
n
d
 e
ff
e
c
t 
o
f 
n
e
b
u
liz
e
d
 a
lb
u
te
ro
l 
in
 a
c
u
te
 e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
C
O
P
D
. 
C
h
e
st
 2
0
0
5
 J
u
l;
1
2
8
(1
):
4
8
-5
4
. 
E
4
1
 
N
ie
w
o
e
h
n
e
r 
D
E
, 
R
ic
e
 K
, 
C
o
te
 C
, 
P
a
u
ls
o
n
 D
, 
C
o
o
p
e
r 
J
A
, 
J
r.
, 
K
o
rd
u
c
k
i L
, 
e
t 
a
l.
 P
re
v
e
n
ti
o
n
 o
f 
e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
 w
it
h
 
ti
o
tr
o
p
iu
m
, 
a
 o
n
c
e
-d
a
ily
 i
n
h
a
le
d
 a
n
ti
c
h
o
lin
e
rg
ic
 b
ro
n
c
h
o
d
ila
to
r:
 a
 r
a
n
d
o
m
iz
e
d
 t
ri
a
l.
 A
n
n
 I
n
te
rn
 M
e
d
 2
0
0
5
 S
e
p
 6
;1
4
3
(5
):
3
1
7
-2
6
. 
E
4
2
 
N
o
u
ir
a
 S
, 
M
a
rg
h
li 
S
, 
B
e
lg
h
it
h
 M
, 
B
e
sb
e
s 
L,
 E
la
tr
o
u
s 
S
, 
A
b
ro
u
g
 F
. 
O
n
c
e
 d
a
ily
 o
ra
l 
o
fl
o
x
a
c
in
 i
n
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
 e
x
a
c
e
rb
a
ti
o
n
 r
e
q
u
ir
in
g
 
m
e
c
h
a
n
ic
a
l 
v
e
n
ti
la
ti
o
n
: 
a
 r
a
n
d
o
m
is
e
d
 p
la
c
e
b
o
-c
o
n
tr
o
lle
d
 t
ri
a
l.
 L
a
n
c
e
t 
2
0
0
1
 D
e
c
 1
5
;3
5
8
(9
2
9
8
):
2
0
2
0
-5
. 
E
4
3
 
P
a
g
g
ia
ro
 P
L,
 D
a
h
le
 R
, 
B
a
k
ra
n
 I
, 
F
ri
th
 L
, 
H
o
lli
n
g
w
o
rt
h
 K
, 
E
ft
h
im
io
u
 J
. 
M
u
lt
ic
e
n
tr
e
 r
a
n
d
o
m
is
e
d
 p
la
c
e
b
o
-c
o
n
tr
o
lle
d
 t
ri
a
l 
o
f 
in
h
a
le
d
 f
lu
ti
c
a
so
n
e
 p
ro
p
io
n
a
te
 i
n
 
p
a
ti
e
n
ts
 w
it
h
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
In
te
rn
a
ti
o
n
a
l 
C
O
P
D
 S
tu
d
y
 G
ro
u
p
. 
La
n
c
e
t 
1
9
9
8
 M
a
r 
1
4
;3
5
1
(9
1
0
5
):
7
7
3
-8
0
. 
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E
4
4
 
P
la
n
t 
P
K
, 
O
w
e
n
 J
L,
 E
lli
o
tt
 M
W
. 
E
a
rl
y
 u
se
 o
f 
n
o
n
-i
n
v
a
si
v
e
 v
e
n
ti
la
ti
o
n
 f
o
r 
a
c
u
te
 e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
 o
n
 g
e
n
e
ra
l 
re
sp
ir
a
to
ry
 
w
a
rd
s:
 a
 m
u
lt
ic
e
n
tr
e
 r
a
n
d
o
m
is
e
d
 c
o
n
tr
o
lle
d
 t
ri
a
l.
 L
a
n
c
e
t 
2
0
0
0
 J
u
n
 3
;3
5
5
(9
2
1
9
):
1
9
3
1
-5
. 
E
4
5
 
R
a
b
e
 K
F
, 
B
a
te
m
a
n
 E
D
, 
O
'D
o
n
n
e
ll 
D
, 
W
it
te
 S
, 
B
re
d
e
n
b
ro
k
e
r 
D
, 
B
e
th
k
e
 T
D
. 
R
o
fl
u
m
ila
st
--
a
n
 o
ra
l 
a
n
ti
-i
n
fl
a
m
m
a
to
ry
 t
re
a
tm
e
n
t 
fo
r 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 
d
is
e
a
se
: 
a
 r
a
n
d
o
m
is
e
d
 c
o
n
tr
o
lle
d
 t
ri
a
l.
 L
a
n
c
e
t 
2
0
0
5
 A
u
g
 1
3
;3
6
6
(9
4
8
5
):
5
6
3
-7
1
. 
E
4
6
 
R
e
n
k
e
m
a
 T
E
, 
S
c
h
o
u
te
n
 J
P
, 
K
o
e
te
r 
G
H
, 
P
o
st
m
a
 D
S
. 
E
ff
e
c
ts
 o
f 
lo
n
g
-t
e
rm
 t
re
a
tm
e
n
t 
w
it
h
 c
o
rt
ic
o
st
e
ro
id
s 
in
 C
O
P
D
. 
C
h
e
st
 1
9
9
6
 M
a
y
;1
0
9
(5
):
1
1
5
6
-6
2
. 
E
4
7
 
R
e
n
n
a
rd
 S
I,
 S
c
h
a
c
h
te
r 
N
, 
S
tr
e
k
 M
, 
R
ic
k
a
rd
 K
, 
A
m
it
 O
. 
C
ilo
m
ila
st
 f
o
r 
C
O
P
D
: 
re
su
lt
s 
o
f 
a
 6
-m
o
n
th
, 
p
la
c
e
b
o
-c
o
n
tr
o
lle
d
 s
tu
d
y
 o
f 
a
 p
o
te
n
t,
 s
e
le
c
ti
v
e
 i
n
h
ib
it
o
r 
o
f 
p
h
o
sp
h
o
d
ie
st
e
ra
se
 4
. 
C
h
e
st
 2
0
0
6
 J
a
n
;1
2
9
(1
):
5
6
-6
6
. 
E
4
8
 
R
e
n
n
a
rd
 S
I,
 F
o
g
a
rt
y
 C
, 
K
e
ls
e
n
 S
, 
Lo
n
g
 W
, 
R
a
m
sd
e
ll 
J
, 
A
lli
so
n
 J
, 
e
t 
a
l.
 T
h
e
 s
a
fe
ty
 a
n
d
 e
ff
ic
a
c
y
 o
f 
in
fl
ix
im
a
b
 i
n
 m
o
d
e
ra
te
 t
o
 s
e
v
e
re
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 
p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
A
m
 J
 R
e
sp
ir
 C
ri
t 
C
a
re
 M
e
d
 2
0
0
7
 M
a
y
 1
;1
7
5
(9
):
9
2
6
-3
4
. 
E
4
9
 
R
ic
e
 K
L,
 L
e
a
th
e
rm
a
n
 J
W
, 
D
u
a
n
e
 P
G
, 
S
n
y
d
e
r 
LS
, 
H
a
rm
o
n
 K
R
, 
A
b
e
l 
J
, 
e
t 
a
l.
 A
m
in
o
p
h
y
lli
n
e
 f
o
r 
a
c
u
te
 e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
A
 
c
o
n
tr
o
lle
d
 t
ri
a
l.
 A
n
n
 I
n
te
rn
 M
e
d
 1
9
8
7
 S
e
p
;1
0
7
(3
):
3
0
5
-9
. 
E
5
0
 
R
ic
e
 K
L,
 R
u
b
in
s 
J
B
, 
Le
b
a
h
n
 F
, 
P
a
re
n
ti
 C
M
, 
D
u
a
n
e
 P
G
, 
K
u
sk
o
w
sk
i M
, 
e
t 
a
l.
 W
it
h
d
ra
w
a
l 
o
f 
c
h
ro
n
ic
 s
y
st
e
m
ic
 c
o
rt
ic
o
st
e
ro
id
s 
in
 p
a
ti
e
n
ts
 w
it
h
 C
O
P
D
: 
a
 r
a
n
d
o
m
iz
e
d
 
tr
ia
l.
 A
m
 J
 R
e
sp
ir
 C
ri
t 
C
a
re
 M
e
d
 2
0
0
0
 J
u
l;
1
6
2
(1
):
1
7
4
-8
. 
E
5
1
 
R
o
d
ri
g
u
e
z-
R
o
is
in
 R
. 
To
w
a
rd
 a
 c
o
n
se
n
su
s 
d
e
fi
n
it
io
n
 f
o
r 
C
O
P
D
 e
x
a
c
e
rb
a
ti
o
n
s 
1
. 
C
h
e
st
 2
0
0
0
 M
a
y
;1
1
7
(5
 S
u
p
p
l 
2
):
3
9
8
S
-4
0
1
S
. 
E
5
2
 
S
a
c
h
s 
A
P
, 
K
o
e
te
r 
G
H
, 
G
ro
e
n
ie
r 
K
H
, 
v
a
n
 d
e
r 
W
a
a
ij 
D
, 
S
c
h
ip
h
u
is
 J
, 
M
e
y
b
o
o
m
-d
e
 J
o
n
g
 B
. 
C
h
a
n
g
e
s 
in
 s
y
m
p
to
m
s,
 p
e
a
k
 e
x
p
ir
a
to
ry
 f
lo
w
, 
a
n
d
 s
p
u
tu
m
 f
lo
ra
 d
u
ri
n
g
 
tr
e
a
tm
e
n
t 
w
it
h
 a
n
ti
b
io
ti
c
s 
o
f 
e
x
a
c
e
rb
a
ti
o
n
s 
in
 p
a
ti
e
n
ts
 w
it
h
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
 in
 g
e
n
e
ra
l 
p
ra
c
ti
c
e
. 
Th
o
ra
x
 1
9
9
5
 J
u
l;
5
0
(7
):
7
5
8
-6
3
. 
E
5
3
 
S
e
e
m
u
n
g
a
l 
TA
, 
D
o
n
a
ld
so
n
 G
C
, 
P
a
u
l 
E
A
, 
B
e
st
a
ll 
J
C
, 
J
e
ff
ri
e
s 
D
J
, 
W
e
d
zi
c
h
a
 J
A
. 
E
ff
e
c
t 
o
f 
e
x
a
c
e
rb
a
ti
o
n
 o
n
 q
u
a
lit
y
 o
f 
lif
e
 i
n
 p
a
ti
e
n
ts
 w
it
h
 c
h
ro
n
ic
 o
b
st
ru
c
ti
v
e
 
p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
A
m
 J
 R
e
sp
ir
 C
ri
t 
C
a
re
 M
e
d
 1
9
9
8
 M
a
y
;1
5
7
(5
 P
t 
1
):
1
4
1
8
-2
2
. 
E
5
4
 
S
e
th
i S
, 
B
re
to
n
 J
, 
W
y
n
n
e
 B
. 
E
ff
ic
a
c
y
 a
n
d
 s
a
fe
ty
 o
f 
p
h
a
rm
a
c
o
k
in
e
ti
c
a
lly
 e
n
h
a
n
c
e
d
 a
m
o
x
ic
ill
in
-c
la
v
u
la
n
a
te
 a
t 
2
,0
0
0
/1
2
5
 m
ill
ig
ra
m
s 
tw
ic
e
 d
a
ily
 f
o
r 
5
 d
a
y
s 
v
e
rs
u
s 
a
m
o
x
ic
ill
in
-c
la
v
u
la
n
a
te
 a
t 
8
7
5
/1
2
5
 m
ill
ig
ra
m
s 
tw
ic
e
 d
a
ily
 f
o
r 
7
 d
a
y
s 
in
 t
h
e
 t
re
a
tm
e
n
t 
o
f 
a
c
u
te
 e
x
a
c
e
rb
a
ti
o
n
s 
o
f 
c
h
ro
n
ic
 b
ro
n
c
h
it
is
. 
A
n
ti
m
ic
ro
b
 A
g
e
n
ts
 
C
h
e
m
o
th
e
r 
2
0
0
5
 J
a
n
;4
9
(1
):
1
5
3
-6
0
. 
E
5
5
 
S
p
e
n
c
e
r 
S
, 
C
a
lv
e
rl
e
y
 P
M
, 
B
u
rg
e
 P
S
, 
J
o
n
e
s 
P
W
. 
Im
p
a
c
t 
o
f 
p
re
v
e
n
ti
n
g
 e
x
a
c
e
rb
a
ti
o
n
s 
o
n
 d
e
te
ri
o
ra
ti
o
n
 o
f 
h
e
a
lt
h
 s
ta
tu
s 
in
 C
O
P
D
. 
E
u
r 
R
e
sp
ir
 J
 2
0
0
4
 M
a
y
;2
3
(5
):
6
9
8
-
7
0
2
. 
E
5
6
 
S
to
c
k
le
y
 R
A
, 
C
h
o
p
ra
 N
, 
R
ic
e
 L
. 
A
d
d
it
io
n
 o
f 
sa
lm
e
te
ro
l 
to
 e
x
is
ti
n
g
 t
re
a
tm
e
n
t 
in
 p
a
ti
e
n
ts
 w
it
h
 C
O
P
D
: 
a
 1
2
 m
o
n
th
 s
tu
d
y
. 
Th
o
ra
x
 2
0
0
6
 F
e
b
;6
1
(2
):
1
2
2
-8
. 
E
5
7
 
S
u
zu
k
i 
T,
 Y
a
n
a
i M
, 
Y
a
m
a
y
a
 M
, 
S
a
to
h
-N
a
k
a
g
a
w
a
 T
, 
S
e
k
iz
a
w
a
 K
, 
Is
h
id
a
 S
, 
e
t 
a
l.
 E
ry
th
ro
m
y
c
in
 a
n
d
 c
o
m
m
o
n
 c
o
ld
 in
 C
O
P
D
. 
C
h
e
st
 2
0
0
1
 S
e
p
;1
2
0
(3
):
7
3
0
-3
. 
E
5
8
 
S
za
fr
a
n
sk
i 
W
, 
C
u
k
ie
r 
A
, 
R
a
m
ir
e
z 
A
, 
M
e
n
g
a
 G
, 
S
a
n
so
re
s 
R
, 
N
a
h
a
b
e
d
ia
n
 S
, 
e
t 
a
l.
 E
ff
ic
a
c
y
 a
n
d
 s
a
fe
ty
 o
f 
b
u
d
e
so
n
id
e
/f
o
rm
o
te
ro
l 
in
 t
h
e
 m
a
n
a
g
e
m
e
n
t 
o
f 
c
h
ro
n
ic
 
o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
. 
E
u
r 
R
e
sp
ir
 J
 2
0
0
3
 J
a
n
;2
1
(1
):
7
4
-8
1
. 
E
5
9
 
Th
o
m
p
so
n
 W
H
, 
N
ie
ls
o
n
 C
P
, 
C
a
rv
a
lh
o
 P
, 
C
h
a
ra
n
 N
B
, 
C
ro
w
le
y
 J
J
. 
C
o
n
tr
o
lle
d
 t
ri
a
l 
o
f 
o
ra
l 
p
re
d
n
is
o
n
e
 i
n
 o
u
tp
a
ti
e
n
ts
 w
it
h
 a
c
u
te
 C
O
P
D
 e
x
a
c
e
rb
a
ti
o
n
. 
A
m
 J
 R
e
sp
ir
 
C
ri
t 
C
a
re
 M
e
d
 1
9
9
6
 A
u
g
;1
5
4
(2
 P
t 
1
):
4
0
7
-1
2
. 
E
6
0
 
Th
y
s 
F
, 
R
o
e
se
le
r 
J
, 
R
e
y
n
a
e
rt
 M
, 
Li
is
tr
o
 G
, 
R
o
d
e
n
st
e
in
 D
O
. 
N
o
n
in
v
a
si
v
e
 v
e
n
ti
la
ti
o
n
 f
o
r 
a
c
u
te
 r
e
sp
ir
a
to
ry
 f
a
ilu
re
: 
a
 p
ro
sp
e
c
ti
v
e
 r
a
n
d
o
m
is
e
d
 p
la
c
e
b
o
-c
o
n
tr
o
lle
d
 
tr
ia
l.
 E
u
r 
R
e
sp
ir
 J
 2
0
0
2
 S
e
p
;2
0
(3
):
5
4
5
-5
5
. 
E
6
1
 
v
a
n
 d
e
r 
V
a
lk
 P
, 
M
o
n
n
in
k
h
o
f 
E
, 
v
a
n
 d
e
r 
P
a
le
n
 J
, 
Z
ie
lh
u
is
 G
, 
v
a
n
 H
e
rw
a
a
rd
e
n
 C
. 
E
ff
e
c
t 
o
f 
d
is
c
o
n
ti
n
u
a
ti
o
n
 o
f 
in
h
a
le
d
 c
o
rt
ic
o
st
e
ro
id
s 
in
 p
a
ti
e
n
ts
 w
it
h
 c
h
ro
n
ic
 
o
b
st
ru
c
ti
v
e
 p
u
lm
o
n
a
ry
 d
is
e
a
se
: 
th
e
 C
O
P
E
 s
tu
d
y
. 
A
m
 J
 R
e
sp
ir
 C
ri
t 
C
a
re
 M
e
d
 2
0
0
2
 N
o
v
 1
5
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De afgelopen vijf jaar heb ik mogen ervaren hoeveel werk het is om een gerandomi-
seerd onderzoek op te zetten en uit te voeren. Zonder de toewijding en inzet van een 
enorme groep mensen zou het een onmogelijke opgave zijn geweest om COPE-II tot 
een goed eind te brengen.  
 Mijn eerste dank gaat uit naar de patiënten. Deelname aan het COPE-II onderzoek 
betekende een enorme investering. De uitgebreide metingen, bijeenkomsten, dagelijkse 
dagboekjes en het intensieve bewegingsprogramma, het was niet niks wat wij u vroe-
gen. Toch zijn opvallend weinig van u voortijdig met het onderzoek gestopt. Mijn dank 
is groot en ik ben trots op u! 
 Natuurlijk is het hierna tijd om mijn promotoren en co-promotoren te bedanken. Ik 
besef dat ik het enorm heb getroffen met zo’n leuke en kwalitatief goede begeleidings-
groep. Gerhard Zielhuis, je hebt me vanaf het begin op scherp gezet. Onze zeer 
regelmatige onderzoeksbesprekingen waren erg inspirerend en leerzaam, je commen-
taar op mijn stukken altijd positief kritisch, zorgvuldig en oplossingsgericht. Ik heb de 
afgelopen jaren zeer veel van je geleerd, dank hiervoor! Huib Kerstjens, je kritische 
commentaar, kennis van de pulmonaire onderzoekswereld en enthousiasme hebben 
heel wat leuke discussies, goede ideeën en een continue aanscherping van artikelen 
opgeleverd, waarvoor dank! Job van der Palen en Paul van der Valk, jullie stonden aan 
de basis van dit proefschrift. Jullie aanpak bruist en stimuleert! Ik heb ontzettend van 
onze samenwerking genoten, er erg veel van geleerd en ga er vanuit dat we deze in de 
toekomst zullen voortzetten. Job, ik zal onze dagelijkse (niet altijd werkgerelateerde) 
overlegmomenten, jouw innovatieve ideeën, vaak praktische oplossingen, vliegens-
vlugge en goede commentaren en de gedeelde chocoladerepen missen. Paul, ik heb van 
de productieve discussies aan de keukentafel, de woordgrapjes en de openvliegende 
deuren genoten! Allebei bedankt voor al die extra dingen die jullie zelf als zo vanzelf-
sprekend beschouwen! 
 Zonder mijn datamanager Betty Rinsma was ik waarschijnlijk halverwege de weg 
kwijt geraakt. Betty, dank voor je inzet, je zorgvuldige werkwijze, de stapjes extra die je 
vaak hebt gezet, de gezelligheid en je nuchtere kijk op de wereld om je heen! Petra 
Meerlo, ik denk niet dat veel mensen beseffen hoeveel werk jij hebt verzet. Je bent de 
stille kracht achter het COPE-II onderzoek geweest en ik waardeer je enorm. Ontzet-
tend bedankt! Irma Wissink, je hebt je altijd 100% ingezet voor de metingen: rende je 
vaak de benen uit het lijf en had amper tijd om te lunchen. Jouw inzet en nauwkeurig-
heid zijn erg bepalend geweest voor de kwaliteit van onze dataverzameling! Clara van 
Ommeren, je hebt een grote bijdrage geleverd aan het opzetten en de uitvoering van de 
zelfmanagementcursus. Als professional en als persoon ben je erg belangrijk geweest 
voor COPE-II en ik heb van onze samenwerking genoten! Annelies Wilmink, bedankt 
voor het zorgvuldig leiden van de zelfmanagementcursussen en voor het plegen van 
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de vele telefoontjes na afloop. Nicole Bathoorn, dank voor je inbreng bij de start van de 
cursus. Simone Bos en Astrid Boudrie, bedankt voor jullie hulp bij het datamanage-
ment, de metingen en jullie interesse! Marja Osinga, bedankt voor je hulp bij allerlei 
praktische medische zaken en Mandy de Jonge, je hulp met de dagboekjes was erg 
welkom, dank! Tot slot wil ik Sjouke, Wiebe en Thijs Rinsma, Annika Keizer en Step-
hanie Maathuis bedanken voor het stoïcijns invoeren van de ellenlange datareeksen. 
 Het COPE-II onderzoek zou nooit mogelijk geweest zijn zonder de inzet van de 
longfunctieafdeling: Silvia Achterberg, Roelien Bekkema, Willemien Boersma, Simone 
Bos, Mirjam Floor, Monique Groot, Petra Hemeltjen, Gerry Kruger, Moniek van der 
Meulen, Hans Nieland, Martijn Nuis, Marcel Penterman, Carmen Roelofs, Karin Smits, 
Marcel Vlutters, Irma Wissink, Loes Wansing, Cor Wegerif en Marquerite Zengerink. 
Allemaal bedankt voor het opvangen van alle patiënten met exacerbaties, de metingen, 
het meedenken en de gezelligheid tijdens de koffiepauzes! 
 Ook wil ik alle arts-assistenten die gedurende de loop van COPE-II werkzaam zijn 
geweest op de afdeling longgeneeskunde noemen. Jullie hebben ettelijke steentjes bij-
gedragen door het (tijdrovende) COPE-protocol te volgen wanneer de COPE’ers zich 
meldden met een exacerbatie. Mijn dank hiervoor is groot!  
 Ik wil de maatschap longziekten bedanken voor de medewerking aan COPE-II. 
Dank: Wendy van Beurden, Michiel Eijsvogel, Nicolle Hekelaar, Frans de Jongh, Jaap 
Klein, Louis van der Maas, Albert Polman, Hugo Schouwink, Paul van der Valk, Ilonka 
van Veen en Michiel Wagenaar. Daarnaast wil ik het secretariaat bedanken voor hun 
steun aan het onderzoek.  
 Zonder het enthousiasme en professionaliteit van de betrokken particuliere fysio-
therapeuten was het nooit gelukt om COPE-actief van de grond te krijgen en te laten 
slagen. Ik vond het enorm stimulerend om met jullie samen te werken. Bedankt: Nicole 
Bekhuis, Ben Boerrigter, Mirjam Diepenmaat, Fokke Dijkstra, Maarten Golbach, Rita 
Graave, Sander Greve, Nannette Groothuis, Ruud Hesselink, Marieke Hoogkamer, 
Matthieu Jansen, Frank Koehorst, Hayke Kotte, Anne-Marie Kreuwel, Marianne Meer-
man, Robert Morsink, Gerard Mulder, Gary Noordman, Steven Peters, Sandra Platvoet, 
Anoukh Taverne, Zwanita Veendam, Margo Versteeg, Jeroen Vinke, Ans de Visscher, 
Erik Vunderink, Dirk van de Walle, Paul Weltevreden, Raymond Westhoff, Wim te 
Wierik, Rik Willemsen, Haydi Wolbert en Frank Zuijdgeest. 
 De afdeling fysiotherapie van het MST is bij heel wat facetten van COPE-II betrok-
ken geweest. Luut Tip, dank voor je hulp bij het opzetten van de COPE-actief cursus, 
dit was zonder jouw inzet niet gelukt! Jolien Jentink, Rensje Hommes, Marjon Kramer 
en Rob Vergeer zijn betrokken geweest bij het opzetten en leiden van de zelfmanage-
mentcursussen, het PULMOFIT-progamma en zijdelings bij het COPE-actief gedeelte. 
Bedankt voor jullie inzet! 
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 Martijn Spruit, ik wil jou bedanken voor de kennis die je met me hebt willen delen 
aangaande bewegingsprogramma’s bij patiënten met COPD. De discussies die we heb-
ben gevoerd en de feedback die je me hebt gegeven hebben ertoe geleid dat ik samen 
met onze groep fysiotherapeuten een gedegen fysiotherapieprogramma heb kunnen 
neerzetten. Hayke Kotte en Paul Weltevreden, bedankt voor al jullie extra inzet omtrent 
COPE-actief. Hayke, ons eerste bezoek aan Leuven heeft tot een heel mooi product en 
een hechte vriendschap geleid! Alex van ’t Hul en Jaap Trappenburg, bedankt voor de 
tijd en moeite die jullie hebben genomen om mij in te wijden in het onderwerp COPD 
en fysiotherapie.  
 Ansje Uunk en Henriëtte Kosters, bedankt voor het uitvoeren van het stoppen-met-
roken programma dat was gekoppeld aan het COPE-II onderzoek. Gerda Hamers, 
Hennie Hekkema en Hans Konter verdienen ook een woord van dank voor het opvul-
len van het zelfmanagementprogramma met informatie over het Astma Fonds.  
 Manon Krabbenbos, jij hebt als stagiaire het onderzoek naar de compliance van fy-
siotherapeuten gedragen en een erg mooi product afgeleverd. Ook als datamanager 
was je vervolgens een juweeltje. Dank voor al je inzet voor COPE-II!  
 Caroline Kampshoff, wat heb jij een werk verricht tijdens je stage. Je hebt vol over-
gave het ambitieuze PULMOFIT-project getrokken en het uiteindelijk in goede banen 
weten te leiden. Respect! Veel succes in Engeland! 
 Jan Vercoulen, tijdens de consensusbijeenkomsten over COPD zelfmanagement en 
het schrijven van een artikel hierover heb ik erg veel van je geleerd omtrent voorwaar-
den voor gedragsverandering. Ik heb deze kennis proberen te verwerken in de 
discussie van mijn proefschrift. Ik wil je bedanken voor het inzichtelijk maken van deze 
materie en voor je toestemming je woorden in de discussie te gebruiken.  
 Speciale dank gaat uit naar de mensen en afdelingen die het mogelijk hebben ge-
maakt om de COPE-II en de hieraan verbonden studies uit te voeren. Ik wil de afdeling 
spoedeisende hulp bedanken voor het opvangen van patiënten met exacerbaties. De 
afdeling radiotherapie voor het beschikbaar stellen van hun gang voor onze looptesten. 
De verpleegafdelingen A4 en C4 voor hun medewerking aan het PULMOFIT-project. 
Alle apothekers en hun assistenten voor het leveren van apotheekgegevens. De huisart-
sengroep Oosterpoort en de huisartsen Bijland, ten Brinke, Davids, van Halteren, 
Machiels, Reinders Folmer en Ros voor hun hulp met de inclusie van patiënten. En tot 
slot Marjolein Wobben voor het beheren van het budget van COPE-II. 
 Onze bijeenkomsten van de ‘promovendusclub’ waren altijd gezellig, relativerend 
en leidden tot het uitwisselen van heel wat interessante informatie. Yvette Bulthuis, 
Lieke Christenhusz, Marjolein Brusse-Keizer, Astrid Boudrie, Martine Veehof en Eve-
lyn Monninkhof, ik heb van onze saunabezoekjes en etentjes genoten! Evelyn, ik ben je 
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erg dankbaar dat je mij destijds voor COPE-II naar voren hebt geschoven en vind het 
erg leuk dat je wilt plaatsnemen in mijn commissie! 
 Voor het onderzoek naar de compliance van fysiotherapeuten is nauw samenge-
werkt met Marcel Pieterse en Karen Zwijze-Koning. Bedankt voor deze leerzame 
samenwerking. Kristel Broekkamp, dank voor het interviewen van de tweede reeks pa-
tiënten.  
 De opvolger van COPE-II, de CHEST-studie, komt eraan. Marlies Zwerink ik hoop 
dat je er net zo van gaat genieten als ik. Heel veel succes!  
 De leden van de leescommissie, Prof.dr. P.N.R. Dekhuijzen, Prof.dr. R. Gosselink 
en Dr. T.R.J. Schermer bedank ik voor het kritisch beoordelen van mijn proefschrift.  
 Het COPE-II onderzoek zou niet mogelijk zijn geweest zonder de bijdragen van het 
Nederlands Astma Fonds, dank hiervoor. Daarnaast wil ik de Dr. G.J. van Hoytema- 
stichting, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Novartis Pharma, AstraZe-
neca, Nutricia Advanced Medical Nutrition en Nycomed bedanken voor hun financiële 
bijdrage aan de kosten voor het drukken van dit proefschrift.  
 Lieve Marjolein (Brusse-Keizer), ik ben enorm blij dat jij de afgelopen jaren mijn 
kamergenoot bent geweest. Paul had gelijk, je hebt in het onderzoek een maatje nodig, 
maar ik denk niet dat hij had gedacht dat het zo goed zou klikken. Onze gesprekken, 
werkgerelateerd maar ook privé, hielpen vaak de dingen op een rijtje te zetten. Ik vind 
het dan ook geweldig dat we allebei tegelijk een punt achter ons promotietraject kun-
nen zetten en het met een feest kunnen afsluiten. Mayo, ik ga je missen! 
 Betty Rinsma en Karin Effing-Schopman, ik ben erg blij dat jullie mijn paranimfen 
willen zijn. Lieve Betty, ik vind het erg fijn dat je me bijstaat in het nemen van deze 
laatste spannende stap in mijn promotietraject. Wat zullen we genieten van dat glaasje 
port als het achter de rug is! Lieve Karin, mijn grote zusje, ik ben blij dat je ook tijdens 
mijn promotie als paranimf achter me wilt staan! Dank voor al je (telefonische) support 
en je hulp bij de laatste loodjes! Dikke kus!  
 Dory en Herman, door jullie zorg voor Liv in Down Under kon ik met een gerust 
hart aan mijn proefschrift werken. Dank! 
 Lieve mam en pap, jullie hebben me altijd gestimuleerd in al mijn keuzes, ook al 
zorgen die soms letterlijk voor wat afstand. Mede dankzij jullie ligt dit proefschrift er. 
Door jullie nooit afnemende steun en de praktische hulp aan het eind, kon ik de dead-
line halen. Dank hiervoor! 
 Lieve Bas, dit proefschrift had er zonder jou niet gelegen. Je bent mijn steun en toe-
verlaat. De combinatie zwangerschap, emigratie en promotie was niet de meest 
handige, maar haalbaar omdat je me de afgelopen periode heel wat zaken uit handen 
hebt genomen. De komende tijd wordt er een van ‘relatieve’ rust, oftewel met onze lie-
ve kleine meid genieten van de keuzes die we hebben gemaakt!  
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Tanja Wilma Effing-Tijdhof werd op 17 november 1975 in Blomberg (Duitsland) gebo-
ren. In 1994 behaalde ze haar VWO diploma aan ’t Thijcollege te Oldenzaal. Zij ging 
vervolgens Gezondheidswetenschappen studeren aan de Universiteit van Maastricht. 
Gedurende deze studie koos ze de afstudeerrichting Bewegingswetenschappen. In 1998 
behaalde ze haar doctoraal. Na een periode van reizen (Australië en Thailand), startte 
ze in 1999 met de verkorte opleiding fysiotherapie aan de hogeschool van Utrecht. De-
ze studie combineerde ze met onderzoek gerelateerde functies op revalidatiecentrum 
de Hoogstraat / Universitair Medisch Centrum Utrecht. Na haar afstuderen in 2002 
volgde wederom een periode van reizen in Australië en Nieuw-Zeeland. In augustus 
2003 begon zij aan haar promotieonderzoek op de longafdeling van Medisch Spectrum 
Twente in Enschede. Gedurende de daarop volgende jaren bekwaamde zij zich in de 
epidemiologie middels het volgen van refereerbijeenkomsten, cursussen en het bijwo-
nen van symposia en congressen, met onder andere als doel het verwerven van de 
registratie Epidemioloog B. In september 2007 organiseerde ze een internationale con-
sensusbijeenkomst rondom COPD zelfmanagement. In augustus 2008 is ze samen met 
haar man, Bas Tijdhof, naar Adelaide (Australië) verhuist, waar ze in oktober 2008 is 
bevallen van een dochter, Liv. De komende jaren hoopt ze haar onderzoekskwaliteiten 
in het algemeen en met betrekking tot COPD-zelfmanagement in het bijzonder verder 
te ontwikkelen aan de Flinders University / Repatriation General Hospital in Adelaide.  
